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Summary 
Pharmaceutical compounds, originating mainly from industrial 
production and public consumption, are detected at extremely low levels 
(ng·L-1 –µg·L-1) in groundwater, surface water, and wastewater. So far, the 
adverse effects of pharmaceuticals and their intermediates have been widely 
reported, and include toxicity to humans and ecosystem, and enhancement 
of antimicrobial resistance. These effects call for the elimination of 
pharmaceuticals from water. This can be done by both abiotic and biotic 
degradation in the presence of oxygen (aerobic conditions) or in the absence 
of oxygen (anaerobic conditions). The technologies under anaerobic 
conditions are generally more sustainable and attractive because they 
require less energy and produce less pollutants, such as greenhouse gas, 
compared to technologies under aerobic conditions. Anaerobic degradation 
with metal oxides such as manganese (Mn) or iron (Fe) oxides has clear 
advantages in both drinking water treatment and wastewater treatment. 
Therefore, anaerobic degradation of pharmaceuticals in water with Mn or 
Fe is promising to study and develop into applicable techniques. This thesis 
investigates the feasibility of anaerobic degradation of pharmaceuticals in 
Mn- and Fe-mediated systems via both abiotic removal processes and by 
biodegradation. In Chapter 1, the scientific and technological motivation of 
the thesis is proposed. 
Applications and scientific developments of Mn- or Fe-based 
technologies to remove pharmaceuticals from water are reviewed and 
discussed in Chapter 2. Based on the removal mechanisms found in nature 
and technical systems, these Mn- or Fe-based technologies can be classified 
into 3 groups – physico-chemical removal, chemical removal, and 
biologically-related removal. A review of previous research indicates that 
pharmaceutical removal with Mn- or Fe-based technologies from water is 
efficient, and the removal efficiency varies whit the different technologies 
applied. Positive and negative aspects of these processes, such as 
(non-)specificity, treatment conditions, formation of and effects of 
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intermediates and by-products, and effects of Mn or Fe compounds were 
evaluated. Based on that, new and promising Mn- or Fe-based technologies 
are proposed as future potential effective and sustainable pharmaceutical 
removal technologies. Among these proposed technologies, the 
dissimilatory Mn or Fe reduction is identified as a most attractive, 
sustainable, and low-cost technology because this novel technology requires 
neutral conditions and the bacteria involved are able to completely 
mineralize the pharmaceuticals. 
The anaerobic biodegradation of pharmaceuticals coupled to 
dissimilatory Mn(IV) or Fe(III) reduction is tested with different types of 
Mn(IV) and Fe(III) (Chapter 3). With a mixture of adapted sediment to 
metoprolol and chemically synthesized Mn(IV), anaerobic biodegradation 
with amorphous, chemically synthesized Mn(IV) can effectively remove 
caffeine (26%) and naproxen (52%) after 42 days of incubation. Further 
experiments with Mn(IV) obtained from drinking water treatment plants 
show that this type of Mn(IV) can be used to remove metoprolol and 
propranolol, with respectively 96% and 31% after 72 days of incubation. 
The inoculum can also use Fe(III) as alternative electron acceptor to degrade 
metoprolol. Results show that metoprolol degradation with insoluble 
chemically synthesized Fe(III) and soluble Fe(III)-citrate reaches 57% and 
52%, respectively. No significant removal is observed in all the abiotic 
controls, showing that the biodegradation is the main removal mechanism 
in pharmaceutical removal with Mn(IV) or Fe(III). 
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Abiotic removal of selected pharmaceuticals with MnO2 is compared 
under aerobic conditions and anaerobic conditions (Chapter 4). Results 
show that anaerobic conditions promote diclofenac removal, while it 
inhibits removal of metoprolol and propranolol. In demineralized water 
(demiwater), diclofenac removal under anaerobic conditions is 78%, and 
higher than the 59% found under aerobic conditions. In 50 mM phosphate 
buffer, and under aerobic conditions, the diclofenac removal achieves 
complete removal. Under anaerobic conditions the observed removal is 
similar as in demiwater. Preliminary investigation shows that diclofenac 
removal with MnO2 under anaerobic condition is better at acidic pH (pH 4 
– 5) and the removal is higher when applying amorphous MnO2 compared
to applying crystalline MnO2. The key factors determining the extent of
pharmaceutical removal with MnO2 under anaerobic conditions are the
following: the chemical structure and molecular properties of the
pharmaceuticals, and the properties and activity of reactive sites on the
MnO2 surface.
Applying MnO2 under anaerobic conditions to remove diclofenac from 
water is further investigated (Chapter 5). Results show that increasing the 
temperature from 10 to 30°C leads to an increase in the diclofenac removal, 
whereas further increase of temperature to 40°C results in a decrease in the 
removal. The latter effect is possibly due to Ostwald ripening and/or aging 
processes. Increasing the amount of MnO2 increases the diclofenac 
degradation, as this provides more reactive sites for diclofenac conversions. 
Further shifting the molar ratio of MnO2 and diclofenac from 2200:1 to 
8900:1, however, does not further increase diclofenac removal, probably 
due to limited oxidation capacity of MnO2. The presence of metal ions 
strongly inhibits the diclofenac removal following the order of Mn2+> Ca2+ 
≈ Mg2+ >Fe3+. The metal ions appear to adsorb onto the MnO2 surface and 
compete with diclofenac for reactive sites. Phosphate has a diverse effect on 
diclofenac degradation: low concentrations inhibit and high concentrations 
promote the removal. The humic acids significantly promotes diclofenac 
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removal, probably caused by affecting MnO2 reactive surface sites. 
To reuse the Mn or Fe during pharmaceutical removal under anaerobic 
conditions, biological production of Mn(IV) or Fe(III) is investigated under 
oxygen-limiting conditions, or with nitrate as electron acceptor (Chapter 6). 
Mn(IV) is successfully produced with Mn(II)-oxidizing bacteria under O2-
limiting conditions, and the produced Mn(IV) is amorphous. 
Pharmaceutical removal with the Mn(II)-oxidizing bacteria is not observed. 
In abiotic pharmaceutical removal, using Mn(IV) from a drinking water 
production plant, is effective to remove metoprolol and propranolol. The 
successful production of Fe(III) is also observed under NO3--reducing 
conditions via biological processes. The biologically produced Fe(III) is 
also amorphous. There is no significant removal of pharmaceuticals coupled 
to the biological Fe(III) production. When comparing the biologically 
produced Fe(III) and other types of Fe(III), only Fe(III) from a drinking 
water production plant and one Fe(III)-based sorbent can remove 
propranolol. 
Finally, the outcomes of this thesis are discussed and provide insights 
into the application of anaerobic degradation of pharmaceuticals with 
mediation of Mn and Fe oxides (Chapter 7). The removal mechanisms 
include adsorption, chemical oxidation, and biodegradation and are 
identified to contribute to the different removal processes. The anaerobic 
Mn(IV)- and Fe(III)-mediated pharmaceutical degradation processes are 
evaluated on the basis of removal performance, environmental and 
operational conditions, sustainability of the processes, as well as the Mn and 
Fe types involved. Results described in this thesis provide a proof of 
principal for anaerobic Mn(IV)- or Fe(III)-mediated degradation in 
removing pharmaceuticals from water. To translate the process into a 
pharmaceutical removal technology for water treatment, three steps are 
proposed including (1) exploring the limits of anaerobic Mn- or Fe-
mediated pharmaceutical degradation processes; (2) simulating the process 
in practice with a controlled systems, and (3) translating the processes to a 
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pilot-scale system before a full-scale application. In addition, research 
topics are identified that can help to meet these challenges in the future. In 
summary, anaerobic Mn(IV)- or Fe(III)-mediated systems can remove 
pharmaceuticals from water through both abiotic removal and biotic 
degradation. These are promising processes which can be developed into a 
robust, sustainable, affordable, and environmentally friendly technology to 
remove pharmaceuticals from water. 

Chapter 1 
Introduction: Pharmaceuticals in the 
environment and pharmaceutical removal 
technologies 
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1.1 Pharmaceuticals in water 
Pharmaceuticals, commonly known as medicines or drugs, are 
chemical compounds used in the medical diagnosis, cure, treatment, or 
prevention of disease. These compounds have been detected in the aquatic 
environment including surface water and groundwater. Pharmaceuticals in 
water originate from waste streams of human activities, such as industrial 
production and an increase in consumption and emissions due to population 
growth, aging, and rising levels of obesity [161]. In the European Union (EU), 
production by the pharmaceutical industry increased 76% from 2000 to 
2014 [57]. More production leads to more wastewater from manufacturing 
containing the raw materials as well as pharmaceuticals. Moreover, 
pharmaceutical consumption keeps increasing. The World Health 
Organization (WHO) reports that the pharmaceutical consumption in the 
investigated countries increased 20 – 30% from 2000 to 2008 [181]. It is 
predicted that the global pharmaceutical consumption in 2020 will increase 
24% from that in 2015, reaching 4.5 trillion dosages [2]. Pharmaceuticals 
consumed for curing illness or increasing animal productivity are generally 
not completely degraded in humans or animals. These pharmaceuticals, 
together with pharmaceuticals disposal from household, healthcare facilities, 
and industries, will enter the aquatic environment primarily through 
discharged wastewaters (Table 1.1, Figure 1.1) [30, 367, 369]. 
Pharmaceuticals can be transformed to intermediates in the body, water 
treatment facility, and in the environment, and both parent and intermediates 
can be toxic to ecosystems [41]. One well-documented case is the 34 – 95% 
decrease of vulture population in Pakistan between 2000 and 2003 due to 
the indirect consumption of diclofenac and its residues [219]. Studies also 
describe the "cocktail effects" of pharmaceuticals, which may lead to more 
significant effects than predicted based on the individual compounds. For 
example, a higher toxicity on Daphnia magna is observed with a mixture of 
diclofenac, ibuprofen, and clofibric acid, than the individual compounds [88]. 
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While toxic effects on ecosystems are relevant, the public focuses more on 
human exposure to pharmaceuticals, especially the pharmaceuticals in 
drinking water. Some pharmaceuticals have mutagenic activity, which may 
cause a somatic mutation that can lead to cancer [234, 236]. Previous studies 
evaluated 1048 marketed pharmaceuticals, and nearly half of them are 
positive in the genotoxicity test or conflicting in results from different 
studies [24, 283]. Furthermore, despite the extremely low concentrations of 
which pharmaceuticals are found in water resources, concern can be raised. 
Considering the toxicity of the individual compound, one pharmaceutical 
can have negligible effects at this low concentration on human's health or 
an ecosystem. However, the multitude of these compounds present in water 
potentially inducing synergistic long-term toxic effects are still unclear [129]. 
Results show that the long-term toxicity (chronic toxicity) of 
pharmaceuticals occurred at lower concentration (at μg·L-1) than short-term 
toxicity (acute toxicity, at mg·L-1) [233]. The antimicrobial resistance 
developed by microorganisms when exposed to antimicrobial 
pharmaceuticals, cause an increase in human mortality as a result of 
antimicrobial resistant pathogens [343]. To deal with all these potential threats, 
it is vital to better understand the sources causing emissions of 
pharmaceuticals to the environment, the fate, and effects of these chemicals 
on the environment. Moreover, specific technologies should be developed 
to remove these compounds from water, which is the focus of this thesis. 
1.2 Pharmaceutical degradation techniques 
Due to their unclear eco- and human toxic effects and their association 
with antimicrobial resistance, pharmaceuticals are considered as unwanted 
chemicals, even at the low concentrations currently observed in water 
resources (ng·L-1 – μg·L-1) [297, 298]. Many processes have been used to 
remove pharmaceuticals from water [170, 255]. In some processes, physical or 
chemical mechanisms are used to remove the compound. These abiotic 
removal processes include various types of advanced oxidation, activated 
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carbon adsorption, or membrane filtration, and usually can achieve high 
removal efficiencies. For example, photodegradation catalysed by TiO2 can 
completely remove diclofenac and propranolol, and remove over 70% of 
carbamazepine and ibuprofen in both demineralised water and WWTP 
effluent [95, 354]. Activated carbon (AC) adsorption including both powder 
and granular activated carbons is widely studied and used to remove 
pharmaceuticals as well as other micropollutants [50]. The AC adsorption 
capacities differ for specific pharmaceuticals. For less hydrophobic 
pharmaceuticals such as ibuprofen, AC has a relatively low adsorption 
capacity of 12 – 56 mg·g-1. For hydrophobic pharmaceuticals like 
trimethoprim and paracetamol, the AC adsorption capacity is much higher, 
in the range of 120 – 300 mg·g-1 [255, 280].   
FIGURE 1.1 Source and pathways of pharmaceuticals in the environment 
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In contrast to abiotic processes, biotic processes are regarded as cost-
effective and environmentally friendly measures for removing 
pharmaceuticals from the aquatic environment (Table 1.2). In conventional 
wastewater treatment processes, both activated sludge and membrane 
bioreactor systems proved efficient in removing ibuprofen, atenolol, and 
some other pharmaceuticals [151, 198, 289]. A wide range of biological species 
including bacteria, plants, fungi, and algae can remove pharmaceuticals 
from water. Pure microbial cultures like Rhodococcus rhodochrous or 
Pseudomonas have been reported to efficiently degrade various types of 
medical chemicals [72, 364]. Mixed microbial cultures, for instance, obtained 
from activated sludge and adapted to the specific pharmaceuticals, show an 
improved removal compared to unadapted groups, such as for ibuprofen and 
diclofenac [151]. Complete removal of ibuprofen has been demonstrated by 
the plant Phragmites australis, often used in wetlands [94]. The white-rot 
fungus Trametes versicolor has been tested, and it can degrade 
pharmaceuticals including ibuprofen, clofibric acid, and carbamazepine [192]. 
In the algae-based water treatment systems, both biodegradation and 
photolysis contributed to the complete removal of ibuprofen [49]. 
TABLE 1.2 Comparison of abiotic and biotic processes in pharmaceutical removal 
Advantages Challenges 
Abiotic processes 
(chemical and 
physical removal) 
 High and fast removal
 Relatively high
mineralization
 Efficient for nearly all
pharmaceuticals
 Efficient for other
(micro)pollutants
 Improve the
biodegradability
 High cost
 Special operation conditions
 Radical formation
 Toxic intermediates
Biotic processes 
(biodegradation) 
 Commonly moderate
operation conditions
 Less energy input, cost-
effective
 Less toxic intermediates
 Resistance to shock
 Slow removal &
mineralization
 Developing antimicrobial
resistant
 Only efficient for selected
pharmaceuticals
 Produce waste sludge
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1.3 Pharmaceutical degradation techniques using 
metal species 
The role of metal species in organic compound degradation is widely 
studied, and can either have a purely chemical, heterogenic catalytic nature 
or can occur in interaction with biotic processes [248]. In previous studies, 
manganese (Mn)- or iron (Fe)-based technologies have been shown to 
remove pharmaceuticals via both abiotic removal and biodegradation [170]. 
Using Mn or Fe to remove pharmaceuticals has some clear advantages 
(Table 1.3). Mn and Fe are abundant, and they are essential to transforming 
organic contaminants in nature [175]. Hence, these materials can be easily and 
cheaply obtained from natural resources. Furthermore, Mn is unwanted in 
drinking water because it is toxic to humans [226] and needs to be removed 
from drinking water resources. Fe is an unwanted species in drinking water 
as well, since it affects the appearance and taste of the water, and can lead 
to clogging of water pipes and hinder the functioning of faucets and valves. 
Using these waste metal species to remove pharmaceuticals is economically 
and environmentally attractive in drinking water and wastewater treatment. 
Therefore, the abiotic removal and biodegradation of pharmaceuticals by 
these metals in various speciation are worth studying. Studying the Mn- and 
Fe-mediated pharmaceutical removal will contribute to an increased basic 
understanding of the fate, and specifically the transformation of 
pharmaceuticals in the environment. Also, investigating Mn or Fe species to 
remove pharmaceuticals from water is promising for the development of a 
novel cost-effective water treatment technology. To achieve this goal, 
further research is required to meet the challenges mentioned for various 
processes (Table 1.3). 
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TABLE 1.3 Comparison of using Mn or Fe, and other chemicals in pharmaceutical removal 
processes 
Advantages Challenges 
Using Mn or Fe  Abundant in nature, easy to
obtain
 Cheap
 Reuse Mn or Fe
 High removal efficiency
 Extra pollutants Mn2+ or
Fe2+
 Strict anaerobic
condition requires
(biodegradation)
 Slow growth of bacteria
(biodegradation)
Using other 
chemicals  
(O3, NO3-, etc.) 
 High & rapid removal efficiency
 Bacteria are easy to cultivate
(biodegradation)
 High cost of materials
 High operational skills
Eliminating pharmaceuticals from water is an important step to reduce 
the negative effects of these compounds on ecosystem and human. The ideal 
pharmaceutical removal technology should produce less direct and indirect 
pollution including toxic intermediates and greenhouse gases, and consume 
less energy. The technologies under anaerobic conditions (absence of 
oxygen) are most suitable for this purpose. Previous studies with various 
metal species have shown pharmaceutical degradation under anaerobic 
conditions via abiotic and biological processes [74, 170, 182]. 
Using Mn or Fe in anaerobic abiotic processes to remove 
pharmaceuticals is considered as more sustainable compared to aerobic 
processes (presence of oxygen) due to the low energy input needed for 
aeration.  Some studies find that the presence oxygen can both promote the 
Mn or Fe mediated removal of sulfamethazine [69], inhibit the removal of 
metoprolol and propranolol [172], or does not affect the removal of 
levofloxacin [163]. In the absence of oxygen, the use of Mn oxides to remove 
pharmaceuticals from water is widely studied [248], and the role and function 
of oxygen vary among the different investigations. Mohatt, et al. [206] have 
reported the abiotic removal of sulfamethoxazole in soil by the mediation of 
Fe species. Further detailed investigations on the underlying mechanisms 
are missing. Therefore, the abiotic removal of pharmaceuticals with Mn or 
Fe under anaerobic conditions is essential for further studies. 
17 
Biodegradation under anaerobic conditions is known to be more 
efficient to degrade some recalcitrant pollutants, like highly halogenated 
aromatic compounds [324]. Under anaerobic conditions, microorganisms can 
use different alternative electron acceptors, including nitrate, Mn, Fe, 
sulphate, and CO2 [74]. The biodegradation of various pharmaceuticals has 
been observed under these different redox conditions [74, 339]. However, in 
comparison with other redox conditions, biodegradation of pharmaceuticals 
under Mn and Fe reducing conditions has been insufficiently addressed. The 
biodegradation of organic compounds under Mn and Fe reducing conditions 
is through dissimilatory Mn or Fe reduction [175]. A promising process is 
dissimilatory Mn(IV) or Fe(III) reduction process. In these anaerobic Mn- 
or Fe-mediated systems, bacteria use Mn(IV) or Fe(III) as the electron 
acceptor to remove organic pollutants like aromatic compounds [152, 175, 335]. 
Since pharmaceuticals are mainly aromatic compounds, these processes 
potentially can also remove pharmaceuticals. Therefore, studying the 
process can form the basis for developing a specific removal technology for 
aromatic structure based pharmaceuticals.  Previous studies on 
pharmaceutical degradation with different electron acceptors show that 
pharmaceuticals like naproxen can be efficiently removed under Mn and Fe 
reducing conditions [268]. The limited studies so far indicate that further 
studies on anaerobic biodegradation of pharmaceuticals with Mn or Fe are 
desired. 
In the Mn- and Fe-mediated system, the Mn and Fe species is important. 
The Mn(IV)- and Fe(III)-(hydr)oxides are widely studied Mn and Fe species, 
and they can efficiently remove pharmaceuticals in both abiotic and biotic 
processes [65, 170, 327]. The Mn and Fe species from drinking water production 
are also (hydr)oxides, and could be suitable metal species to start detailed 
studies on anaerobic abiotic removal and anaerobic biodegradation of 
pharmaceuticals with Mn or Fe. 
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FIGURE 1.2 Anaerobic Mn(IV)- or Fe(III)-mediated pharmaceutical removal processes 
through (1) anaerobic abiotic removal and (2) anaerobic biodegradation 
 
In summary, anaerobic Mn(IV) or Fe(III) mediated abiotic and biotic 
degradation (Figure 1.2) offers the potential for developing a sustainable 
technology to remove pharmaceuticals from water. Such a technology 
requires limited energy and therefore produces little indirect pollution in the 
form of greenhouse gasses (CO2). Moreover, Mn(IV) and Fe(III) containing 
waste sludge of the drinking water industry may be reused for the 
degradation of pharmaceuticals. 
1.4 Aim and Scope of this thesis 
As discussed, Mn(IV) or Fe(III) mediated abiotic and biotic anaerobic 
degradation of pharmaceuticals is promising in water treatment and 
attractive to both drinking water and wastewater treatment. The objective of 
this dissertation is to first provide a proof of principle and subsequently 
further explore  anaerobic Mn(IV)- or Fe(III)-mediated pharmaceutical 
degradation processes (Figure 1.3). This pharmaceutical removal process 
needs to be based on new fundamental insights into the transformation of 
pharmaceuticals in the Mn(IV)- or Fe(III)-mediated systems. Both Mn(IV) 
and Fe(III) are studied in abiotic and biotic systems to assess the potential 
of the various processes to remove pharmaceuticals as well as the potential 
of the recycling of the Mn(IV) and Fe(III) used. 
Developing Mn- or Fe-based technologies for pharmaceutical removal 
is discussed by reviewing current and past studies reported in the literature 
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(Chapter 2). All reported Mn- or Fe-mediated systems are classified into 
three groups according to their removal mechanisms – physico-chemical 
processes, chemical processes, and biological processes. Removal 
efficiency and relevant parameters of these technologies and processes are 
put in inventory, and the advantages and challenges of these technologies 
and processes are discussed. Based on the review, several promising Mn- 
and Fe-mediated systems are proposed, which are currently not yet used to 
remove pharmaceuticals. The dissimilatory Mn(IV) or Fe(III) reduction 
process is identified and expected to have a high potential for removing 
pharmaceuticals from water. 
After that, the biodegradation of pharmaceuticals in the anaerobic Mn- 
or Fe-mediated systems is tested by laboratory research (Chapter 3). The 
degree to which Mn and Fe species can function as electron acceptors in 
pharmaceutical biodegradation is studied. Batch experiments are carried out 
with pharmaceutical mixtures in water, using a microbial inoculum adapted 
to Mn(IV) and metoprolol. The removal efficiency of selected 
pharmaceuticals with Mn(IV) is subsequently investigated. The same 
microbial inoculum ((Mn(IV) adapted) is cultivated with metoprolol and 
Fe(III) species, namely Fe(III) hydroxides and Fe(III)-citrate, to test Fe(III) 
as an electron acceptor. Further tests with Mn(IV) and Fe(III) from drinking 
water treatment plants, and two Fe(III)-based sorbents are performed to find 
the best source of Mn(IV) and Fe(III) for pharmaceutical degradation.  
After the biological studies, the studies into the potential of abiotic Mn 
and Fe mediated removal processes are described in Chapter 4. The 
anaerobic abiotic removal of pharmaceuticals is compared to that under 
aerobic conditions, to test and reveal the influence of oxygen. In addition, 
the effects of process parameters such as phosphate, pH, and MnO2 
morphologies are investigated. To this end batch experiments are carried out 
in the different matrices including solutions of the seven test 
pharmaceuticals as a mixture and as single compound (diclofenac) in 
demineralized water or phosphate buffer. The abiotic removal of diclofenac 
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in the absence of oxygen is described in detail because anaerobic conditions 
promote diclofenac removal, which has not been reported before. The next 
chapter (Chapter 5), continues with the MnO2 based abiotic processes to 
further elucidate the effects of parameters relevant for technology 
application. In this chapter, diclofenac is selected as a model pharmceutical 
to study the influence of temperature, amount of MnO2 per volume or per 
amount of pharmaceutical dosed, and co-solutes such as metal ions, 
phosphate, and organics in wastewater treatment plant effluents. 
The Mn(IV) and Fe(III) can be regenerated from the Mn(II) and Fe(II) 
produced during the anaerobic Mn- or Fe-mediated pharmaceutical 
degradation. The biological production of Mn(IV) and Fe(III) is tested 
(Chapter 6). To better reuse, the regenerated Mn(IV) and Fe(III), the 
production of these metals is carried out under oxygen-limiting conditions 
for Mn(IV), and nitrate-reducing conditions for Fe(III). Removal of 
pharmaceuticals is tested during the biological metal production processes. 
In addition, anaerobic abiotic removal of pharmaceuticals with Mn(IV) and 
Fe(III) from different sources are compared.  
In the final synthesis chapter, all processes described in the thesis are 
discussed regarding scientific progress, technology development and 
application potential (Chapter 7). A system for evaluating the performance 
of metal-oxide based pharmaceutical removal from water is presented. The 
potential remaining challenges of this proposed pharmaceutical removal 
technology are identified and discussed. Finally, an outlook and 
recommendation for research and application in water reuse are presented.
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FIGURE 1.3 Schematic outline of the research topics in this thesis 
 
 
  
Chapter 2 
Pharmaceutical removal from water with 
manganese- or iron-based technologies: 
A review 
A modified version of this chapter is published as 
Liu, W.; Sutton, N. B.; Rijnaarts, H. H. M.; Langenhoff, A. A. M., 
Pharmaceutical removal from water with iron- or manganese-based 
technologies: A review. Critical Reviews in Environmental Science and 
Technology 2016, 46, (19-20), 1584-1621, DOI: 
10.1080/10643389.2016.1251236
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ABSTRACT 
Pharmaceuticals are detected at trace levels in waters. Their adverse effects 
on aquatic ecosystems and human health demand novel pharmaceutical 
removal technologies for treating wastewater effluents. Manganese (Mn) or 
iron (Fe) may play important roles in these new technologies since these 
metals are abundantly available at low costs and are known to contribute to 
organic conversions via physico-chemical, chemical, and biologically 
related processes. Few reviews describe and discuss Mn- or Fe-based 
technologies for the purpose to remove pharmaceuticals from water. 
Therefore we review the current literature sorted into the three removal 
mechanisms, that is, through physico-chemical, chemical and biological 
processes. The principals, performance, and influential parameters of these 
three types of technologies are described. Current and potential applications 
of these technologies are critically evaluated in order to identify advantages 
and challenges. In addition, the Fe- or Mn-based technologies which are 
currently not used but promising to further develop to remove 
pharmaceuticals cost efficiently are proposed.  
 
KEYWORDS: biologically-related removal; chemical removal; iron- or 
manganese-based technology; pharmaceutical removal; physico-chemical 
removal; water 
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2.1 Introduction 
Removing pollutants from water is crucial to human as well as 
ecosystem health. Micropollutants are a growingly popular subject due to 
their low concentration and potential hazard. Among the micropollutants, 
pharmaceuticals are well studied and can be used as a representative case 
for a variety of micropollutants. Pharmaceuticals, commonly known as 
medicines or drugs, are a vast array of chemical compounds used 
for medical diagnosis, cure, treatment, or prevention of disease [255]. 
Improvements in analytical technologies have resulted in detection 
techniques to quantify pharmaceuticals at trace concentrations (ng·L-1 – 
µg·L-1) in wastewater, groundwater and surface water, and even in drinking 
water [38, 54, 106, 194]. Pharmaceuticals in water can threaten the quality of 
drinking water resources, can lead to spread of antibiotic resistance [241, 348] 
and can be toxic to some aquatic organisms [147, 263]. The presence and fate 
of these compounds have become a growing worldwide concern for 
politicians and the general public [118, 342]. For example, U.S. Environmental 
Protection Agency and European Union have added pharmaceuticals to their 
watch list for water quality [60, 314]. Due to adverse effects of pharmaceuticals 
in water on the quality of drinking water and food supply to humans, and on 
the functioning of ecosystems, regulators start to call for cost-efficient 
removal technologies to reduce emissions of such compounds. 
Pharmaceuticals from human consumption, excretion, and disposal 
mainly enter the environment via wastewater [113]. If they are not removed, 
these compounds will pass through wastewater treatment trains and enter 
water bodies directly [207, 306]. Advanced technologies are employed to 
remove these pharmaceuticals from water [11, 68, 95, 139, 270, 357]. Manganese (Mn) 
and iron (Fe) play important roles in many water treatment technologies, 
including physico-chemical removal (e.g. polyferric coagulation) [345], 
chemical removal (e.g. Fenton) [160, 186], and biologically related removal (e.g. 
biogenic Mn oxides oxidation) [65, 67]. Mn- or Fe-based technologies for 
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treating organic chemicals and heavy metals in general are reviewed in the 
literature [45, 158, 300]. None of these is specifically oriented on 
Pharmaceuticals. The number of studies that have examined the processes 
and applications of Mn- or Fe-based technologies to remove 
pharmaceuticals is growing. These studies indicate the special character of 
pharmaceuticals, that is, their complex chemical structures, which strongly 
influence compound specific physico-chemical and biological processes 
related to Mn or Fe reactive species. Therefore, an integrated review of this 
literature, on Mn- or Fe-based technologies and assessment of their 
scientific soundness, application potential, and main prevailing knowledge 
gaps is highly needed.  
This paper reviews Mn- or Fe-based technologies which are used to 
remove pharmaceuticals from water. All these technologies are sorted based 
on 3 removal mechanisms: physico-chemical removal, chemical removal, 
and biologically related removal. We evaluate the benefits and limitations 
of these technologies and discuss their application. In addition, we suggest 
promising Mn- or Fe-based technologies that should be explored for 
pharmaceutical removal. The results of this review are thus a critical 
assessment of the currently available and future potential Mn- or Fe-based 
technologies for pharmaceutical removal.  
2.2 Processes review 
2.2.1 Physico-chemical removal 
Mn and Fe compounds are used in water treatments, which involve 
physical and physico-chemical processes such as flocculation and 
coagulation, adsorption, and co-precipitation. These processes will be 
discussed in more detail in the following sections. Generally, pollutants are 
immobilized by interaction with Mn or Fe particles, which are subsequently 
settled. These physico-chemical technologies are used to remove 
pharmaceuticals from the water phase but not to convert or to degrade them. 
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2.2.1.1 Flocculation and coagulation 
In flocculation and coagulation, the soluble or colloidal compounds are 
taken out of solution or suspension in the form of a floc or flake by using 
chemical flocculants or coagulants; subsequently, the formed particles are 
settled. Flocculation is the aggregation of particles while coagulation is a 
physico-chemical destabilization of the colloidal system [18]. In literature, 
the flocculation and coagulation is interchangeable, and in this review, we 
will use the term “flocculation and coagulation” to refer to either or both of 
these related processes as used in Bratby [25]. These flocculants and 
coagulants can be organic polymers, metal salts such as FeCl3, and 
prehydrolized metal salts such as polyferric sulphate [18, 203].  
Ferric salts, including FeCl3 and Fe2(SO4)3, are commonly used in 
flocculation and coagulation processes for organic matter removal from 
drinking water and wastewater [28, 168, 199]. Excess Fe(III) is generated by 
zero-valent iron/H2O2 system and improves flocculation and coagulation of 
organic pollutants [131, 212]. Recently, polyferric sulphate (PFS), an inorganic 
polymeric flocculant, is used as a new coagulant to remove pharmaceuticals. 
In wastewater from a pharmaceutical production facility where the main 
organic COD (chemical oxygen demand) consisted of the pharmaceuticals, 
such as cefpirome, latomoxef, aztreonam, cefoperazone, cefatridine, 
ceftazidime, and other chemicals like propylene glycol, over 70% of 3300 
mg·L-1 COD was removed by flocculation and coagulation with PFS [345]. 
Results indicate that both the pH and PFS concentration influenced the 
removal, with the highest removal being obtained at an optimum pH of ~ 4 
with 300 mg·L-1 PFS. At pH 4, the COD removal increases from 0 to 80% 
with increasing PFS concentrations from 0 to 200 mg·L-1; when 200 – 900 
mg·L-1 PFS was dosed, COD removal only increased 10% [345]. PFS contains 
large amounts of polynuclear complex ions such as (Fe2(OH)3)3+, 
(Fe2(OH)2)4+, (Fe8(OH)20)4+, which leads to higher removal performance of 
organic compounds [318, 379], as compared to conventional flocculation and 
coagulation like FeSO4 and FeCl3.  
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2.2.1.2 Adsorption 
Mn, Fe and their oxides can be used as adsorbents, especially when 
present as nanoparticles, that is, particles ranging in size between 10 and 
100 nm. During adsorption, the pollutant is removed from the liquid phase 
through transfer to the surface of adsorbent. Especially nanoscale metal 
oxides, have an extremely large specific surface area supporting efficient 
removal of pharmaceuticals [310]. If the adsorbent has a preferential affinity 
for certain compounds in the liquid phase, the efficiencies can then be 
further enlarged with orders of magnitude [203].  
MnO2 can be used to remove pharmaceuticals and other pollutants by 
adsorption including antibacterial agents like sulfonamides and tetracycline, 
and endocrine disruptors [19, 248]. Results showed that clarithromycin and 
roxithromycin can be rapidly absorbed onto this amorphous MnO2 at pH 5 
[61], but adsorption did not contribute to carbamazepine removal with 
amorphous MnO2 [93, 248]. Adsorption of pharmaceuticals onto MnO2 is 
through surface complex forming. The different properties of 
pharmaceuticals affect the surface complex and will lead to different 
performances of adsorption. 
The performance of pharmaceutical adsorption to Fe(III) has been 
evaluated by previous studies [26, 61, 358]. Two human-used macrolide 
antibacterial agents, clarithromycin and roxithromycin, are strongly 
adsorbed (> 90%) to Fe(III) in the form of ferrihydrate. This is probably due 
to the macrolide antibacterial agents that can form a complex on the surface 
of Fe(III) [61]. Due to the different properties of pharmaceuticals, the ability 
to form a complex with Fe(III) is different for each pharmaceutical, which 
leads to selective adsorption. The results indicate that the efficiency of 
adsorption is closely related to the process condition. For example, at 
weakly acidic pH (~ 6), the highest adsorption is achieved due to changes 
in the Fe(III) surface chemistry, thus making Fe(III) more selective for the 
carboxylic group of the investigated pharmaceuticals such as [358].  
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Nanoparticles and nanoscale materials including nano Fe species can 
also remove pollutants by adsorption. Due to their small size, ranging from 
10 to 100 nm, and large specific surface area, nanoscale materials such as 
nanoscale zero-valent iron (nZVI) can efficiently remove pharmaceuticals 
via adsorption [138]. For example, nZVI adsorption can contribute to the 
removal of carbamazepine [277], amoxicillin, and ampicillin [76]. Supportive 
materials such as polyethylene glycol (PEG) and zeolite are used to improve 
the performance of nZVI as an adsorbent. Results show 10% more 
amoxicilline removal and 30% more ampicilline removal by PEG-nZVI, 
while nearly 30% more ampicilline removal is found by zeolite-nZVI [76]. 
Another nanoscale Fe-related adsorbent in pharmaceutical removal is 
magnetic permanently confined micelle arrays (Mag-PCMAs), which has a 
magnetite core confined in a silica porous layer [104, 331]. Pharmaceuticals 
including atenolol, gemfibrozil, and sulfamethoxazole can be absorbed and 
removed at mg·L-1 level by these Mag-PCMAs from water [104]. Magnetic 
iron oxide nanoparticles (MxFe3-xO4) are used to remove organic pollutants 
via adsorption, where M represents one or more components from Fe, Mn, 
Co, Li, Ni, Zn, etc. MFe2O4 (M=Fe, Mn, Co, Zn) can remove more than 96% 
of tetracycline, oxytetracycline, and chlortetracycline at 100 µg·L-1 by 
adsorption within 5 min [12]. Incorporation of MxFe3-xO4 into other chemicals 
like activated carbon (AC) can also be used to remove pharmaceuticals. For 
example, the maximum adsorption capacity of MnFe2O4/AC to 
sulfamethoxazole is 159 mg·g-1 at pH 7 [325], and maximum adsorption of 
hierarchically porous MgFe2O4/γ-Fe2O3 magnetic microspheres to 
minocycline is 201 mg·g-1 [180]. Metal-organic framework (MOF) is a class 
of highly crystalline porous materials consisting of a metal ion and an 
organic linker molecule [136]. It is used to remove hazardous organics from 
water by adsorption and photocatalysis [136, 332]. MIL-100-Fe is a type of Fe-
organic framework, and it is used in adsorption processes to remove 
pharmaceuticals including naproxen and clofibric acid [91], as well as other 
organic pollutants like bisphenol A [110, 242]. The adsorption capacity of MOF 
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MIL-100-Fe can reach 100 mg·g-1, which is even higher than granular 
activated carbon (~50 mg·g-1) [91].  
2.2.1.3 Co-precipitation 
Coprecipitation is a process in which soluble compounds are removed 
by sequestration in a precipitating phase [218, 240]. Pharmaceutical removal 
through coprecipitation is observed with Fe species including Fe corrosion 
products [63, 76, 218]. For example, amoxicillin and ampicillin can be 
sequestered by precipitation with Fe(OH)3 [76]. Triazole, the raw material to 
produce antimycotic drugs such as terconazole, is also removed with zero-
valent iron (ZVI) by co-precipitation [120, 216].  
2.2.2 Chemical removal 
In chemical removal of pharmaceuticals, Mn and Fe play important 
roles as oxidants, reductants, or catalysts such as Fe(II) in Fenton processes 
[31, 87, 140, 248, 271]. Chemical removal of pharmaceuticals in water treatment 
occurs through chemical oxidation via oxidizing agents (Fe(III), Fe(VI), 
Mn(IV), Mn(VII)) or chemical reduction via reducing agents like nZVI to 
degrade a compound or a group of compounds [87, 155]. In addition to 
conventional oxidation processes, advanced oxidation processes (AOPs) 
including Fenton, photolysis, and ozonation are used to remove 
pharmaceuticals. In these processes, Mn and Fe species work as catalysts in 
the formation of free radicals such as hydroxyl radicals (OH•) and sulfate 
radicals (SO4•-), which are used as strong oxidants to destroy organic 
compounds.  
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2.2.2.1 Chemical oxidation 
(1) Mn and Fe as oxidants
Mn(VII) and Mn(IV) are used to remove pharmaceutical compounds
and other pollutants in water and wastewater due to their high standard 
redox potential (+ 1.23 V for Mn(IV) and + 1.52 V for Mn(VII), see Figure 
2.1(a)) [69, 93, 163, 200, 248, 312]. Permanganate (MnO4-) can be used to remove 
pharmaceuticals and other micropollutants containing electron-rich 
moieties [87, 96]. One study found that ciprofloxacin, lincomycin, and 
trimethoprim are removed in a second-order reaction from drinking water 
by Mn(VII), with rate constants of 0.61, 1.6, 3.6 M-1·s-1, respectively [102, 103]. 
In a second study, more than 90% of sulfamethoxazole at concentrations 
between 0.5 and 5 mg·L-1 is removed with 2 mg·L-1 Mn(VII) at pH 7 [70]. 
Mn(VII) is also used to oxidize nonsteroidal anti-inflammatory drugs 
ibuprofen, diclofenac, naproxen, ketoprofen, fenoprofen, indomethacime, 
and salicylic acid [256]. Results showed diclofenac and indomethacime were 
completely removed, while the others decrease less than 30% [256].  
Mn(IV) (+ 1.23 V) has a stronger oxidation potential than the Fe(III) 
(+ 0.77 V). This is observed in the faster transformation of clarithromycin 
and roxithromycin by Mn(IV), which has a 2 – 3 times higher reaction rate 
per surface unit than Fe(III) [61]. Studies show that amorphous MnO2 can be 
used to remove pharmaceuticals such as carbamazepine, sulfamethazine, 
and diclofenac [69, 93, 163, 200, 312]. This chemical removal process is pH-
dependent, and effective when pH < 6 [69, 93]. Over 70% of diclofenac at 
about 3 mg·L-1 is removed by oxidation in a MnO2 bed filter with 
amorphous MnO2 in natural environment, where adsorption of both parent 
compound and by-products of diclofenac oxidation is observed [108, 109]. 
Similarly, 95% of amoxicillin at around 360 mg·L-1 is oxidised in 4 hours 
with 1×1 molecular sieve-structured MnO2 while only 4.5% of amoxicillin 
is removed by adsorption [146].  
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FIGURE 2.1 Eh-pH diagram for Metal in water at 25˚C ((a) for Mn; (b) for Fe). Adapted 
from previous data [294] using Material Project website [116] 
 
In addition to pH, other environmental parameters also affect chemical 
oxidation of pharmaceuticals by MnO2. For instance, MnO2 oxidation is 
negatively influenced by cosolute compounds, such as metal ions and 
natural organic compounds which inhibit the chemical reaction by 
occupying the reactive surface site of MnO2 [93, 96, 167, 360]. In addition, 
reactant loading has influence on this oxidation process. For example, 
loading for triclosan, ciprofloxacin, and carbadox has no effect on reaction 
rate constants because of the fixed number of reactive surface sites on MnO2 
surface [359]. In contrast, higher loading for tetracycline leads to lower 
reaction rate constants because of the self-competition for the same reactive 
surface sites of MnO2 [359]. 
Most studies using MnO2 to remove pharmaceuticals are carried out 
under aerobic condition. There are only two published studies using 
anaerobic condition as control group. Results show that anaerobic condition 
has no influence on fluoroquinolone removal [361] while it can inhibit the 
sulfamethazine removal [69]. 
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Fe(III), Fe(V) and Fe(VI) are used to oxidize pharmaceuticals from 
water, including tetracycline, clarithromycin, and roxithromycin [328]. Both 
Fe(V) and Fe(VI) have a higher standard redox potential of + 2.2 V under 
acidic pH 4 – 5 than under neutral pH 7 (Figure 2.1(b)) [34, 122, 123]. These 
ferrate compounds can react with pharmaceuticals which contain electron-
rich moieties [121, 124, 155, 349], which leads to the formation of nontoxic by-
products and Fe(III) [121, 274]. The removal efficiency varies for the different 
compounds at 10 – 100 µg·L-1 were: ciprofloxacin > 60%, naproxen > 40%, 
and n-acetyl sulphamethoxazole < 10% [121, 124, 349]. In addition, 88% removal 
efficiencies were achieved for selected pharmaceuticals and other 
micropollutants by combining oxidation, and flocculation and coagulation 
with Fe(VI) [349]. Owing to the high standard redox potential of Fe(III) 
species (+ 0.770 V, Figure 2.1(b)), the removal of tetracycline antibiotics, 
including tetracycline, oxytetracycline, and chlorotetracycline, with Fe(III) 
is 2 – 20 times higher than without Fe(III) [328]. This process is influenced 
by pharmaceutical concentrationas well as the concentration of Fe(III) [328]. 
At pH 7 and 20ºC, increasing of initial tetracycline concentration caused a 
decrease in the reaction rate, while increasing the initial Fe(III) 
concentration resulted in an increases in the reaction rate. 
(2) Mn and Fe as catalysts
 Mn can function as catalyst to remove pharmaceuticals. Manganese 
oxide supported or doped by other compounds has been used in catalytic 
ozonation process. Alumina-supported manganese oxide suspension is used 
as catalyst in ozonation to remove phenazone, ibuprofen, diphenhydramine, 
phenytoin, and diclofenac. Results show that more than 90% TOC of 
pharmaceuticals mixture is removed with alumina-supported manganese 
oxide whereas only 20% is removed without a catalyst [350]. Carbon 
nanotube-supported manganese oxides are used to assist ozone to remove 
ciprofloxacin. Ciprofloxacin removal increases within 15 min from 26.7% 
of 10 mg·L-1 to 87.5% when the catalyst was added [296]. MnO2-CuO/γ-Al2O3 
catalyst is also used to remove ibuprofen in ozonation [21]. Ibuprofen 
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removal increases from 27% of 5 mg·L-1 to 55% in the presence of the 
catalyst. A novel Ce-doped manganese oxide octahedral molecular sieve is 
generated recently and used as a catalyst in ozonation [365]. 81% 
ciprofloxacin of 10 mg·L-1 was removed in the ozonation process with the 
catalyst. Both Mn-Ce-O catalyst prepared in the laboratory and commercial 
Fe-Mn-O catalyst are used in catalytic ozonation process and show similar 
catalytic capacity [195]. Approximately 60% COD of the mixture of 
sulfamethoxazole and diclofenac is removed in the presence of either 
catalyst within 120 min. Tetracycline can complex with dissolved Mn2+ ions, 
thus improving tetracycline removal by oxygen. At pH 8 – 9.5, over 90% 
removal of tetracycline is achieved in Mn2+-mediated system, and the 
reactivity trend is as follows: oxytetracycline > tetracycline >> 
isochlorotetracycline [35].  
In classic Fenton’s reagent (Fe/H2O2 system), a mixture of Fe(II) and 
hydrogen peroxide generates OH• (Figure 2.2) [212, 238]. OH• can oxidize 
pharmaceuticals [10, 111, 160] together with another oxidant produced in the 
process, for instance Fe(IV) species at pH >5 (Equation 2.1) [107, 221]. For 
example, more than 90% berberine at around 1000 mg·L-1 and over 70% 
metronidazole at 1 mg·L-1 are removed in Fe/H2O2 oxidation systems [44, 275]. 
In addition, nearly complete removal of paracetamol, chloramphenicol, and 
diclofenac is obtained [10]. In Fenton’s reaction, ethylenediaminetetraacetic 
acid (EDTA) is used to improve the removal performance [15, 133, 150, 375]. The 
complex of Fe(II) and EDTA reduces dissolved O2 and produces H2O2 and 
OH• [15, 150]. In addition, the presence of EDTA enhances the Fe(III) solubility, 
thus preventing Fe(III) precipitation as well as possible Fe(II) 
coprecipitation with Fe(III) [15, 133]. Additional flocculation and coagulation 
by Fe(III) improves removal in Fenton’s reaction [302]. 
 
Fe(II) + H2O2 ──> Fe(IV) (e.g. FeO2+) +H2O    (2.1) 
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Other Fe species or compounds containing Fe can work as catalysts in 
Fenton’s reactions. In these processes, pharmaceuticals and other 
micropollutants can be removed via oxidation [48, 270, 277]. For example, ZVI 
and nZVI are used as a catalyst in Fenton’s reaction with H2O2 to remove 
pharmaceuticals [270, 277] and other pollutants [145, 159, 271]. Under acidic 
conditions (pH < 3), ZVI is oxidized to Fe(II) on the surface of the metal 
and then Fe(II) catalyzes the Fenton process. In the presence of 1.2 g·L-1 
ZVI, 3.2 g·L-1 H2O2, and 0.1 g·L-1 total organic carbon (TOC), 80% of a 
mixture of pharmaceuticals and other organic pollutants are removed in 1 
hour from pharmaceutical wastewater with a pH of 3 [270]. Similarly, 
carbamazepine can be totally removed from both distilled water and 
groundwater with 20 mg·L-1 nZVI and 25 mg·L-1 H2O2 [277].  
Furthermore, the Fenton’s reaction can be enhanced by ultraviolet–
visible photo, electronic, and ultrasonic irradiation [8, 9], which are 
photo/Fe/H2O2 system, electro/Fe/H2O2 system, and sono/Fe/H2O2 system, 
respectively. In the photo/Fe/H2O2 system, it is reported that a wavelength 
below 254 nm, or higher than 300 nm enhances the photolysis of Fe(III) to 
Fe(II) (Figure 2.2) [47, 311, 316]. Via photo/Fe/H2O2 system, completely 
removal of 16 mg·L-1 metoprolol and 17.6 mg·L-1 atenolol are obtained 
within 150 min [316], while 76% of 10 mg·L-1 sulfamethoxazole is removed 
within 7 hours [311].  
Electro-Fe(II)/H2O2 system is another advanced process in which H2O2 
is generated continuously if sufficient O2 is present at a suitable cathode 
(Equation 2.2, Figure 2.2) [27]. In addition, the production of OH• is 
accelerated by the regeneration of Fe(II) from soluble Fe(III) (Equation 2.3). 
O2(g) + 2H+ + 2e- ──> H2O2 (2.2) 
Fe3+ + e- ──> Fe2+ (2.3) 
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FIGURE 2.2 Activated species generated in Fe-based advanced oxidation processes (AOPs) 
where (A) is for OH• based AOPs [48, 90, 212, 238] and (B) is for SO4•- based AOPs [75, 119], (1) 
generated activated species from Fe/H2O2, photo/Fe/H2O2, electro/Fe/H2O2, sono/Fe/H2O2, 
etc.; (2) generated activated species from ZVI/O2; (3) generated activated species from photo 
degradation, electro degradation, sono degradation, etc.; (4) generated activated species from 
Fe/persulfate 
 
Experiments with electro/Fe/H2O2 system indicate that this process is 
efficient for pharmaceutical removal [114, 224, 282]. For example, 40% 
mineralization of atenolol at 158 mg·L-1 [114] and nearly 30% mineralization 
of ranitidine at 33.8 mg·L-1 [224] are obtained. Additionally, a combination of 
photo and electro irradiation for photo- electro/Fe/H2O2 system increases the 
performance in pharmaceutical removal even further [114, 224]. Results 
showed the complete removal of atenolol and 80% mineralization of 
ranitidine by photo-electro/Fe/H2O2 system with solar radiation. This is due 
to (1) the production of more OH• than photo/Fe/H2O2 system or 
electro/Fe/H2O2 system alone (Figure 2.2), and (2) the regeneration of Fe(II) 
also contributes to the removal [114, 224]. Sono/Fe/H2O2 system has been 
employed to remove pharmaceuticals as ultrasonic irradiation improves the 
Fenton’s reaction. Complete removal of levofloxacin is obtained by 
sono/Fe/H2O2 system in the presence of Fe3O4 magnetic nanoparticles [336].  
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Persulfate can be activated at pH 6 by different Fe species, such as ZVI, 
Fe(II), and Fe3O4. This process generates free SO4•- as well as other active 
species, such as OH• (Figure 2.2) [75, 119, 347]. Standard redox potential of SO4•- 
is + 2.6 V, which is similar to OH• with + 2.72 V [211]. Sulfate radical-based 
advanced oxidation processes (SR-AOPs) are new methods to oxidize 
pharmaceuticals in water [75, 119, 273, 347].  
In previous studies, Fe-activated persulfate has been used to remove 
pharmaceuticals. Fe(II)-activated persulfate oxidation removes 50% 
carbamazepine at 6 mg·L-1 [245], and 96% ciprofloxacin and 75% 
sulfamethoxazole both at 7.6 mg·L-1 [119]. In micrometric ZVI-activated 
persulfate oxidation, 10 mg·L-1 sulfamethoxazole is completely removed 
after 60 min [75]. Additionally, more than 90% removal efficiency of 
sulfamonomethoxine at 16.8 mg·L-1 is observed with Fe3O4-activated 
persulfate oxidation [347]. Together with simulated solar light irradiation, 
complete removal of carbamazepine is obtained by an Fe(II)/persulfate/UV-
Vis system, in which persulfate is activated by Fe(II) [1]. Furthermore, Fe 
can activate peroxymonosulfate (KHSO5, PMS) to generate SO4•-. One 
study shows that this Fe(II)-activated PMS can completely remove triclosan, 
sulfamethoxazole, and acetaminophen, which is more effective than Fe(II)-
activated persulfate under the same conditions [213].  
MXFe3-XO4, including incorporation of MXFe3-XO4 to other chemicals, 
has also been used in catalytic oxidation processes to remove 
pharmaceuticals. A new synthetic material, core-shell structured Fe3O4/α-
MnO2 microspheres (Fe3O4/α-MnO2), is used to remove pharmaceuticals 
via catalytic oxidation with persulfate. In one previous study, removal is 
observed for ciprofloxacin: 90% of 50mg·L-1 by Fe3O4/α-MnO2-activated 
persulfate, 80 % by α-MnO2-activated persulfate, and almost 30% by Fe3O4-
activated persulfate [370]. 
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Similarly to Fenton’s reaction, Fe can work as a catalyst in other 
advanced oxidation processes including photo degradation, sono 
degradation, and ozonation. However, as opposed to Fenton or Fenton-like 
processes, these AOPs do not use H2O2 to generate OH• [5, 31, 51, 112]. Fe-ZnO 
is used in catalytic photo degradation, catalytic sono degradation, and 
catalytic photo-sono degradation, in which irradiation of ultrasonic 
frequencies or/and visible light can generate reactive radicals from water 
through forming vapor cavities [187]. Results show that the removal rates for 
diclofenac increase in the following order: catalytic photo degradation 
(0.4×10-7 M·min-1) < catalytic sono degradation (14.3 ×10-7 M·min-1) < 
catalytic photo-sono degradation (15.3×10-7 M·min-1) [187]. 
Even without H2O2, ZVI can catalyse processes in the presence of O2 
(Figure 2.2) [15, 48, 84]. 96% diazepam at 25 mg·L-1 is removed by the ZVI/O2 
system after 60 min. Moreover, 60% diazepam is mineralized [15]. However, 
complexation of Fe may increase yield of H2O2 and change the nature of the 
reactive oxidant such as Fe(V) [133]. 
Ozonation effectively removes pharmaceuticals because ozone is a 
strong oxidant with a standard redox potential of + 2.08 V [17, 105]. Fe species 
are used in catalytic ozonation process and showed a high, stable catalytic 
activity [183]. Removal efficiencies of more than 90% of herbicides and 
pharmaceuticals were achieved within 40 min with magnetic cobalt-doped 
Fe3O4 (FeCo), whereas less than 40% is removed without the catalyst. 
Hematite (α-Fe2O3) and Fe3O4 show catalytic activity in ozonation as well. 
The order of catalytic activity is FeCo > Fe3O4 > α-Fe2O3 [184]. 
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2.2.2.2 Chemical reduction 
Chemical reduction is often used to remove pollutants such as heavy 
metals [320] and nitrate [100]. However, its application for pharmaceutical 
removal has not been extensively studied. During chemical reduction, 
pharmaceuticals receive electrons from other chemical compounds. For 
example, (n)ZVI can reduce pharmaceuticals, resulting in the oxidation of 
Fe; this occurs alone or in conjunction with other removal processes such as 
adsorption [76, 217, 247, 277, 376]. Previous studies showed that pharmaceutical 
compounds with certain functional groups (such as C-N, N=N, nitro or 
halogens) can be reduced by (n)ZVI via chemical reduction [247]. Results 
indicated rapid reduction of amoxicillin and ampicillin, while less than 12.6% 
removal of carbamazepine is observed [76]. Diazepam is removed by 
chemical reduction for almost 65% [15]. In addition, complete removal of 
chloramphenicol is obtained [344]. 
2.2.3 Biological-related removal 
There are pharmaceutical removal processes related to the metal-
related activity of different types of microorganisms, including bacteria and 
fungi [130, 225]. In these processes, microorganisms can produce Mn- or Fe-
oxides, which are used to remove pharmaceuticals by chemical oxidation. 
In addition, bacteria or fungi can work in advanced oxidation together with 
Fe which is known as biologically catalyzed advanced oxidation [86, 192].  
Biogenic Mn oxides (bioMnOx, also known as Mn bio-oxides) can 
efficiently remove pharmaceuticals [64, 67] and other pollutants [97, 202]. These 
bioMnOx are produced by oxidation of Mn(II) by bacteria such as 
Pseudomonas putida MnB6 (BCCM/LMG 2322) and Bacillus sp. SG-1, or 
fungi [97, 301]. Enrichment of P. putida which was used to generate bioMnOx 
was achieved under nitrifying conditions in a down flow sponge reactor with 
artificial wastewater [29]. As compared to synthetic MnO2, microbially 
produced bioMnOx has a unique structure, yielding a variety of advantages 
for oxidation. BioMnOx are reactive under neutral pH (~7), instead of the 
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acidic conditions required for abiotically produced MnOx [146, 248]. 
Additionally, the bacteria can bind the intermediate Mn(III) compounds via 
ligands, thus effectively increasing the oxidative power of a Mn-bacteria 
mixture [200]. As a result, diclofenac removal via adsorption and chemical 
oxidation with bioMnOx is 10-times faster than with synthetic MnO2 [65]. 
Additionally, complete removal of ciprofloxacin [312], and 17% removal of 
carbamazepine is obtained [64]. Studies also show that the performance will 
increase in the presence of trace metals, such as Ag or Pb. The interaction 
between the metals and the microorganism cell leads to formation of 
reactive oxygen species [200]. These reactive species can improve the 
pharmaceutical removal [200, 321].  
Manganese peroxidase (MnP) is an extracellular enzyme from the 
lignin-degrading basidiomycetes fungi such as Phanerochaete 
chrysosporium, which can oxidize Mn2+ to Mn3+. Mn3+ can act as a mediator 
to oxidize phenolic compounds. The presence of Mn2+ also stimulates the 
MnP production and functions as a substrate for MnP. The MnP is a key 
factor for fungi to remove pharmaceuticals including carbamazepine [80, 265]. 
Recently, a crude MnP is produced by white-rot fungi Phanerochaete 
chrysosporium and used as a biocatalyst to remove tetracycline and 
oxytetracycline via enzymatic degradation [337]. Results show that 72.5% of 
50 mg·L-1 tetracycline and 84.3% of 50 mg·L-1 oxytetracycline are removed 
at 40 U·L-1 within 4 h.  
Biological Fenton-like system is a recently discovered biological 
advanced oxidation process in which radicals are generated in the presence 
of white-rot fungi Trametes versicolor. The biological Fenton-like reaction 
occurs in the presence of lignin-derived quinone (2,6,-dimethoxy-1,4-
benzoquinone, DBQ) and Fe(III) (Figure 2.3) [86, 192]. In this process, DBQ 
is reduced to hydroquinone (DBQH2) in the presence of an intracellular 
quinone reductase produced from the fungi, followed by the generation of 
semiquinone radicals (DBQ•-) via subsequent oxidation of DBQH2 by 
lignin-modifying enzymes (laccases and peroxidases) which are also from 
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the white-rot fungi. Fenton’s reagent is formed by DBQ•- auto-oxidation 
catalyzed by Fe(III), and OH• is produced via this cycling [81, 193]. In this 
system, removal efficiencies of 80% were achieved for lofibric acid, 
carbamazepine, atenolol, and propranolol; more than 20% of the observed 
carbamazepine removal could be attributed to biological activity by this 
white-rot fungi [193].  
FIGURE 2.3 Biological Fenton’s-like system catalysed by white-rot fungi [193] (1) fungi 
catalyse the conversion of BDQ to DBQH2 by an intracellular quinone reductase from the 
fungi; (2) oxidation of DBQH2 to DBQ•- by lignin modifying enzymes (laccases and 
peroxidases) from the white-rot fungi; (3) Fenton’s reagent is formed by semiquinone radicals 
autoxidation catalyzed by Fe(III) 
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2.3 Evaluation and discussion 
Mn- and Fe-based water treatment technologies have the potential to 
play important roles in pharmaceutical removal processes. However, there 
are some challenges to the direct application of available water technologies 
for the removal of pharmaceuticals. The four main challenges, including 
advantages and challenges, will be explained in detail in the section 2.3.1 – 
2.3.4. 
First of all, most described technologies are nonspecific, meaning that 
they can remove various pharmaceuticals as well as other pollutants. While 
this versatility can be an advantage, it can also lead to more consumption of 
reagents in order to also remove pharmaceuticals. Secondly, the high 
removal efficiency obtained with Mn- or Fe-based technologies require 
specific reaction conditions, which may result in more consumption of 
energy or chemicals. Finally, some Mn- or Fe-based technologies can 
oxidize the pharmaceuticals into by-products or intermediates. While these 
intermediates may be more biodegradable than the parent pharmaceutical, 
in some cases, these daughter compounds are either toxic or recalcitrant to 
further removal. Finally, the crystal structures and morphologies will also 
affect pharmaceutical removal performance. Additionally, using these Mn- 
and Fe-based technologies will introduce Mn- or Fe-compounds into the 
environment. In general, the presence of Fe or Mn in the environment is safe. 
However, some compounds used in Mn- or Fe-based technologies such as 
nZVI or persulfate can be toxic to the native microorganisms. 
In the following section, we will evaluate the positive and negative 
aspects of using the currently available Mn- or Fe-based technologies for 
pharmaceutical removal, highlighting the challenges of application but also 
the potential of these technologies. 
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2.3.1 Nonspecificity 
Many physico-chemical, chemical, and biologically related 
pharmaceutical removal processes with Fe or Mn are nonspecific. This 
improves the robustness and versatility of the technology, as most of these 
processes can remove various pharmaceuticals (Table 2.1). For example, 
Fe/H2O2/system is suitable for removing compounds with a range of 
chemical properties, including antibiotics, analgesics, beta-blockers, and 
lipid-lowering drugs. However, this versatility means that pharmaceuticals 
will be removed together with other organic and inorganic pollutants. For 
instance, bioMnOx is used to remove pharmaceuticals, and also heavy 
metals, such as Pb and As [97]. This nonspecificity towards pharmaceuticals 
can reduce the removal efficiency, as other pollutants will be removed 
together with pharmaceuticals, thus competing for the available Mn or Fe. 
For example, organic compounds and colloids can compete for the surface 
of amorphous MnO2, leading to lower removal of carbamazepine [93]. Even 
with selective oxidation processes like ferrate and permanganate oxidation, 
they will not only attack pharmaceuticals containing electron-rich organic 
moieties, but also aliphatic and aromatic organic compounds [77, 305], 
phosphate [155], and taste and odor compounds [287]. Thus, other compounds 
in the matrix compete with the pharmaceuticals for Mn or Fe. While this can 
achieve the goal of removing both common pollutants and pharmaceuticals, 
the nonspecificity of the process will increase the reagent consumption for 
removal of a certain amount of pharmaceuticals. 
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2.3.2 Treatment conditions 
There are a variety of robust technologies that can achieve high 
pharmaceutical removal efficiencies. However, efficient and reliable 
removal can only be obtained under specific treatment conditions. Almost 
all pharmaceuticals can be completely removed by all AOPs, including SR-
AOPs (Table 2.1). In addition, direct chemical oxidation (e.g. Fe(III), 
Mn(IV), ferrate, and permanganate oxidation) and chemical reduction (ZVI 
and nZVI reduction) result in more than 90% removal of pharmaceuticals. 
In order to achieve optimal removal, chemical treatments usually require 
acidic conditions (pH < 6). The sterilized condition for pure culture 
cultivation is used in biologically related pharmaceutical removal process. 
BioMnOx used for pharmaceutical removal can be produced by P. putida 
MnB6 (BCCM/LMG 2322), which grows in synthetic medium [64, 65, 67, 200]. 
Similarly, the biological Fenton-like system with the white-rot fungi T. 
versicolor [192] requires an acidic medium (pH=4.5) for the cultivation of this 
fungi [43, 86, 192, 193]. Thus, specific cultivation equipment and sterile 
conditions are needed, and this might limit further application of these 
technologies in pharmaceutical removal technologies. 
2.3.3 Intermediates and by-products 
In most pharmaceutical removal processes with Fe or Mn, incomplete 
mineralization may occur. For example, only 30% – 40% mineralization is 
obtained in electro/Fe/H2O2 system processes [114, 224]. The presence and 
accumulation of by-products can be advantageous for further downstream 
treatment. For example, processes like Fe/H2O2/system will result in partial 
oxidation of compounds, thus improving the biodegradability of the 
pharmaceuticals in wastewater [10, 302]. A previous study using 
Fe/H2O2/system as pretreatment shows improved BOD/COD ratios from 
0.25 to 0.50 following chemical oxidation, indicating improved 
biodegradability [10]. Thus, combining chemical oxidation of the 
pharmaceutical with biological treatment of the by-products can result in 
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complete mineralization. Similarly, after ferrate treatment, biodegradation 
of water containing beta-blockers improves from nonbiodegradable to 14% 
– 70% biodegradation [338].
While improved biodegradability can be observed, some by-products 
will be similarly or even more toxic or recalcitrant as their parent 
compounds, especially by-products from the oxidation process. In a 
previous study, the toxicity of atenolol’s intermediates from photo/Fe/H2O2 
system process is higher than the parent compound [316]. Moreover, 
sulfamethoxazole removal from wastewater by solar photo/Fe/H2O2 system 
increases the toxicity of the wastewater from 16 to 86%, as assessed by 
Vibrio fischeri bioassays [311]. Another important product in these 
pharmaceutical removal processes is Mn(II) or Fe(II). Even though they are 
less threat to human health, they can have a negative effect on the taste, 
appearance, and staining of water. These results indicate that (1) these 
treatment technologies must go beyond merely considering removal of the 
parent pharmaceutical, and (2) many treatment technologies will require a 
downstream step to ensure complete removal of all toxic compounds. 
2.3.4 Effects of Fe or Mn compounds 
Mn or Fe compounds exist in different crystal structures and 
morphologies, and this can lead to different pharmaceutical removal 
performance. For example, the oxidation efficiency of naproxen with α-
MnO2 nanomaterials follows the order of commercial particles < nanorods 
< flower-like nanostructures < nanoparticles [368]. Similarly, comparing 
different types of iron particles for pharmaceutical removal, ZVI has a faster 
rate for removal of ampicillin than nZVI [76].  
In general, Mn or Fe compounds in pharmaceutical removal processes 
are safe to human or ecosystem. For example, nanomaterials like nZVI and 
MNPs are promising materials for pharmaceutical removal, but they are also 
potentially toxic to the environment. Previous studies show that nZVI 
results in ecotoxicity to organisms in both fresh and marine water [134, 235]. 
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Daphnia magna survival exposed to nZVI (Fe ≥ 5mg·L-1) drops within 96 
h [134]. In addition, nZVI is also potentially toxic to nerve cells, animal cells, 
and human cells [42, 137, 235]. One possible explanation is the physical 
disruption of cell membranes by nZVI. It can also enhance the biocide effect 
of Fe [154]. Toxicity to microorganisms is also observed with other Mn- or 
Fe-containing nanoparticles [16]. Other compounds used in Mn- and Fe-
based technologies like peroxymonosulfate are also harmful to human [222].  
2.4 Outlooks 
The challenges and limitations of current Mn- or Fe--based 
pharmaceutical technologies discussed above require either further 
optimizing current technologies or developing new technologies (Figure 
2.4). These new technologies have many of the treatment advantages 
mentioned in section 2.2.3, including nonspecificity, high removal 
efficiency, and/or potentially biodegradability improvements. These 
promising technologies require less specific treatment conditions and/or the 
products will be less toxic, thus addressing some of the challenges 
mentioned in section 2.2.3. 
2.4.1 Fe- or Mn-enhanced processes 
There are some existing technologies for pharmaceutical removal 
which could be further enhanced through the addition of Mn and Fe. After 
improvement or enhancement, these technologies are likely to more 
efficiently remove pharmaceuticals. 
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Powdered activated carbon (PAC) adsorption is a physico-chemical 
removal process for pharmaceuticals [166, 191] and other pollutants [73, 98, 244]. 
Studies show that addition of Fe species can improve the performance of 
PAC adsorption [89, 231]. Research investigating the removal of bisphenol A 
and natural organic matter shows that the adsorption capacities were in the 
following sequence: bare PAC < hematite/PAC < magnetite/PAC < 
ferrihydrite/PAC [231]. These results show that adding Fe species can 
improve the adsorption of compounds onto PAC, which is a known physico-
chemical process for pharmaceutical removal. While the adsorption on 
Fe/PAC is a nonspecific pharmaceutical removal process, this physio-
chemical technique does not result in toxic products formation. 
AOPs such as photo degradation and sono degradation can be 
accelerated by catalysts. Fe can work as a doping agent for catalysts such as 
TiO2 in catalytic photo degradation and sono degradation. In catalytic photo 
degradation, Fe-doped catalyst can improve the removal of volatile organic 
compounds acetone and benzyl alcohol [286, 373]. Similarly, sono degradation 
catalysed by Fe-doped TiO2 shows notably higher removal of the dyes Blue 
4 dye and azo fuchsine than undoped TiO2 [117, 329].  
Wet oxidation is the oxidation of organic and inorganic substances in 
an aqueous solution or suspension by means of oxygen or air at 200˚C – 
320˚C and 2 – 20 MPa either with or without [139, 142, 157, 378]. Wet oxidation 
includes wet air oxidation and wet peroxide oxidation and is used as a 
pretreatment technology for pharmaceutical wastewater [99, 201, 357, 371]. 
Results show that Mn and Fe (together with Ce, Pt or C) can catalyse wet 
oxidation for phenolic compounds removal [40, 71, 251, 264]. AOPs can form OH• 
and other active oxygen species which are efficient and nonspecific in 
pharmaceutical removal processes. In previous studies, Mn is used as a 
catalyst in supercritical water oxidation to treat pharmaceutical laboratory 
wastewater [259]. In addition, results show wet oxidation can significantly 
improve the biodegradability of pharmaceutical wastewater from 
pharmaceutical industry [82, 230, 357]. For example, the ratio of BOD5/COD in 
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pharmaceutical wastewater increases from 0.1 to 0.75 by catalytic wet air 
oxidation at 220 ˚C [357]. 
2.4.2 Advanced Mn or Fe compounds 
Advanced Mn or Fe compounds such as Fe-organic framework, nZVI, 
and bioMnOx are used to remove pharmaceuticals. These Fe or Mn 
compounds will be synthesized by combining with other materials as well 
as developing new generation processes. These advanced Fe or Mn 
compounds may lead to better pharmaceutical removal. 
Some advanced Mn or Fe compounds are used as catalysts in AOPs 
(Fenton, photo degradation, and SR-AOPs), which are currently employed 
to remove pharmaceuticals. Nano particulate Fe–oxides (nano FeOx) is a 
newly synthetic Fe compound which can catalyse Fenton’s reaction [355, 356]. 
Results show that higher concentrations of nano FeOx leads to a higher 
reaction rate [355, 356]. Moreover, nano FeOx can improve the removal of 
pollutants via adsorption because of the large specific surface area of these 
nanoparticles [355, 356]. Metal-organic framework containing Fe or Mn is used 
as a catalyst in photo degradation with both visible and UV irradiation [326]. 
Another new synthetic AOPs catalyst are ferrite nanoparticles (MxFe3-xO4 
nanoparticles, M=Mn, Fe, Co, etc.). For example, MnFe2O4 (MFN) can 
catalyse photo degradation or Fenton’s reactions. Over 90% removal of dye 
compounds was obtained [190]. MFN can also activate PMS, which is used 
to remove pollutants via SR-AOPs [353]. In this removal process, adsorption 
is an important mechanism [333]. Incorporation of MxFe3-xO4 to metal oxides 
or carbon is also promising in pharmaceutical removal. For example, Fe3O4-
Cr2O3 magnetic nanocomposite (MNC) is used to catalyse photo 
degradation. This MNC shows efficient removal of 4-chlorophenol under 
UV irradiation, good magnetic separation for recovery, and recyclability [281]. 
Kaolinite-supported nZVI (k-nZVI) is recently synthesized [36, 315]. It is 
proven that nZVI can- remove pharmaceuticals through adsorption and 
chemical reduction [76, 277], and it can catalyse Fenton-like processes to 
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remove pharmaceuticals. In addition, kaolinite alone can remove the 
pharmaceutical metoprolol by adsorption together with talc [165]. Thus, this 
newly synthesized k-nZVI is a promising reagent for pharmaceutical 
removal.  
Biologically produced MnOx have been shown to remove 
pharmaceuticals. Similar to bioMnOx, Fe oxides can also be generated by 
microbial activity, resulting in bioFeOx [97]. Their potential to remove 
pollutants has been observed. The large surface area of bioFeOx leads to the 
adsorption of heavy metals as well as potential adsorption of 
pharmaceuticals [64, 97]. In addition, bioFeOx is effective in dehalogenation 
reactions of organic pollutants, including chlorinated solvents, pesticides 
and freons [97, 141]. For pharmaceuticals containing halogens like diclofenac, 
applicability of dehalogenation by bioFeOx should be investigated. 
2.4.3 Other promising processes 
Some novel processes with Mn or Fe compounds are also promising in 
pharmaceutical removal. These processes should be explored to determine 
their application for pharmaceutical removal. Due to the similar properties 
between Mn and Fe (Figure 2.1), Mn can work as a catalyst in Fenton’s 
reaction [143, 185, 353]. In Mn/H2O2 system, both amorphous and crystalline 
Mn(IV) compounds are used as catalysts to remove carbon tetrachloride, 
with removal efficiencies of ~ 90% at pH 6 [334]. OH• is generated in 
Mn/H2O2 system and it is applicable to remove pharmaceuticals. Moreover, 
the OH• is generated at nearly neutral conditions (pH 6), instead of the acidic 
conditions at pH 3 that are needed for Fe/H2O2 system [238]. Consequently, 
Mn/H2O2 will be more cost-efficient for pharmaceutical removal in practice. 
Dissimilatory Mn or Fe reduction is demonstrated as a process to 
remove organic pollutants [33, 175, 179, 261]. In this process, dissimilatory Fe-
reducing bacteria (DIRB) such as Geobacter metallireducens, metabolically 
degrade organic matter while respiring on Fe(III) or Mn(IV). Dissimilatory 
Mn(IV) or Fe(III) reduction has been applied for the removal of 
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monoaromatic compounds, such as benzene, toluene, ethylbenzene and 
xylene isomers (BTEX) [4, 115, 153, 175, 323]. A previous study shows the 
complete removal of BTEX with Fe(III) at a rate of 0.19 μmol·L-1·d-1 [323]. 
Dissimilatory iron reduction has been shown for a variety of soluble and 
insoluble Fe(III) forms, indicating the versatility of this process [176, 177]. We 
assume that biological processes which can remove phenolic or aromatic 
compounds might have the potential to remove pharmaceuticals, as many 
pharmaceuticals contain at least one aromatic ring. Thus, dissimilatory Fe 
reduction was potential to remove pharmaceuticals. 
Mn(IV) has similar characteristics and an even higher standard redox 
potential compared to Fe(III). In addition, Mn(IV) can be used as an 
alternative electron acceptor by some DIRB [175]. Together with Mn(IV)-
reducing bacteria, the process is employed to remove aromatic compounds, 
e.g. BTEX [53, 323]. Results show that complete biodegradation of BTEX [323]
and > 60% naphthalene is mineralized to CO2 with Mn(IV) as the terminal
electron acceptor [153].
The mentioned dissimilatory Mn or Fe reduction requires a neutral pH 
and anaerobic conditions, so there are no needs to adjust the pH or add large 
amounts of oxygen. These prerequisites make it an attractive, sustainable 
and low-cost technology. This biological removal process will remove not 
only pharmaceuticals but also other organic materials. If given enough time, 
bacteria will degrade and eventually completely mineralize the 
pharmaceuticals. Products of the process, Mn(II) or Fe(II), can be oxidized 
into Mn(IV) or Fe(III), thus be recycled and reused for the removal process. 
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2.5 Conclusions 
Mn- or Fe-based technologies are capable of removing 
pharmaceuticals in water systems. Removing pharmaceuticals decrease the 
possibility of developing antibiotic-resistant gene or antibiotic-resistant 
bacteria. Furthermore, the AOPs using Mn or Fe compounds can also 
remove antibiotic-resistant gene and antibiotic-resistant bacteria [204, 285]. 
These technologies are efficient for a wide variety of pharmaceuticals, as 
well as other pollutants under favourable conditions. As discussed in this 
review, the removal mechanism involved physico-chemical, chemical, and 
biologically-related processes. So far, current Mn- or Fe-based technologies 
to remove pharmaceuticals focus on chemical removal. The Mn or Fe 
compounds are generally safe to the human and environment, but there are 
still some of them like nZVI can be toxic. Even when these technologies 
partially remove pharmaceuticals, their by-products can be more 
biodegradable than the parent compounds. These challenges require further 
attention to optimize these technologies. We have also discussed that Fe- or 
Mn-based technologies look promising in pharmaceutical removal 
processes and are worth studying, for example, based on combined 
technologies and/or biological processes. Especially biological processes 
are interesting, due to their mild operational conditions and environmental-
friendly characteristics.  
The combination of current and potential Fe- or Mn-based processes is 
therefore promising to develop novel technologies for the removal of 
pharmaceuticals from (waste)water. Furthermore, all these Mn- or Fe-based 
technologies are also valuable for removal both conventional pollutants and 
micropollutants.  
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Chapter 3 
Anaerobic biodegradation of pharmaceutical 
compounds coupled to dissimilatory 
manganese (IV) or iron (III) reduction 
A modified version of this chapter is in preparation for publication as 
Liu, W.; Sutton, N. B.; Rijnaarts, H. H. M.; Langenhoff, A. A. M., Anaerobic 
biodegradation of pharmaceutical compounds coupled to dissimilatory 
manganese (IV) or iron (III) reduction. 
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ABSTRACT 
Pharmaceutical compounds in water are regarded as emerging contaminants 
due to their adverse effects on aquatic ecological systems. Anaerobic 
pharmaceutical biodegradation coupled to dissimilatory manganese 
(Mn(IV))- or iron (Fe (III))- (hydr)oxides reduction is a potentially efficient 
but relatively unexplored process to remove these pharmaceuticals from 
water. In this study, batch experiments were carried out using different types 
of Mn(IV) and Fe(III) species with a microbial inoculum adapted to 
pharmaceutical biodegradation with 15 mM chemically synthesized Mn(IV) 
and 10 mg·L-1 metoprolol. Results show an anaerobic degradation of 26% 
for caffeine and 52% for naproxen with Mn(IV) as a terminal electron 
acceptor and insignificant biodegradation for other pharmaceuticals tested. 
Reduction of Mn(IV) from Mn-rich sludge from a drinking water treatment 
plant is coupled to anaerobic biodegradation of metoprolol and propranolol, 
resulting in removal efficiencies of 96% and 31%, respectively. The results 
indicate that adsorption contributes to the pharmaceutical removal during 
the first 10 days of incubation, while biodegradation is the main removal 
mechanism in the whole period. Fe(III) can also be used as electron acceptor 
in anaerobic pharmaceutical biodegradation. More than half of the added 
metoprolol is degraded with both chemically synthesized Fe(III) and 
Fe(III)-citrate as terminal electron acceptors. However, such a process did 
not occur when using Fe(III) in the form of Fe-rich sludge from drinking 
water treatment processes or Fe(III)-based sorbents. This study indicates 
that anaerobic pharmaceutical biodegradation coupled to dissimilatory 
Mn(IV) or Fe(III) reduction is possible, which is promising for application 
to cleaning wastewater treatment plant effluents. 
 
KEYWORDS: anaerobic conditions; biodegradation; Mn(IV) or Fe(III) 
reduction; pharmaceuticals  
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3.1 Introduction 
In the last decades, there is concern about pharmaceutical chemicals in 
water due to the increased consumption of these compounds and 
improvements in the detection of these compounds. These chemicals are 
observed in surface water, groundwater, wastewater, and even drinking 
water in the range from ng·L-1 to µg·L-1 [6, 164]. Previous studies have shown 
that pharmaceuticals have adverse effects. For example, propranolol could 
be harmful to aquatic organisms [197]. Consequently, pharmaceuticals as 
emerging contaminants are unwanted even at low level concentrations, and 
compounds like diclofenac or clarithromycin have been classified as a 
priority substances in water quality watch lists [20, 60].  
Conventional wastewater treatment facilities insufficiently remove 
pharmaceuticals such as diclofenac, carbamazepine, and β-blockers. The 
removal efficiency is generally less than 50% [330]. To eliminate these 
pharmaceuticals from water, technologies such as advanced oxidation 
processes, activated carbon adsorption, and membrane filtration are applied. 
For example, complete removal of the pharmaceuticals propranolol and 
diclofenac as well as 75% carbamazepine removal can be achieved in 
catalytic photodegradation [95, 354]. However, some intermediates from these 
advanced technologies can be more toxic than their parent compounds, 
which is undesired [223]. Furthermore, the high energy consumption will 
increase the ecological footprint and potential cost in construction and 
operation, making these technologies less attractive [151].  
Biodegradation can be a less energy consuming way to efficiently 
remove pharmaceuticals, and different redox conditions can be applied in 
biodegradation [71, 74, 151]. Under aerobic conditions, biodegradation of 
ibuprofen and diclofenac can achieve 75 – 100% removal [151]. Under 
nitrate-reducing conditions, biodegradation is efficient for β-blockers like 
atenolol and propranolol [268]. Under sulphate-reducing conditions, over 50% 
atenolol can be biodegraded within one week [13]. Under methanogenic 
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conditions, more than 80% of pharmaceuticals such as diclofenac were 
found to be biodegraded [262]. However, alternative electron acceptors such 
as Mn(IV)- or Fe(III) are less studied compared to the other redox conditions.  
Anaerobic biodegradation under Mn(IV)- or Fe(III)-reducing 
conditions is also known as dissimilatory Mn(IV) or Fe(III) reduction. 
During the process, Mn(IV)- or Fe(III)- (hydr)oxides are used as terminal 
electron acceptor in the anaerobic biodegradation of organic compounds [175]. 
Previous studies show that anaerobic biodegradation with Mn(IV) as 
terminal electron acceptor can efficiently remove aromatic compounds such 
as benzene, toluene, and poly aromatics: for example, naphthalene is 
mineralized to CO2 and water for more than 60% [153]. To date, anaerobic 
degradation of naproxen and atenolol under Mn(IV)- or Fe(III)-reducing 
conditions is described [13, 268]. These results indicate that anaerobic 
biodegradation coupled to dissimilatory Mn(IV) or Fe(III) reduction can 
remove pharmaceuticals as a wastewater treatment technology. During this 
anaerobic pharmaceutical biodegradation, Mn(IV) and Fe(III) are consumed 
as terminal electron acceptor.  
In addition to pharmaceutical removal efficiency, the influence of 
Mn(IV) or Fe(III) from different sources are important for application. 
Chemically synthesized Mn(IV) or Fe(III) (labelled as Mn(IV)chem-synthesis 
and Fe(III)chem-synthesis) as well as the Mn(IV) or Fe(III) from natural source 
are commonly used, and reported in literature [153, 175]. Compared to these 
compounds, Mn(IV) or Fe(III) produced during the drinking water 
treatment (labelled as Mn(IV)DWTP and Fe(III)DWTP) could be a more 
desirable source. Mn(IV)DWTP and Fe(III)DWTP are waste streams from the 
drinking water treatment plants [135]. Thus, these materials could be a cheap 
alternative for Mn(IV)chem-synthesis and Fe(III)chem-synthesis. For example, 
Fe(III)DWTP usually consist of FeOOH, which is a suitable electron acceptor 
in anaerobic biodegradation processes [175, 220]. In addition, different types of 
Mn(IV) or Fe(III) can serve as electron acceptor during anaerobic 
biodegradation of organic compounds [175]. To the best of our knowledge, 
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there are no studies reported directly using Mn(IV)DWTP or Fe(III)DWTP in 
dissimilatory metal reduction, nor using it coupled to the removal of 
pharmaceuticals with these Mn(IV) or Fe(III) species as electron acceptor. 
In this study, we tested the anaerobic biodegradation of 
pharmaceuticals with different types of Mn(IV) or Fe(III). Since anaerobic 
biodegradation of aromatic compounds with Mn(IV) or Fe(III) as electron 
acceptor has been observed, the process is also expected to be effective in 
removal of aromatic pharmaceuticals. The results presented provide 
information on anaerobic pharmaceutical biodegradation coupled to 
dissimilatory Mn(IV) or Fe(III) reduction and that contributes to 
understanding the fate and transfer of pharmaceuticals in the environment, 
where Mn(IV) or Fe(III) are ubiquitous, and which opens new ways towards 
application in waste water treatment.  
3.2 Methods and materials 
3.2.1 Chemicals 
Anaerobic water was prepared as previously described by boiling 
either ultrapure water (18.2 MΩ·cm, TOC=18 ppb, Millipore, USA) or 
demineralized water (demiwater) for 5 min, followed by cooling down to 
room temperature under a gentle N2 flow [172]. The anaerobic water was 
stored in closed glass bottles at room temperature. All the solutions in this 
study were prepared with anaerobic water unless specified.  
Six pharmaceuticals were purchased from Sigma-Aldrich or MP 
Biomedicals including caffeine, carbamazepine, ibuprofen, metoprolol, 
naproxen, and propranolol. The chemical structure and properties of these 
compounds have been described previously [172]. A stock solution of the 
pharmaceutical mixture was prepared with anaerobic ultrapure water, at a 
concentration of 20 mg⋅L-1 for each pharmaceutical. Stock of metoprolol 
and propranolol (1 g⋅L-1) were prepared separately with anaerobic ultrapure 
water.  
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Other chemicals were purchased from Sigma-Aldrich. For solid 
chemicals, the purity was greater than 98% while the liquids had a purity at 
HPLC or UPLC quality. 
3.2.2 Preparation of Mn(IV) or Fe(III) 
Different types of Mn(IV) and Fe(III) were used in this study (Table 
S3.1). The Mn(IV)chem-synthesis was prepared as described previously [172]. The 
Mn(IV)DWTP (Figure S3.1(a)) originated from drinking water production 
plant ‘Noordbargeres’ in Emmen, kindly provided by Water Laboratorium 
Noord (WLN, the Netherlands) [23].  
Soluble Fe(III)-citrate was dissolved with boiled demiwater. After 
cooling down under N2 flush to room temperature, the pH of Fe(III)-citrate 
was adjusted to pH 7 with 1N NaOH and diluted to 40 mM. The Fe(III)-
citrate solution was stored in a closed glass bottle and covered with 
aluminium foil to avoid photodegradation. 
Fe(III)chem-synthesis was prepared based on the method described 
previously [153]. In brief, 0.4 M FeCl3 was neutralized with 1 N NaOH until 
pH 7. Thereafter, Fe(III)chem-synthesis was washed and stored as Mn(IV)chem-
synthesis. Fe(III)DWTP was obtained from Evides Waterbedrijf (the Netherlands, 
Figure S3.1(b)). These Fe(III)DWTP granules are a mixture of Fe(III) from 
different drinking water treatment plants and then pelletized. Two types of 
Fe(III)-based sorbents, Fe(III)FerroSorp®Plus and Fe(III)FerroSorp®RW, were both 
obtained from HeGo Biotec GmbH in granular form (Germany, Figure 
S3.1(b)).  
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3.2.3 Experimental setup 
(1) Inoculum
Inoculum used in the experiments with Mn(IV), Fe(III)chem-synthesis and
Fe(III)-citrate consisted of a mixture of anaerobic sediments in the effluent 
channel of wastewater treatment plants in the Netherlands (Text S3.1). This 
sediment mixture was adapted with 10 mg·L-1 metoprolol and 15 mM 
Mn(IV)chem-synthesis over 800 days in cultivation medium described previously 
(Table S3.2) [178]. In the experiments with Fe(III)chem-synthesis, the mixture 
samples were taken out after 100 day incubation. These samples were used 
as a new inoculum for the experiments with Fe(III)DWTP, Fe(III)FerroSorp®Plus 
and Fe(III)FerroSorp®RW. 
(2) Experimental preparation
All experiments were performed in the same medium, as previously
described [178]. The medium was prepared under anaerobic conditions in an 
anaerobic glovebox. In the experiment with Mn(IV), 0.02% yeast extract 
was added to the medium, in order to provide sufficient nutrient compounds 
but in the experiments with Fe(III), no yeast extract is in the medium. 
The experiments with Mn(IV)chem-synthesis were carried out in duplicate 
in 250 mL bottles, filled with 100 mL anaerobic medium. The experimental 
bottles were prepared in the anaerobic glovebox. A selected amount of 
Mn(IV)chem-synthesis was distributed to the bottles, achieving a final 
concentration of 15 mM Mn(IV). The stock solution of pharmaceutical 
mixture was added to reach a final concentration of 10 mg·L-1 for each 
pharmaceutical. 10 mL inoculum mixture was transferred to the 
experimental bottles. 
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The experiments with Mn(IV)DWTP (granule and grinded powder) were 
performed in duplicate in 120 mL bottles, filled with 50 mL medium inside 
an anaerobic glovebox. About 4 g dry Mn(IV)DWTP was added into the 
bottles, resulting in a final concentration of 15 Mm Mn(IV). Only 
metoprolol and propranolol were tested to minimalize the potential 
influence of pharmaceuticals on inoculum. 0.5 mL metoprolol stock 
solution and 0.5 mL propranolol stock solution were added to the bottles. 
The final concentration for each pharmaceutical was 10 mg·L-1. 5 mL 
inoculum mixture was transferred to the experimental bottles.  
Fe(III) is hypothesised as an alternative electron acceptor of Mn(IV) in 
anaerobic pharmaceutical biodegradation. With Fe(III)chem-synthesis, the 
experiments were repeating the adaption of the inoculum but in the process, 
40 mM Fe(III)chem-synthesis was used instead of 15 mM Mn(IV)chem-synthesis. The 
experiments with Fe(III)-citrate were also the same but the 40 mM Fe(III)-
citrate solution replaced the anaerobic water during the medium preparation. 
Only 1 mL metoprolol stock solution was added to reach a final 
concentration of 10 mg·L-1. 
The experiments with Fe(III)DWTP, Fe(III)FerroSorp®Plus and 
Fe(III)FerroSorp®RW (all ground powder) were the same as those with 
Mn(IV)DWTP in a 120 mL bottles in duplicate. The final concentration of 
Fe(III) in these experiments was 40 mM. Only metoprolol was added into 
the experiments at a final concentration of 10 mg·L-1.  
When the bottles were ready, all the bottles were closed with butyl-
rubber stoppers and taken out of the glovebox. The bottles were sealed with 
aluminium crimp caps, and the headspace was exchanged to N2/CO2 
(80%/20%). All experiments were conducted at 30ºC in the dark without 
shaking. Abiotic controls were prepared similarly, with additional aliquots 
of HgCl2 (0.1 gHg·L-1) and NaN3 (0.3 mM) to inhibit biotic activity.  
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3.2.4 Sample preparation and analysis 
Liquid samples for pharmaceutical analysis were taken every 3 weeks. 
After sampling, the samples were centrifuged for 10 min at 10000 rpm. The 
supernatant was diluted and transferred to amber vials. All the samples were 
stored at -20ºC before analysis. Pharmaceutical analysis was performed by 
an ultra-performance liquid chromatography with a diode array detector 
(UPLC, ultimate 3000, Thermo, USA), as previously described [95].  
The samples for pH were taken at the beginning and at the end of the 
experiments, and were analysed immediately with a pH-meter (MeterLab 
PHM210, Radiometer Analytical). 
The samples for morphologies of the Mn(IV) and Fe(III) were prepared 
by grinding if the raw materials were granular. The morphology was 
analysed by an X-ray powder diffraction (XRD, Bruker D8 advance).  
Samples for Mn content in Mn(IV)DWTP were reduced by 0.5 mM 
NH2OH·HCl (1 mL·mg-1 sample). The samples for Mn(II) measurement 
were also taken at the end of the experiments. The samples were centrifuged 
at 10000 rpm for 10 min. The supernatant was collected and stored at -4ºC 
before analysis. The Mn content and Mn(II) were both measured at 
wavelength 257.610 nm by an inductively coupled plasma optical emission 
spectrometry (ICP-OES,VISTA-MPX CCD Simultaneous, VARIAN co.). 
Samples for Fe analysis were prepared by a modified HCl extraction 
method [52]. Briefly, 0.5 mL samples were mixed with 0.5 mL 1 M HCl to 
fix Fe(II). Thereafter, Fe(II) was analyzed directly by colourmetric methods 
(Hach Dr. Lange Kit 340). The samples were analysed immediately. The Fe 
content in Fe(III)DWTP, Fe(III)FerroSorp®Plus and Fe(III)FerroSorp®RW was measured 
by the same ICP-OES at the wavelength 238.204 nm, while the Fe(II) 
generated during the experiments was measured using a Hach Dr. Lange Kit 
(LCK 340).   
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3.3 Results and discussion 
3.3.1 X-ray diffraction of Mn(IV) and Fe(III) 
First, the Mn(IV) and Fe(III) were characterized by X-ray diffraction 
(XRD), to identify the morphologies of these compounds and to assess if 
they are able to be used in dissimilatory Mn(IV) or Fe(III) reduction. The 
XRD pattern shows that the Mn(IV)chem-synthesis is amorphous with two small 
but broad XRD peaks, which is similar as previously described by others 
(Figure 3.1) [93]. The morphology of Mn(IV)DWTP could not be clarified by 
an XRD analysis. Since Mn(IV)DWTP is MnO2-coated sand, the XRD pattern 
highly match the pattern of quartz (Figure 3.1 (a), Figure S3.2(a)).  
The XRD pattern of Fe(III)chem-synthesis shows amorphous Fe(III) with 
two small but broad XRD peaks, which is a similar pattern as Fe(OH)3 
(Figure 3.1(b), Figure S3.2(b)). The XRD patterns of Fe(III)DWTP, 
Fe(III)FerroSorp®Plus and Fe(III)FerroSorp®RW are all partially similar to those of 
Fe2O3 and Fe3O4, indicating a semi-crystalline morphology. The 
morphology of Fe(III)DWTP is closest to an amorphous one, and 
Fe(III)FerroSorp®RW is closer to a crystalline morphology. 
Based on the literature, the amorphous Mn(IV) and Fe(III) are 
commonly used Mn and Fe species in dissimilatory Mn(IV) or Fe(III) 
reduction, and different types of Mn(IV) and Fe(III) such as crystalline 
hematite, goethite, akaganeite, and magnetite, are also suitable for the 
process[175, 177]. Therefore, the amorphous and semi-crystalline Mn(IV) and 
Fe(III) in this study are expected to remove pharmaceuticals coupled to the 
dissimilatory Mn(IV) or Fe(III) reduction. 
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FIGURE 3.1 XRD patterns of different types of (a) chemically synthesised Mn(IV) 
(Mn(IV)chem-synthesis) and Mn(IV) from a drinking water treatment plant (Mn(IV)DWTP); and (b) 
chemically synthesised Fe(III) (Fe(III)chem-synthesis), Fe(III) from a drinking water treatment 
plant (Fe(III)DWTP), and two Fe(III)-based sorbents Fe(III)FerroSorp®Plus and Fe(III)FerroSorp®RW 
3.3.2 Anaerobic biodegradation of pharmaceuticals with 
Mn(IV) 
(1) Chemically synthesized Mn(IV)
Anaerobic biodegradation with Mn(IV)chem-synthesis was tested with a
mixture of six commonly used pharmaceuticals. Our results show that the 
anaerobic biodegradation is effective within 40 days (Figure 3.2). In this 
period, 26% of the applied caffeine, and 52% of the dosed naproxen is 
removed. Carbamazepine and propranolol are removed within 42 days at 
lower levels, namely12% and 16%, respectively. No removal is observed 
for ibuprofen and metoprolol. During the anaerobic biodegradation of 
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pharmaceuticals, 5.4 mM Mn(IV) is reduced (Table 3.1), indicating that the 
Mn(IV) is the electron acceptor in the anaerobic biodegradation. In the 
abiotic controls, no degradation of pharmaceuticals is observed (Figure 3.2), 
further indicating that the observed degradation is linked to Mn(IV) 
reduction. 
Based on previous studies, anaerobic biodegradation of 
pharmaceuticals coupled to dissimilatory Mn(IV) reduction may occur via 
two pathways [175]. First of all, the pharmaceuticals could be hydrolysed or 
fermented by different bacteria to easier degradable components, such as 
sugars, amino acids, long chain fatty acid, and/or simpler aromatic 
intermediates [175, 196]. These components can be further converted to 
fermented acids and hydrogen and then consumed by bacteria. In addition, 
the pharmaceuticals, as well as the potential aromatic intermediates, can 
also be oxidised directly by bacteria like Geobacter matallereducens. 
Mn(IV) reduction in this process provides energy for these bacteria [175].  
 
 
FIGURE 3.2 Biodegradation of pharmaceuticals with chemically synthesized Mn(IV) oxides 
after 42 days incubation. Experimental conditions: [MnO2]0=15 mM, [pharmaceutical]0=10 
mg·L-1, pH 6.5 – 7.5, T= 30ºC. Error bars are the difference between duplicate 
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Since the pharmaceutical removal coupled to dissimilatory Mn(IV) 
reduction is a biological process, the process is expected to be more effective 
for readily biodegradable pharmaceuticals. In this study, the removal of 
naproxen and caffeine is higher than other compounds. Previous studies 
have shown that naproxen and caffeine are efficiently removed under 
anaerobic conditions [66, 268] while the rest of pharmaceuticals are resistant 
[268, 290]. That indicates that naproxen and caffeine could be more 
biodegradable than other pharmaceuticals. Apparently, removal of naproxen 
and caffeine is also more effective in anaerobic biodegradation with 
Mn(IV)chem-synthesis as shown here.  
Mn(IV) reduced in the experiments is more than two time higher than 
that in theoretical calculation (Table 3.1), taking the depleted 
pharmaceutical amounts as the quantity of consumed electron donor (Text 
S3.2, Table S3.3). The dis-match is most likely due to the presence of yeast 
extract, which also contains a lot of organic compounds. Therefore, the 
bacteria will use yeast extract not only as a nutrient source, but also as 
electron donor to reduce Mn(IV). As a result, more Mn(IV) reduction is 
observed than calculated for pharmaceutical removal. 
TABLE 3.1 The reduction of Mn(IV) or Fe(III) during the anaerobic biodegradation of 
pharmaceuticals 
Mn or Fe used in 
experiments a 
Theoretical Mn(IV) or Fe(III) 
reduced (mM) b 
Measured Mn(IV) or Fe(III) 
reduced (mM) c 
Mn(IV)chem-synthesis 1.8 5.4 
Mn(IV)DWTP 2.2 4.9 
Fe(III)chem-synthesis 1.7 1.8 
Fe(III)-citrate 1.2 8.8 
a Mn(IV)chem-synthesis=Chemically produced Mn(IV) oxides, Mn(IV)DWTP=Mn(IV) oxides 
from drinking water treatment plants, Fe(III)chem-synthesis=Chemically synthesized Fe(III) 
hydroxides 
b The calculation methods of Mn(IV) or Fe(IV) reduced described in Text S3.2 and Table 
S3.3 
c Measured Mn(IV) or Fe(IV) reduced is calculated by the difference between the biotic 
experiments and abiotic controls 
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(2) Mn(IV) from drinking water treatment plants 
Mn(IV)DWTP, both as granules and ground powder, is tested whether it 
is suitable to be used in anaerobic pharmaceutical biodegradation coupled 
to dissimilatory Mn(IV) reduction. Results show that Mn(IV)DWTP granules 
can remove these two β-blockers via biodegradation. In the first 10 days, 
the two pharmaceuticals are removed with Mn(IV)DWTP from the medium in 
both biotic experiments and abiotic controls (Figure 3.3). Thereafter, no 
removal of metoprolol is observed in biotic experiments between day 10 and 
day 35, while 72% is removed in the later 37 days incubation between day 
35 and day 72. The removal of propranolol in biotic experiments is less 
pronounced, and resulted in a final removal of 31% after 72 days of 
incubation. However, the removal of propranolol is 52% in the first 10 days 
incubation. During the anaerobic biodegradation with metoprolol and 
propranolol, 4.9 mM Mn(IV) is reduced (Table 3.1). The abiotic controls 
remained stable after 10 days of incubation, with max. 15% metoprolol 
removal, and 9% propranolol removal. No removal of metoprolol or 
propranolol is observed in the presence of Mn(IV)DWTP powder, (< 5% 
removal , data not shown).  
 
 
FIGURE 3.3 Biodegradation of metoprolol (●) and propranolol (■) with Mn(IV) oxides 
from drinking water treatment plants (Mn(IV)DWTP). Experimental conditions: [MnO2]0=15 
mM, [pharmaceutical]0=10 mg·L-1, pH 6.5 – 7.5, T= 30ºC. Error bars are the difference 
between duplicate  
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The differences between biotic groups and abiotic controls of both 
propranolol and metoprolol clearly show that the removal of these two 
pharmaceuticals is via biodegradation. In addition, adsorption is also 
responsible for the removal of the two pharmaceuticals with Mn(IV)DWTP. 
In the first 10 days, removal of two pharmaceuticals is observed in both 
abiotic controls and biotic experiments, but the removal in biotic 
experiments is higher. These findings shows that the biodegradation of 
pharmaceuticals is the main removal mechanisms, but that adsorption also 
contributes. After, adsorption reached equilibrium biodegradation becomes 
the dominant removal process. The removal of propranolol shows that the 
adsorption of this pharmaceuticals onto MnO2 could be reversible, leading 
to the decrease of removal from 52% to 31% after 10 days incubation. In 
addition, metoprolol biodegradation consumes Mn(IV)DWTP during the 
removal process, probably releasing the propranolol that is adsorbed onto 
Mn(IV). The Mn(IV) reduced in this experiments is also higher than 
expected due to the presence of yeast extract. 
3.3.3 Anaerobic biodegradation of metoprolol with Fe(III) 
(1) Chemically synthesized Fe(III) and Fe(III)-citrate
Fe(III) is hypothesised as a suitable electron acceptor for anaerobic
biodegradation of pharmaceuticals, because it has been reported that the 
bacteria involved can use both Mn(IV) and Fe(III) [175]. We used both 
insoluble Fe(III)chem-synthesis and soluble Fe(III)-citrate to test the anaerobic 
biodegradation of metoprolol coupled to dissimilatory Fe(III) redcution. 
Our results show that Fe(III) is an alternative electron acceptor for 
dissimilatory Mn(IV) reduction, which can be coupled to biodegradation of 
metoprolol (Figure 3.4). Within 162 days, 57% metoprolol is degraded with 
Fe(III)chem-synthesis and about 52% with Fe(III)-citrate. Based on the 
theoretical calculation, when 1 mM metoprolol is totally mineralized, 85 
mM Fe(III) is reduced (Text S3.2, Table S3.3). During the anaerobic 
metoprolol biodegradation with Fe(III), 1.8 mM Fe(III) was reduced when 
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Fe(III)chem-synthesis is applied, and 8.8 mM Fe(III) is reduced when Fe(III)-
citrate is applied.  
Insignificant removal of metoprolol was found in the abiotic controls 
(<5%). This shows that the removal of metoprolol with two different types 
of Fe(III) occurs through biodegradation and both can be used by our 
inoculum that was adapted to Mn(IV). Previous studies have reported that 
some bacteria can use both Mn(IV) and Fe(III) as electron acceptor [175, 177]. 
Therefore, the inoculum adapted to Mn(IV) is also active with Fe(III), 
indicating that Mn(IV) and Fe(III) are exchangeable in application. 
 
 
FIGURE 3.4 Biodegradation of metoprolol with chemically produced Fe(III) hydroxides 
(Fe(III)chem-synthesis) (♦) and Fe(III)-citrate (▲). Experimental conditions: [Fe(III)]0=40 mM, 
[metoprolol]0=10 mg·L-1, pH 6.5 – 7.5, T= 30ºC. Error bars are the difference between 
duplicate  
 
In this study, the use of soluble Fe(III)-citrate is expected to result in 
more removal than insoluble Fe(III)chem-synthesis, because the soluble form is 
more accessible to bacteria. However, our results show no obvious 
difference between the soluble and insoluble Fe(III). Previous studies reveal 
that bacteria can directly transfer electrons from organic compounds to 
insoluble Fe(III) during dissimilatory Fe(III) reduction, without the 
formation of compounds that serve either as chelator or as the electron 
shuttle [175]. As a result, the solubility of Fe(III) then does not influence its 
use by bacteria. In addition, Fe(III)-citrate contains an additional carbon 
source, citrate, which is an easier degradable organic compound than 
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metoprolol. Results show that Fe(III) reduction during metoprolol 
biodegradation with Fe(III)-citrate is much higher than stoichiometrically 
needed for the degraded amount of metoprolol (Table 3.1). Based on the 
theoretical calculation, to remove 52% metoprolol from 10 mg·L-1 requires 
1.2 mM Fe(III). If the citrate is also taken into account and assuming it is 
totally removed, the Fe(III) required is increased to 721.2 mM. The higher 
Fe(III) consumption indicates that citrate is also used as electron donor in 
the reduction of Fe(III). Citrate will outcompete metoprolol for Fe(III), 
leading to less Fe(III) available for biodegradation of metoprolol.  
Even though the metoprolol removal with two Fe(III) is similar, the 
different intermediates formed in the processes are different (Figure S3.3). 
This indicates that the metoprolol biodegradation with two Fe(III) may be 
through different pathway. The reason could be that citrate also participates 
in the biodegradation of metoprolol, and/or that bacteria use soluble Fe(III) 
and insoluble Fe(III) in different ways. 
(2) Other Fe(III) types 
Inoculum obtained from the experiments with Fe(III)chem-synthesis was 
tested for its ability to use other insoluble Fe(III) types to remove metoprolol, 
such as Fe(III) from drinking water treatment plants or commercial Fe(III) 
compounds. In this study, Fe(III) from drinking water treatment plants 
(labelled as Fe(III)DWTP) and two commercial Fe(III)-based sorbents are 
selected because they are cheap, widely available, and theoretically suitable 
for bacteria in dissimilatory Fe(III) reduction. These Fe(III) compounds can 
be a good source for electron acceptors in anaerobic biodegradation of 
pharmaceuticals with Fe(III). Results show that in both biotic experiments 
and abiotic controls, the anaerobic metoprolol degradation is less than 10% 
after 62 days incubation, indicating no significant removal of metoprolol 
(Figure 3.5). 
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The insignificant removal of metoprolol with these three types of Fe(III) 
might be due to their semi-crystalline form instead of having an amorphous 
nature. Previous studies show that reduction rate using crystalline Fe(III) in 
dissimilatory Fe(III) reduction is much slower compared to amorphous 
Fe(III) [175]. In addition, the microbial inoculum is adapted to amorphous 
Fe(III), indicating that it could be less active with semi-crystalline Fe(III). 
As a results, no anaerobic metoprolol degradation via dissimilatory Fe(III) 
reduction is observed with these widely available Fe (III) forms. 
 
 
FIGURE 3.5 Degradation of metoprolol with Fe(III) from drinking water treatment plants 
(labelled as Fe(III)DWTP) and two Fe(III)-based sorbents, FerroSorp®Plus (labelled as 
Fe(III)FerroSorp®Plus), and FerroSorp®RW (labelled as Fe(III)FerroSorp®RW) within 62 days. 
Experimental conditions: [Fe(III)]0=40 mM, [metoprolol]0=10 mg·L-1, pH 6.5 – 7.5, T= 30ºC. 
Error bars are the difference between duplicate  
 
3.4 Conclusion 
Our study shows that anaerobic biodegradation coupled to 
dissimilatory Mn(IV) or Fe(III) reduction is promising to remove 
pharmaceuticals. Results show that dissimilatory Mn reduction with 
Mn(IV)chem-synthesis can remove 26% caffeine and 52% naproxen within 42 
days. Based on previous studies, both naproxen and caffeine can be 
efficiently removed under anaerobic conditions while the other selected 
pharmaceuticals are resistant to biodegradation. Mn(IV)DWTP granule can 
also be used to remove metoprolol and propranolol. After 72 days, an almost 
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complete removal of metoprolol, and 31% propranolol is obtained. The 
differences between the biotic groups and abiotic controls clearly show that 
biodegradation of two pharmaceuticals is important. 
Fe(III) can also be used as electron acceptor during anaerobic 
metoprolol biodegradation. Through anaerobic biodegradation, 57% 
metoprolol is removed with Fe(III)chem-synthesis and 52% with Fe(III)-citrate. 
Anaerobic metoprolol biodegradation with Fe(III)DWTP, Fe(III)FerroSorp®Plus, 
and Fe(III)FerroSorp®RW is insufficient, probably due to these semi-crystalline 
form instead of amorphous Fe(III).  
Yeast extract, citrate and other (metal complexing) organic components 
are electron-donor substrates that compete with pharmaceuticals for iron or 
manganese reduction, and may thereby inhibit de dissimilatory removal of 
pharmaceuticals. Care should be taken of competing organic substrates 
during removal of pharmaceuticals from waste water treatment plant 
effluents.  
In summary, anaerobic biodegradation coupled to dissimilatory Mn(IV) 
or Fe(III) reduction can be used for pharmaceutical removal. This 
pharmaceutical removal process is effective with different types of Mn(IV) 
and Fe(III), including some widely available Mn (IV) and Fe (III) forms 
such as Mn(IV) present in sludge waste originating from drinking water 
treatment plants. This study contributes to providing fundamental insight for 
a more sustainable pharmaceutical removal technology in wastewater 
treatment processes, as well as to understanding biotransformation of 
pharmaceuticals in the environment. 
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Chapter 4 
Anaerobic conditions are favourable for 
abiotic diclofenac removal from water with 
manganese oxides 
A modified version of this chapter is submitted as 
Liu, W.; Sutton, N. B.; Rijnaarts, H. H. M.; Langenhoff, A. A. M., Anoxic 
conditions are favourable for abiotic diclofenac removal from water with 
manganese oxides.  
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ABSTRACT  
This is the first study published addressing pharmaceutical removal under 
anaerobic conditions with MnO2. This study compares the abiotic removal 
of seven pharmaceuticals with reactive MnO2 particles in the presence 
oxygen (aerobic conditions) and in the absence of oxygen (anaerobic 
conditions). Due to the novelty of pharmaceutical removal under anaerobic 
conditions, the influence of phosphate buffer, pH, and MnO2 morphologies 
are also examined. Results show that over 90% of diclofenac are removed 
under anaerobic conditions. Additionally, we found that: (1) anaerobic 
conditions promote diclofenac removal with MnO2; (2) phosphate buffer 
affects the pharmaceutical removal efficiencies; (3) higher pharmaceutical 
removal is obtained at acidic pH compared to neutral or alkaline conditions; 
and (4) amorphous MnO2 removes pharmaceuticals better than crystalline 
MnO2. The pharmaceutical molecular structure and properties, MnO2 
properties especially reactive sites of the MnO2 surface, are important for 
degradation kinetics. This study provides a fundamental basis towards 
understanding pharmaceutical degradation with MnO2 under anaerobic 
conditions, and development of a cost-effective, sustainable technology for 
removal of pharmaceuticals from water. 
 
KEYWORDS: manganese oxides; abiotic pharmaceutical removal; in the 
absence of O2; pH effects; MnO2 morphologies; MnO2 reactivity 
mechanism 
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4.1 Introduction 
Discharging pharmaceuticals into the water cycle threatens the aquatic 
environment and drinking water resources. Already at low levels (ng·L-1 – 
μg·L-1) [280, 303], pharmaceuticals can be toxic to aquatic organisms [78, 149]. As 
a result, pharmaceuticals discharged to water systems are seen as a priority 
concern of environmental regulators, and the European Union has added one 
of them, diclofenac, to the "Watchlist" [60]. 
Pharmaceutical removal in conventional wastewater treatment is poor, 
due to the low biodegradability and limited sorption properties of many 
pharmaceuticals [319]. Advanced technologies such as ozonation or 
photodegradation successfully remove selected pharmaceuticals from water 
and wastewater [17, 95]. However, these technologies require more energy 
inputs and operational costs, in addition to often high construction and 
maintenance costs, and unknown environmental effects of formed 
intermediate compounds. 
A promising alternative method may be based on using manganese 
oxides (MnO2) to remove pharmaceuticals from water. MnO2 is a common 
oxidant in soil, sediment, and marine environments which include local 
environments with either presence of oxygen (aerobic conditions) or 
absence of oxygen (anaerobic conditions) [146, 276, 359]. Most studies using 
MnO2 to remove pharmaceuticals and other micropollutants are conducted 
under aerobic conditions [248]. Previous studies also show that 
pharmaceutical removal with MnO2 is more effective under acidic 
conditions [248]. Little is known about the abiotic removal of pharmaceuticals 
under anaerobic conditions with MnO2. Furthermore, the effect of oxygen 
on pharmaceutical removal is inconsistent in different studies. For example, 
oxygen can accelerate sulfamethazine oxidation by participation in the 
formation of intermediates [69], while for levofloxacin removal rates under 
aerobic and anaerobic conditions are indifferent [163]. Therefore, more 
studies are required to address pharmaceutical removal with MnO2 under 
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both aerobic and anaerobic conditions, and to improve the understanding of 
the removal mechanisms. From an application perspective, water treatment 
technologies commonly include aerobic and anaerobic steps. Investigating 
pharmaceutical removal under anaerobic conditions with MnO2 may extend 
the application of this technology. Additionally, applying anaerobic 
conditions can reduce the construction and operation cost of maintaining 
aerobic conditions in water treatment systems. 
Phosphate, pH, and MnO2 morphologies are known to affect the 
removal of organic compounds with MnO2 [69, 276, 352]. For example, various 
MnO2 morphologies have been tested to remove pharmaceuticals and other 
organic compounds, with amorphous MnO2 (birnessite) as most effective 
and most used [248]. However, little is known about how these parameters 
affect the removal process under anaerobic conditions. 
In this study, a series of batch experiments with pharmaceuticals were 
conducted under aerobic and anaerobic conditions simulating the conditions 
encountered in nature as well as in wastewater treatment facilities. Seven 
widely used pharmaceuticals were selected and tested in the experiments. 
The effects of oxygen, phosphate, pH, and MnO2 morphologies were studied 
to better understand the degradation processes involved and to optimize 
these towards the application of technology using reactive MnO2 for 
pharmaceutical removal.   
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4.2 Methods and materials 
4.2.1 Chemicals 
Caffeine, carbamazepine, diclofenac, metoprolol, naproxen, and 
propranolol were purchased from Sigma-Aldrich while ibuprofen was 
purchased from MP Biomedicals (detailed information in Table S4.1). Other 
chemicals were purchased from Sigma-Aldrich at 98% purity (for solids), 
or at HPLC or UPLC quality (for solvents). Pharmaceutical stocks were 
prepared with ultrapure water (18.2 MΩ·cm, TOC=18 ppb, Millipore, USA) 
and stored in amber glass bottles at -20℃. Other solutions were prepared 
with demineralised water (demiwater). Details are described in Text S4.1. 
4.2.2 MnO2 preparation 
Amorphous MnO2 was obtained by freshly synthesizing prior to 
experiments as described [152]. Briefly, equal amounts of MnCl2 and KMnO4 
were mixed, pH was adjusted to ~10 with NaOH, and MnO2 was washed by 
centrifugation (Text S4.2). Amorphous MnO2 was used in all experiments 
unless specification. Crystalline MnO2 was purchased from Sigma-Aldrich 
(Figure S4.1, S4.2). 
4.2.3 Batch experiments 
Glass bottles (125 mL) were filled with 50 mL MnO2 suspension (7 
mM) in demiwater. Aerobic experiments were prepared at atmospheric 
oxygen level. Experiments under anaerobic conditions were prepared in the 
anaerobic glovebox with anaerobic water and closed with a rubber stopper 
and aluminum cap before taking them out of the anaerobic glovebox. 
Outside the glovebox, the headspace was exchanged with 100% N2. All the 
experimental bottles were closed with rubber stoppers, crimped with 
aluminum caps, wrapped in aluminum foil to prevent photodegradation and 
incubated without shaking at 30℃.  
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Experiments were started by spiking bottles to achieve the final 
pharmaceutical concentration of 1 mg·L-1. Aliquots were collected, and 
reactions were quenched immediately for analysis by centrifugation (10000 
rpm for 10 min). Blank experiments without MnO2 were prepared and 
conducted simultaneously with each batch of experiments. Sample 
collection and preparation before analysis are detailed described in 
supplementary materials (Text S4.3).  
Experiments in 50 mM phosphate buffer with only diclofenac were 
conducted to compare the process under aerobic and anaerobic conditions. 
In addition, effects of pH and MnO2 morphologies under anaerobic 
conditions were investigated with phosphate buffer solutions at pH 4 – 5 
(4.5), pH 7.0, and pH 8 – 9 (8.5) (Text S4.1).  
4.2.4 Analysis 
The pharmaceutical analysis was conducted as described previously 
using an ultra-performance liquid chromatography with a diode array 
detector (UPLC, ultimate 3000, Thermo, USA) [95]. pH was determined by 
a pH meter (PHM210, MeterLab, Radiometer analytical). The Mn2+ analysis 
was conducted by an inductively coupled plasma spectrometer with optical 
emission spectroscopy (ICP-OES). MnO2 morphologies were characterized 
by X-ray diffraction. The MnO2 before and after the reaction with diclofenac 
and metoprolol was characterized via a Fournier-Transform Infra-Red 
spectrometer (FTIR, Bruker TENSOR 27). Details are described in 
supplementary materials (Text S4.3).  
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4.3 Results and discussion 
4.3.1 Pharmaceutical removal under aerobic versus 
anaerobic conditions 
In the absence of MnO2, no removal is observed for all seven 
pharmaceuticals within 24 hours under both aerobic and anaerobic 
conditions in all experiments (Table S4.2). In the presence of MnO2, 
metoprolol, propranolol, and diclofenac are removed within 24 hours in 
both demiwater (Figure 4.1(a) and (b)) and phosphate buffer (Figure 4.1(c)), 
while no removal is observed for the other four pharmaceuticals (Figure 
S4.3). Furthermore, the results show that anaerobic conditions promote the 
removal of diclofenac, while higher removal is observed under aerobic 
conditions for metoprolol and propranolol. Diclofenac removal efficiencies 
of 78% under anaerobic conditions and 59% under aerobic conditions were 
observed after 24 hours incubating a solution of mixed pharmaceuticals in 
demineralized water (Figure 4.1(a)). However, only 33% metoprolol was 
removed under anaerobic conditions compared to 69% under aerobic 
conditions. Similarly, 51% propranolol was removed under anaerobic 
conditions compared to 84% under aerobic conditions. Diclofenac 
degradation in a mixture together with other six pharmaceuticals (Figure 
4.1(a) was found to be lower than in a demiwater system which only 
diclofenac was present. Under anaerobic conditions, 92% diclofenac is 
removed with MnO2. While under aerobic conditions, 69% diclofenac 
removal is observed (Figure 4.1(b)). 
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TABLE 4.1 Initial removal rate (robs, init, mg·L-1 ·h-1, R2=0.80 – 0.97) and initial removal rate 
constant (kobs, init, h-1, R2=0.85 – 0.99) of pharmaceutical removal with MnO2 based on pseudo-
first-order in first 5 hours 
Experimental 
solution 
Matrix pH Compound 
robs, init kobs, init 
(10-2 mg·L-1·h-1) (10-2 h-1) 
Aerobic Anaerobic Aerobic Anaerobic 
Mixture of 
seven 
pharmaceutical 
Demiwater ~8.5 
Metropolol 7.39 2.98 a 9.21 3.18 
Propranolol 10.10 4.02 14.18 4.48 
Diclofenac 5.33 6.48 5.96 7.49 
Only diclofenac 
present in 
solution 
Demiwater ~8.5 Diclofenacb 4.70 9.06 5.56 18.13 
Only diclofenac 
present in 
solution 
50 mM 
PO43- 
buffer 
~7.0 Diclofenacb 10.48 8.73 57.32 16.60 
a Both robs, init and kobs, init were calculated within 4 hours 
b Both robs, init and kobs, init were calculated within 9 hours 
Our results show that anaerobic conditions promote (are favourable for) 
diclofenac removal with MnO2. In contrast, previous studies show either no 
effect or lower removal efficiencies under anaerobic conditions [14, 69, 361]. 
This unique result directs our further studies on the mechanism of 
pharmaceutical removal under anaerobic conditions with MnO2. In order to 
eliminate the effects of pH and ionic strength on pharmaceutical removal 
with MnO2 [69, 108], we control pH (~7) with 50 mM phosphate buffer and 
maintain the ionic strength (0.1 M) with NaCl. In further experiments with 
phosphate buffer, 90% of diclofenac is removed under anaerobic conditions 
while nearly complete degradation of diclofenac is observed under aerobic 
conditions (Figure 4.1 (c)). 
TABLE 4.2 Diclofenac removal efficiency under anaerobic conditions at different pH 
conditions with two MnO2 morphologies after 48 hours. Experimental conditions: [MnO2]0=7 
mM, [diclofenac]0=1mg·L-1, [ionic strength]=0.1 M 
MnO2 morphologies ~ pH 4.5 ~ pH 7.0 ~ pH 8.5 
Amorphous MnO2 100% 100% 71 % 
Crystalline MnO2 21% Not detected Not detected 
A pseudo-first-order model with initial incubation period was applied 
to analyze the removal kinetics (Table 4.1), as performed in previous studies 
under aerobic conditions [125, 359, 361]. Comparison of the initial removal rate 
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(robs, init) and the initial removal rate constant (kobs, init) of different 
pharmaceuticals shows that oxygen affects pharmaceutical removal with 
MnO2. In demiwater with the pharmaceutical mixture and with only 
diclofenac, diclofenac removal is accelerated under anaerobic conditions; 
metoprolol and propranolol removal rates are lower under anaerobic 
conditions. Furthermore, diclofenac was removed at the highest rate when 
dissolved as a sole compound in aerobic phosphate buffer containing MnO2. 
4.3.2 Influence of pH and MnO2 morphologies on diclofenac 
removal 
Pharmaceutical removal with MnO2 is affected by pH. Previous studies 
show that MnO2 morphologies also influence pharmaceutical removal [276]. 
However, our novel observation of diclofenac removal under anaerobic 
conditions with MnO2 indicate that the removal mechanisms of 
pharmaceuticals with MnO2 under anaerobic conditions might be different 
from removal under aerobic conditions. Therefore, it is important to 
investigate the effect of pH and MnO2 morphologies on diclofenac removal 
to understand the removal mechanism. We investigate the effect of pH and 
MnO2 morphologies using both amorphous MnO2 and crystalline MnO2 
under anaerobic conditions at pH ~4.5, pH~7.0, and at pH ~8.5 established 
with a 50 mM phosphate buffer. 
Diclofenac removal efficiencies with MnO2 under anaerobic 
conditions are inversely related to pH (Table 4.2). Within 48 hours, 
diclofenac removal under anaerobic conditions varies from 100% at around 
pH ~4.5 and pH ~7.0, to 70% at pH ~8.5 with amorphous MnO2. In contrast, 
diclofenac removal is notably lower with crystalline MnO2. Only 21% of 
diclofenac is removed with crystalline MnO2 at pH ~4.5. In the experiments 
carried out at pH ~7.0 and pH ~8.5, no removal is with crystalline MnO2.  
4.3.3 Discussion 
Under aerobic conditions, pharmaceutical removal can be accelerated 
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by oxygen [69]. However, this fails to explain why anaerobic conditions 
promote diclofenac removal when oxygen is not present to participate in the 
removal process (Text S4.4, Figure S4.4). There are different intermediates 
formed under aerobic and anaerobic conditions during diclofenac removal 
with MnO2 (Text S4.4, Figure S4.4). These intermediates have different 
adsorption affinities for the reactive sites on the MnO2 surface, which is 
possibly the key to explaining the differences between aerobic and 
anaerobic conditions. Based on the results, two factors appear to influence 
the efficiency of pharmaceutical removal and are elaborated below: (1) 
pharmaceutical molecular structure and chemical properties, and (2) the 
MnO2 properties. 
4.3.3.1 Pharmaceutical molecular structure and chemical 
properties 
The molecular structure and chemical properties of pharmaceuticals 
are important in organic compound removal with MnO2. Previous studies 
show that oxidation with MnO2 in the presence of oxygen involves cleavage 
of the C-N bond of the organic compound. Metoprolol and propranolol have 
C-N bonds, in which the N atom is bound to an alkyl group. These
compounds are similar to those tested in previous studies (Table S4.1, S4.3)
in which aerobic conditions promote the removal. This C-N bond cleavage
can result in the formation of radicals in the presence of oxygen [14, 69].
Oxidation of diclofenac involves hydroxylation and decarboxylation instead
of C-N cleavage [108], which is a different mechanism than that of metoprolol
and propranolol. This shows that the removal mechanism is closely related
to pharmaceutical molecular structure and chemical properties.
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The pharmaceutical’s properties are also affected by pH. Due to the 
low pKa of diclofenac (pKa =4.15), lower pH results in a less negatively 
charged compound. This leads to less electrostatic repulsion between 
diclofenac and MnO2, which is also negatively charged. As compared to the 
other two compounds, diclofenac has a higher affinity to adsorb at low pH 
onto MnO2 surface and therefore has a more favourable first step in removal 
with MnO2.  
4.3.3.2 MnO2 properties.  
The properties of MnO2 are affected by pH as well. At acidic pH, MnO2 
is also less negatively charged due to its isoelectric point, resulting in less 
electrostatic repulsion and better adsorption of organic compounds. In 
addition, the MnO2 redox potential increases from 0.76 V at pH 8.0, to about 
0.99 V at pH 4.0 [167]. Thus, the degradation reaction is energetically more 
favorable at lower pH. Both factors may lead to faster degradation, as shown 
in our study (Table 4.2). pH used in this experiment is at neutral pH, which 
was found unfavourable for oxidation of pharmaceuticals in previous 
studies [32, 93, 346]. In addition, there are less protons at the low redox potential 
of MnO2 at higher pH, which is crucial for the electron transfer from Mn(IV) 
to Mn(II). As a result, no removal of caffeine, carbamazepine, ibuprofen, 
and naproxen was observed in this study, while the removal efficiency of 
metoprolol and propranolol is low under both aerobic and anaerobic 
conditions. 
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FIGURE 4.2 The effects of phosphate on diclofenac removal with MnO2 under aerobic and 
anaerobic conditions. Solid lines are processes under both aerobic and anaerobic conditions; 
dashed lines are the processes only under aerobic conditions. (1) MnO2 removes diclofenac 
via oxidation and produces Mn(II) [65, 108]; (2) Mn(III) comes from MnO2 synthesis process 
[248]; (3) Mn(II) is oxidised to Mn(III) by O2; (4) Mn(III) from MnO2 was stabilized by 
Mn3(PO4)2 formed via Eq.1 [127]; (5) Mn(III) oxidises diclofenac and produces Mn(II) 
Different MnO2 morphologies have different properties affecting 
diclofenac removal. In our research, diclofenac removal is better with 
amorphous MnO2 than with crystalline MnO2, which is in line with 
previously reported findings [248, 276, 313]. Amorphous MnO2 particles are 
usually smaller than crystalline particles. Thus the amorphous MnO2 
particles have the larger surface area, which increases pharmaceutical 
removal. Unfortunately, due to the analytical limits, size analysis of 
amorphous MnO2 appeared technically not feasible (Text S4.5, Figure S4.5). 
In addition, amorphous MnO2 contains small amounts of Mn(III) which can 
increase MnO2 reactivity and oxidizing ability [248], thus promoting 
pharmaceutical removal even further.  
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In the presence of phosphate, diclofenac removal with MnO2 is better 
under aerobic conditions than that under anaerobic conditions. Using O2 to 
oxidize Mn(II) to Mn(III) is a thermodynamically favorable reaction. In the 
presence of phosphate buffer, phosphate can form Mn3(PO4)2 with Mn(II) 
from diclofenac oxidation (Equation 4.1) [127]. 
 3𝑀𝑀𝑀𝑀2+ +  2𝑃𝑃𝑃𝑃43− → 𝑀𝑀𝑀𝑀3(𝑃𝑃𝑃𝑃4)2 (4.1) 
 
Computations show that the chemical structure of Mn3(PO4)2 can 
stabilize Mn(III) and thereby facilitate Mn(II) oxidation to Mn(III) under 
aerobic conditions [127]. The Mn2+ analysis shows that the presence of higher 
Mn(II) concentrations in phosphate buffer than in demiwater, which we 
explain as a result of larger amounts of Mn(III) formed under aerobic 
conditions. More Mn(III) is likely the reason that more diclofenac is 
removed than under anaerobic conditions, as we observed (Figure 4.1) and 
mechanistically present in Figure 4.2. 
4.3.3.3 Reactive sites on MnO2 surface 
The adsorption of organic molecules onto a reactive metal oxide 
surface is found to be the key parameter dictating removal of many 
organic compounds, and specifically to the reactive sites on MnO2 
surface [93, 346, 362]. Our results with the mixed pharmaceutical solution 
in the demiwater show competition for reactive sites between 
diclofenac and the other different pharmaceuticals. This is evidenced 
by the lower diclofenac removal in the presence of other 
pharmaceuticals (Figure 4.1(a), (b)).   
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Based on our FTIR results, there was no obvious disappearance of 
reactive sites during diclofenac removal with MnO2 under both aerobic 
and anaerobic conditions (TEXT S4.6, Figure S4.6), possibly due to a 
relatively high concentration of MnO2 in the experiment. However, it 
is clearly that the FTIR spectrums are different between the MnO2 
before and after reacting with diclofenac, especially under anaerobic 
conditions. This indicates that the intermediates from diclofenac 
change the MnO2. This change may contribute to the better diclofenac 
removal with MnO2 under anaerobic conditions. 
In phosphate buffer, phosphate can reduce the diclofenac removal 
by being adsorbed onto the MnO2 surface and competing with DFC for 
the reactive sites of MnO2 [352]. Consequently, although the lower pH in 
phosphate buffer should promote diclofenac removal (pH 7 in buffer 
versus pH 8 – 9 in demiwater), diclofenac removal is better in 
demiwater because MnO2 reactive sites are not blocked by phosphate 
(Table 4.1). However, similar removal efficiencies and kinetics in 
demiwater and phosphate buffer under anaerobic conditions are 
observed (Figure 4.1). This indicates there is a mechanism promoting 
diclofenac removal in phosphate buffer, which competes with the 
inhibition by phosphate adsorbing and occupying the reactive sites on 
MnO2 surface. From previous studies, it is known that Mn(II) can 
occupy reactive sites on MnO2 surface and then inhibit pharmaceutical 
removal [93, 346]. Our removal results in phosphate buffer show that 1.54 
μM Mn2+ was generated under aerobic conditions while 2.16μM was 
generated under anaerobic conditions. Less Mn(II) under aerobic 
conditions resulted in possibly less formation of Mn3(PO4)2 via Eq.1, 
which presumably lead to more available reactive sites for diclofenac 
removal. Under anaerobic conditions, the balance of these promoting 
and inhibiting effects by adsorbing phosphate leads to similar 
diclofenac removal in demiwater and phosphate buffer. 
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4.4 Conclusion 
In conclusion, this study addresses the gap of understanding 
pharmaceutical removal in the absence of oxygen (anaerobic conditions) 
with MnO2. Anaerobic conditions show higher diclofenac removal 
compared to aerobic conditions in demiwater. In phosphate buffer, aerobic 
conditions resulted in about 10% more diclofenac removal. pH and MnO2 
morphologies influence the removal process and its efficiency. Our results 
in both demiwater and phosphate buffer suggest that the process is 
promising in treating water and wastewater containing pharmaceuticals. The 
results show that amorphous MnO2 is the most suitable material for further 
research and application, and the most optimal and applicable conditions are 
at neutral pH in anaerobic systems. By using a more favourable pH (acidic 
pH), the removal of all the pharmaceuticals can be expected under anaerobic 
conditions. To our knowledge, this is the first study discussing 
pharmaceutical removal with MnO2 under anaerobic conditions. Using 
anaerobic conditions is less energy-consuming compared to aerobic 
conditions (aeration), and Mn can be regenerated and recycled via a 
biological or chemical process [126, 301]. Overall, this study makes a  
contribution to (1) understanding pharmaceutical removal in the absence of 
oxygen; (2) improving the knowledge of pharmaceutical removal 
mechanisms with MnO2; and (3) providing fundamental insight into a 
MnO2-based process which may lead to a more sustainable technology for 
pharmaceutical removal.  
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Chapter 5 
Application of manganese oxides under 
anaerobic conditions to remove diclofenac 
from water 
A modified version of this chapter is submitted as 
Liu, W.; Langenhoff, A. A. M.; Sutton, N. B.; Rijnaarts, H. H. M., 
Application of manganese oxides under anoxic conditions to remove 
diclofenac from water. 
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ABSTRACT 
This study investigates diclofenac (DFC) removal with manganese oxides 
(MnO2) under anaerobic conditions (absence of oxygen). DFC removal is 
quantified in terms of efficiency and observed initial kinetics (kobs, init) to 
investigate the effects of temperature, MnO2 amount, and co-solutes. 
Overall, DFC removal and kobs, init both increase upon changing temperature 
from 10 to 30ºC and both decrease after further increasing temperature to 
40ºC. Increasing the amount of MnO2 relative to diclofenac improve 
degradation, as this provides more reactive surface sites for DFC 
conversions. However, increasing the molar ratio of MnO2 and DFC from 
2200:1 to 8900:1 does not further increase diclofenac removal. The presence 
of metal ions inhibits DFC removal, possibly because the ions adsorb onto 
the reactive sites at the MnO2 surface and compete with DFC. Phosphate 
has a diverse effect on diclofenac degradation: low concentrations inhibit 
and high concentrations promote removal. The presence of humic acids 
significantly promotes diclofenac removal, which is probably caused by 
quickly absorbing DFC and attaching to MnO2 surface. Also, humic acids 
can bind the Mn2+ produced during the DFC removal. These findings are a 
first step towards further developing pharmaceutical removal technology 
using MnO2 under anaerobic conditions.  
 
KEYWORDS: manganese oxides; abiotic pharmaceutical removal; 
anaerobic condition; temperature; MnO2 amount; co-solutes 
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5.1 Introduction 
Diclofenac ([2-(2,6-Dichloroanilino)phenyl]acetic acid, DFC) is a 
commonly used pharmaceutical known to have the highest acute toxicity to 
wildlife among the non-steroidal anti-inflammatory drugs [174, 279]. In Europe, 
the mean DFC consumption is around 1300 μg⋅capita-1⋅d-1 [128]. As a result, 
DFC has been detected in surface water, groundwater, and even in drinking 
water in the range of 0 – 1000 ng·L-1 [304]. Due to its toxic effects to the 
environment and ecosystem, the European Union (EU) has added DFC into 
the "Watchlist" [60]. The European Community suggests DFC concentration  
for the environmental quality threshold for good water quality a value of 
100 ng⋅L-1 (annual average) [56]. Various technologies can remove DFC, such 
as advanced oxidation processes like photo-degradation, or algae treatment 
systems, but these technologies often either produce toxic intermediates or 
are too costly [49, 170, 174].  
Using manganese oxide (MnO2) to remove pharmaceuticals can 
achieve high removal efficiencies and may produce less and lower amounts 
of toxic intermediates [32, 108]. Our previous study showed that anaerobic 
conditions (absence of oxygen) are favorable for DFC removal with MnO2, 
opening the way to a new cost-efficient and sustainable pharmaceutical 
removal process based on applying MnO2 under anaerobic conditions, not 
yet studied by others [172]. In order to develop this process into an applicable 
technology, a number of operational parameters were studied, namely 
temperature, the amount of MnO2, and the presence of co-solutes (metal 
ions, phosphate, humic acid). 
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Reactions between MnO2 and organic compounds are endothermic, 
and therefore increasing temperature can accelerate the rates of the removal 
processes [32, 260]. However, observed initial rate constant of oxytetracycline 
removal with MnO2 under aerobic conditions is reported to be lower at 40ºC 
than at 5 to 30ºC [260]. These contradicting results to theory and the lack of 
investigations under anaerobic conditions lead to the necessity of further 
investigating temperature effects. From an application perspective, the 
results will partially determine the applicability of MnO2 technologies in 
different seasons and climates.  
Another important parameter in the application is the amount of MnO2, 
which can be expressed as the molar ratio between the pharmaceutical(s) 
and MnO2. Previous studies show that increasing the ratio between MnO2 
and chlortetracycline in the range of 4:1 to 32:1 leads to faster removal [32]. 
However, no significant change is observed in triclosan, carbadox, and 
ciprofloxacin removal with MnO2 when the ratio changes from 10:1 to 
300:1 [359]. In addition, the ratios studied previously are usually low while 
they can be much higher in application due to the low concentration of 
pharmaceuticals. From an application perspective, optimizing MnO2 
amount can decrease operation costs, by applying minimum amounts of 
MnO2 at maximum DFC removal.  
Co-solutes in water including metal ions, anions (like phosphate), and 
organic compounds are commonly observed. The EU allows 3.57 μM iron 
and 0.91 μM manganese in drinking water [59]. In urban wastewater effluent, 
the phosphate concentration should be < 2 mg P⋅L-1 while the organic 
compounds (expressed as Chemical Oxidation Demand, COD) are allowed 
at 125 mg⋅L-1 based on EU regulation [58]. All these co-solutes can affect 
pharmaceutical removal with MnO2 in WWTP effluents under aerobic 
conditions. Previous studies under aerobic conditions showed that 
pharmaceutical removal could be inhibited by metal ions and phosphate 
(PO43-) [32, 167] while humic acid representing organic matters can both 
promote and inhibit this process [132, 167]. However, none of these parameters 
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are investigated under anaerobic conditions. In this study, four metal ions 
(Mn2+, Ca2+, Mg2+, and Fe3+), PO43-, and different concentrations of humic 
acid are selected to investigate the effects of co-solutes on the application 
of MnO2 under anaerobic to remove DFC. 
In this study, we investigate the efficiencies and reaction kinetics of 
DFC removal from water by MnO2 under anaerobic conditions. The effects 
of temperature, MnO2 amount, and co-solutes were investigated to evaluate 
the application potential and optimal conditions. Removal mechanisms 
under anaerobic conditions are affected by the pharmaceutical chemical 
structure and properties of both pharmaceuticals and MnO2 [69, 172]. The 
results provide the basis for developing a new treatment technology for 
removal of trace organic contaminants from WWTP effluent.  
5.2 Materials and methods 
5.2.1 Chemicals 
Diclofenac sodium salt (DFC) was purchased from Sigma-Aldrich 
(Table 5.1). Other chemical reagents used in the experiments were 
purchased from either Sigma-Aldrich or Merck KGaA (Germany). All the 
chemicals had > 97% purity. The liquid used in these experiments was at 
either high performance liquid chromatographic grade or ultra-performance 
liquid chromatographic grade. Millipore water purification system was used 
to prepare ultrapure water (18.3 MΩ⋅cm, TOC=18 ppb). Anaerobic water 
was prepared by boiling demineralized water (demiwater) for 5 min and 
cooling under N2-flow to the room temperature. All solutions were prepared 
with anaerobic water unless specified otherwise. DFC stock solution was 
prepared in ultrapure water to reach a final concentration of 157 µM in a 50-
mL amber glass bottle. This stock was stored at -20ºC to avoid potential 
decomposition. Humic acid (HA) was purchased from Sigma-Aldrich 
(product No. 53680). HA stock solution was prepared at a final 
concentration of 1000 mg·L-1 in anaerobic water with 1 – 3 drops of 1M 
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NaOH. This stock was stored in a 50 mL glass bottle at 4ºC to avoid 
decomposition.  
 
TABLE 5.1 Chemical structure and properties of diclofenac sodium (DFC)a 
 
CAS No.  15307-79-6  
Empirical Formula C14H10Cl2NNaO2 
Molecular Weight  318.13 g⋅mol-1 
pKa 4.15 
logKow 1.13 
Solubility in water 50mg⋅mL-1 
a The data are collected from Sigma-Aldrich and literature [308]  
 
5.2.2 Synthesis of manganese oxides 
Manganese oxides (MnO2) were freshly synthesized by a modified 
method as previously described [172]. In brief, equal volumes of 0.4 M MnCl2 
and 0.4 M KMnO4 were mixed and adjusted to pH 10 with 1M NaOH. The 
MnO2 was washed six times with anaerobic demiwater via centrifugation 
(15 min at 5000 rpm) and decanting. MnO2 was stored at 4ºC as a suspension 
with N2 headspace and diluted to an appropriate concentration before using. 
5.2.3 Experimental setup 
Batch experiments were prepared under anaerobic conditions in 125 
mL glass bottles. All bottles were sealed with rubber stoppers and aluminum 
crimp-caps, settled at 30ºC without shaking, and covered with aluminum 
foil to avoid photodecomposition. The pH was maintained at 7 for all 
experiments with a 10 mM MOPS (4-morpholinepropanesulfonic acid) 
buffer solution. Sodium chloride (NaCl) was added to adjust the ionic 
strength (I=0.01M). The final concentration of MnO2 in the bottle was 7 mM. 
The 50 ml buffer containing NaCl was added into the experimental bottles. 
The headspace of all bottles was exchanged with N2 to keep the system 
anaerobic.   
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The experiments were started by adding 0.25 – 1 mL DFC stock 
solution (157 µM) into the experimental bottles. All the experiments were 
carried out in triplicate and lasted for 33 hours in most cases. 1.2 mL mixture 
samples were taken regularly during the experimental period. The samples 
were centrifuged immediately at 10000 rpm for 10 min. The supernatant 
was collected and stored at -20ºC until analysis. Sorption of DFC onto MnO2 
were not taken into account because it is insignificant based on previous 
studies [65, 172], but it is still an important removal mechanism.  
Control experiments without MnO2 were prepared and conducted 
simultaneously with each batch of reactions. The effect of temperature was 
investigated by conducting the experiments at 10, 20, 30, or 40ºC. The effect 
of MnO2 amount was investigated by applying different molar ratio between 
MnO2 and DFC from 480:1 to 8900:1 at 20ºC. The effect of co-solutes was 
investigated at 30ºC with different concentrations of metal ions (Mn2+, Ca2+, 
Mg2+, Fe3+ at 0.1 and 0.1 mM), the anion (PO43- at 0.5, 1, and 116 mgP⋅L-1), 
and dissolved organic compound (HA at 5, 10, 15, and 25 mg⋅L-1). In the 
experiments with HA, DFC was added before adding HA. Samples were 
taken before and after adding HA at the beginning of the experiments.  
5.2.4 Analysis 
DFC was measured by ultra-performance liquid chromatography with 
a diode array detector (Ultimate 3000, Thermo co. Ltd.). 10 μL of samples 
were automatically injected into a CSH phenyl-Hexyl column (1.7 μm, 130 
Å, 2.1 × 150 mm, Waters co., USA). The details of analytical methods and 
setting of the machine were described previously [95, 172]. 
Phosphate concentration was analyzed by colorimetric method using 
cuvettes from Hach Lange (LCK 349). All metal ions were analyzed by an 
inductively coupled plasma atomic emission spectroscopy (ICP-OES, 
Perkin Elmer Instruments, USA). pH was determined by a pH meter 
(PHM210, MeterLab, Radiometer Analytical).  
106 
 
5.2.5 Kinetics study  
In literature, different models have been used to describe organic 
compound removal with MnO2: pseudo-first-order model, pseudo-first-
order model with data from the first several hours of the experiments, 
pseudo-second-order model, and mechanism-based kinetics models [32, 260, 
359]. The pseudo-first-order kinetic model has been used to evaluate the 
reaction kinetics of micropollutants and other organic compounds with 
MnO2 [125]. However, in experimental results deviation from this model after 
a certain reaction time was also reported. To better predict long-term 
kinetics of organic compound removal with MnO2, the pseudo-second-order 
model was used [32]. The pseudo-second-order model usually gave a better 
fit during the long period. The mechanism-based model was proposed to fit 
data obtained in long-term experiments. Rubert and Pedersen [260] developed 
the mechanism-based kinetics model to better describe oxytetracycline 
removal with MnO2. Similarly, Zhang, Chen and Huang [359] described 
another kinetic model based on the removal mechanism to describe 
antibacterial agent removal with MnO2. In this study, all four models were 
validated with the results obtained at 30ºC with 7 mM MnO2, 3.14 µM DFC, 
and no co-solutes.  
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5.3 Results and discussion 
5.3.1 Kinetic results 
Our results show that diclofenac (DFC) can be removed by applying 
MnO2 under anaerobic conditions. The pseudo-first-order model fits the 
data poorly (R2=0.84) while the other three models fit the data better and are 
useful for evaluating our kinetic studies (R2=0.96 – 0.99) (Text S5.1, Table 
S5.1, Figure S5.1,). The results show that anaerobic MnO2 mediated DFC 
removal follows a two-stage kinetic process under all experimental 
conditions. Most DFC conversion is obtained in the first 9 hours (following 
the pseudo-first-order reaction) and only about 10% DFC removal is 
obtained in the subsequent 24 hours (from t=9 h to t=33 h, following the 
pseudo-zero-order reaction). Therefore, the pseudo-first-order model with 
data from the first 9 hours was used to calculate the observed removal rate 
constants (kobs,init) (Table 5.2). Without MnO2, no DFC removal is observed 
(Text S5.2, Table S5.2, Figure S5.2).  
5.3.2 Effect of temperature 
Results show that the application of manganese oxides (MnO2) to 
remove diclofenac (DFC) under anaerobic conditions is generally an 
endothermic process (Table 5.2, Figure 5.1). DFC removal increases from 
85 to 90%, and the kobs,init increases from 0.14 to 0.19 h-1, when increasing 
the temperature from 10 to 30ºC. However, when the temperature is further 
increased to 40ºC, both removal and kobs, init drop dramatically to respectively 
38% and 0.04 h-1 (Figure 5.1, Table 5.2). When the temperature is 
subsequently reduced from 40 to 20ºC, only a slight increase in total 
removal is observed and kobs, init remained low. 
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At 40ºC, MnO2 particle aggregation is observed (Figure S3(a-d), 
Figure S5.4). To investigate whether this aggregation plays a role in the 
unexpected drop of DFC removal at 40ºC, an additional experiment was 
performed (Figure 5.1, dashed line). The experiment was started at 40ºC, 
but the temperature was changed to 20ºC t=9 h. The temperature of the 
bottles dropped to 20ºC within 1 hour. Results show that only 22% DFC is 
removed from t=9 h to t=33 h, which is lower than the 48% DFC removed 
in this time period if the experiment is started at 20ºC. The results show that 
the process is irreversible. 
 Aggregation of MnO2 particles was observed at 40ºC which can 
decrease the amount and availability of reactive surface sites on MnO2 for 
DFC removal. This may be a reason for the reduced DFC removal at high 
temperature. The aggregation may be caused by two processes: Ostwald 
ripening and/or aging. Ostwald ripening, also called coarsening or 
competitive growth, occurs in the suspension where large particles grow at 
the cost of small particles [246]. Amorphous particles (or small crystals) 
dissolve and re-precipitate on the largest crystals initially present. As a result, 
the amorphous particles or small crystals grow to relatively large crystals 
[229]. Ostwald ripening is promoted by elevated temperature, as demonstrated 
in previous studies [188, 284]. The aging process is the physical change of 
minerals over time. Aggregation of MnO2 is observed to be a fast process at 
40ºC (hours – days), and a slow process at 20ºC (6 months, the duration of 
our experiments, Text S5.3, Figure S5.3 (e, f)). This indicates that MnO2 
aging process is accelerated when changing the temperature to 40ºC, which 
quickly changes MnO2 morphology irreversibly [293]. As a result, active 
MnO2 precipitates into a more stable form, leading to less DFC removal [208], 
and the reactivity cannot be restored when changing again to lower 
temperatures, i.e. 20ºC (Figure 5.1, dashed line). Overall, the aggregation of 
MnO2 particles leads to less DFC removal. 
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FIGURE 5.1 DFC removal by applying MnO2 under anaerobic conditions at different 
temperatures. The solid lines represent the experiments maintained at one temperature while 
the dashed line represents the experiment in which the temperature changed. Experimental 
conditions: [MnO2]0=7 mM, [DFC]0=3.14 µM, pH~7, I=0.01 M. Error bars are standard 
deviations of triplicate experiments 
 
5.3.3 Effect of MnO2 amount 
The amount of MnO2, expressed as the molar ratio between MnO2 and 
DFC, determines the efficiency of DFC removal under anaerobic conditions. 
Results show that a higher molar ratio between MnO2 and DFC leads to 
higher and faster removal (Table 5.2, Figure 5.2). DFC removal decreases 
from 52% at a molar ratio of MnO2:DFC of 480:1 to 87% at a molar ratio 
of 2200:1, while the kobs,init increases from 0.05 to 0.16 h-1. Further 
increasing the amount of MnO2 to DFC/MnO2 changes from 2200:1 to 
8900:1, both the removal efficiency and kobs,init are slightly decreased and 
the kobs,init values levels off to 0.13 h-1.  
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FIGURE 5.2 DFC removal by applying different amounts of MnO2 (molar ratio 
[DFC]0/[MnO2]0) under anaerobic conditions. Experimental conditions: 20ºC, pH~7, I=0.01 
M. Error bars are the standard deviation of triplicate experiments
When the MnO2 particles are applied in a reactor for treating WWTP 
effluent, the amount of MnO2 is in the mM range while the concentrations 
of DFC and other pharmaceuticals are extremely low, in the nM to μM range. 
Therefore, high ratios between MnO2 and DFC were used in this study to 
mimic those reactor conditions. Results show that increasing the amount of 
MnO2 improves pharmaceutical removal with MnO2. Increasing the amount 
of MnO2 provides relatively more reactive surface sites. As a result, DFC 
can better attach to the MnO2 surface, the first step in its removal. After 
adsorprion, the DFC is removed via chemical oxidation. During this process, 
increasing surface reactive sites will not improve the oxidation of DFC. In 
addition, due to the properties of pharmaceuticals and MnO2, adsorption will 
not be improved by simply increasing the reactive surfaces sites because of 
increasing MnO2 amount. As a result, both the removal and kobs,init are stable 
when the MnO2 : DFC changes from 2200:1 to 8900:1. 
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5.3.4 Effect of metal ions 
Under anaerobic conditions, inhibition of DFC removal is observed in 
the presence of four metal ions at two different concentrations (Table 5.2, 
Figure 5.3). In the absence of metal ions, after 33 hours, 90% of the DFC is 
removed. In the presence of 0.1 mM Mn2+, Ca2+, Mg2+, or Fe3+, 80 – 84% of 
DFC is removed. Results also show that Ca2+ has the least inhibition on DFC 
removal, with a decrease in kobs,init from 0.19 to 0.15 h-1. For the other metal 
ions, kobs,init decreases to about 0.12 h-1. Increasing the concentration of metal 
ions to 1 mM results in further inhibition effects in the order of “metal free” 
< Fe3+ < Ca2+ ≈ Mg2+ < Mn2+. Only 58% of DFC is removed in the presence 
of Mn2+, followed by 77% with Mg2+ and 74% with Ca2+. The least 
inhibitory effect is observed in the presence of Fe3+ with about 88% of DFC 
removed, which is close to the removal (90%) in the absence of metals. The 
inhibition in the kinetics follows the same order as the removal efficiency, 
namely “metal free” < Fe3+ < Ca2+ ≈ Mg2+ < Mn2+ (Table 5.2).  
The inhibitory effect of metal ions is most likely due to competition by 
ions with DFC for reactive surface sites on MnO2. Since the pH 
characterizing the point-of-zero-charge of MnO2 (birnessite) is 0.97 [299], 
MnO2 is negatively charged at neutral pH. Similarly, DFC is also negatively 
charged (pKa=4.15) under the experimental conditions. Therefore, the 
positively charged metal ions are more easily adsorbed onto MnO2 surface 
via electrostatic interactions than DFC via forming complex, resulting in 
fewer reactive surface sites available for DFC removal. The adsorption of 
metal ions onto MnO2 is related to the radius of hydrated ions [83]. At low 
concentration (0.1 mM), abundant reactive sites for DFC removal are 
present, even though some reactive surface sites are used by metal ions. 
Therefore, there is little difference between metal ions and their inhibition 
of DFC removal. However, at a higher concentration (1 mM), the inhibition 
effect of metal ions follows the order of Mn2+ > Ca2+ ≈ Mg2+ > Fe3+. This 
order is roughly the same as the adsorption affinity described previously [209]. 
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The least inhibition of Fe3+ is probably because the radius of Fe3+ (0.064 nm) 
is the smallest among the four metal ions (Mn2+ : 0.080 nm, Ca2+ : 0.103 nm, 
Mg2+ : 0.070 nm). It is reported that the decreasing ionic radius will decrease 
adsorption affinity [269]. In addition, even though Fe3+ was added as ion into 
the bottle, some of them will precipitate at pH 7 in the experiments, which 
also decreases the inhibition effect of Fe.  
FIGURE 5.3 DFC removal by applying MnO2 under anaerobic conditions in the presence of 
different metal ions at (a) 0.1 mM; and (b) 1 mM. Experimental conditions: [MnO2]0=7 mM; 
[DFC]0=3.14 µM, 30ºC, pH~7, I=0.01 M. Error bars are standard deviations of triplicate 
experiments 
5.3.5 Effect of phosphate 
Phosphate (PO43-) is a common pollutant in wastewater which affects 
the removal of micropollutants including pharmaceuticals and other organic 
compounds with MnO2 [32, 85, 248]. Of the studies carried out under aerobic 
conditions, a limited number of studies have looked into the effects of PO43-, 
and no studies are reported for anaerobic conditions [32, 248]. Therefore, we 
investigated the effects of phosphate (PO43-) on the application of MnO2 
under anaerobic conditions to remove DFC (Table 5.3). At low PO43- 
concentration (< 1 mg P⋅L-1 ), DFC removal decreases from 76% with no 
PO43- to 46% at 0.5 mg P⋅L-1. When the PO43- concentration further increases 
to 1 mg P⋅L-1, DFC removal increases slightly to 54%. Complete DFC 
removal is obtained when the concentration is 116 mg P⋅L-1. 
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TABLE 5.3 DFC removal by applying MnO2 under anaerobic conditions in presence of 
phosphate at different concentrations after 33 hours. Experimental conditions: T=30 ℃, 
[MnO2]0 =7 mM; [DFC]0=3.14 µM, pH~7, I=0.1 M 
PO43- (mg P⋅L-1) DFC Removal 
0 76% 
0.5 46% 
1 54% 
116 100% 
 
PO43- can adsorb onto the MnO2 surface, which decreases the reactive 
surface sites for DFC removal [228]. On the other hand, PO43- can decrease 
the inhibition effects of Mn2+ generated from DFC removal by forming 
Mn3(PO4)2 [127]. This mitigates inhibition of DFC removal by Mn2+, leading 
to higher conversion efficiencies at higher PO43- levels. In addition, the 
structure of Mn3(PO4)2 can help in Mn(III) stabilization. As Mn(III) is a 
more active oxidant than Mn(IV), stabilization of Mn(III) by PO43- also 
results in enhanced DFC removal. When the PO43- concentration is low, the 
inhibition effect of PO43 on DFC removal is dominant, resulting in lower 
DFC removal efficiencies. However, increasing PO43- concentration leads to 
a decreasing inhibition effect of Mn2+ and even a stimulation effect due to 
Mn(III) stabilization resulting in more DFC removal.  
5.3.6 Effect of humic acid 
Humic acid (HA), chosen as a representative of organic matter, 
significantly promotes DFC removal under anaerobic conditions (Table 5.4). 
Based on the fast DFC removal observed in the presence of humic acid (HA) 
in a pre-test (data are not shown), initial DFC concentration was increased 
to 5.57 µM. Even when concentration of HA is only 5 mg·L-1, 80% DFC is 
removed within 1 hour. When HA concentration increases from 10 mg·L-1 
to 20 mg·L-1, DFC removal increases from 87 to 96% within 1 hour. 
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TABLE 5.4 DFC removal by applying MnO2 under anaerobic conditions at different humic 
acid (HA) concentrations. Experimental conditions: [MnO2]0=7 mM; [DFC]0=5.57 µM, 
30 ℃, pH~7, I=0.01 M 
HA (mg·L-1) t=0 h, no HA t=0 h, with HA t=0.5 h t=1 h 
0a 0% 0% n.a.b 25% 
5 0% 33% 71% 80% 
10 0% 19% 76% 87% 
15 0% 48% 90% 95% 
20 0% 75% 91% 96% 
a [DFC]0=3.14 µM 
b n.a.= not analysed 
In this study, DFC removal is promoted in the presence of HA. Under 
aerobic conditions, it is reported that HA can form a complex with Mn2+ 
produced from MnO2 during DFC removal [248]. Thus the strong binding 
ability of HA leads to more attractive sorption/complexation sites for Mn2+ 
than MnO2 reactive sites, thus reducing blockage of the reactive surface site 
by Mn2+. As a result, more sites are made available for DFC removal in the 
presence of HA.  
5.3.7 Application potential 
Applying MnO2 under anaerobic conditions to remove DFC is a 
promising and efficient process. This study presents basic boundary 
conditions for application, providing the first step towards transferring this 
process from the lab into a feasible technology. Based on the results, the 
optimal conditions of applying MnO2 under anaerobic conditions to remove 
DFC will be neutral pH, moderate temperature (10 – 30ºC), MnO2:DFC 
ratio ≥ 2200:1, no metal ions, that may be compensated by the presence of 
organic matter (humic acids), and no or very high concentration of PO43- , 
namely ≥ 116 mg P⋅L-1.  
Experiments varying the temperatures show that DFC removal 
efficiency is high and stable in the range 10 – 30ºC. In most temperate and 
subtropical climate areas, the water or wastewater temperature is within this 
range all the year round. Therefore, no extra heating or temperature-control 
systems are necessary, leading to less cost in construction and operation.  
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Supplying MnO2 during this process is another potential cost for 
operation. As mentioned in this paper, amount of MnO2 needed in the 
application can be high under both aerobic and anaerobic conditions due to 
the low pharmaceutical concentrations and possible reactor form (like bed 
filter). In this study, results provide information on optimizing MnO2 dosage 
based on pharmaceutical removal. These results show that the application 
of MnO2 at a certain amount is possible to maintain the high pharmaceutical 
removal efficiency for a long time.  
We studied the effects of typical co-solutes to assess the application of 
this process both in drinking water treatment and in wastewater treatment 
processes. The four selected metal ions are all ubiquitously present in the 
aquatic environment, especially in drinking water. The two concentrations 
tested in this study are at a similar level in drinking water based on World 
Health Organization [340, 341] and EU [59]. In addition, Mn2+ will be produced 
in the process, and this has the strongest inhibition effect among the four 
metal ions. Therefore, incorporation of metal removal processes and 
pharmaceutical removal with MnO2 will be a wise option in application.  
Both PO43- and organic compounds, like HA, are commonly observed 
co-solutes in wastewater. The diverse effects of PO43- on DFC removal 
indicate that the PO43- should be taken into account in design and operation 
of full application technologies. HA can promote DFC removal. In addition, 
the HA can bind the metals including Mg, Ca, and Mn. This reduces the 
inhibition of metal ions on pharmaceutical removal with MnO2. As a result, 
the application of manganese oxides under anaerobic conditions as a tertiary 
treatment has advantages in the application. The organic matter remaining 
after wastewater treatment processes contain often high levels of HA and 
may, therefore, promote DFC removal. 
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5.4 Conclusion 
The application of manganese oxides (MnO2) under anaerobic 
conditions to remove diclofenac (DFC) is effective. Compared to 
pharmaceutical removal technologies under aerobic conditions, anaerobic 
conditions do not require aeration systems to ensure oxygen supply. This 
decreases the costs of construction and operation. The results indicate that 
the optimal control of the MnO2 properties, especially the MnO2 reactive 
surface sites, are important in DFC removal under anaerobic conditions. 
Based on the experimental results, the optimal operational conditions are 
neutral pH, moderate temperature (10 – 30ºC), MnO2/DFC ratio in the range 
2200:1 – 8900:1, no metal ions, no or high concentration of PO43-, and in 
the presence of humic acids. This study is the first step towards translating 
the process into the application. Results show the diverse effects of 
temperature, MnO2 dosage, and phosphate on the DFC removal efficiency 
and the observed initial reaction rate constant (kobs,init). While there is 
obvious inhibition by metal ions, the significant promotion of humic acid to 
DFC removal may be used to compensate for this inhibitory effect, 
including mitigating the inhibitory effect of Mn2+ formed during the process. 
In addition, Mn2+ produced in this process can be oxidized back to MnO2 
using permanganate, manganese oxidizing bacteria, or other oxidation 
processes. The agents, used in the re-oxidation of Mn2+ to MnO2, can also 
remove Pharmaceuticals [67, 101]. The cycling of Mn decreases the 
concentration of Mn2+ in the effluent and recovers valuable manganese for 
reuse. 
In summary, anaerobic MnO2 mediated removal of pharmaceuticals 
from water is a potentially interesting, sustainable and promising 
technology. Therefore we plan to extend our future research to 
pharmaceuticals other than DFC, and to develop the technology further to 
scaling up and application.  
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Chapter 6 
Biological regeneration of manganese (IV) 
using oxygen and iron (III) using nitrate for 
anaerobic metal oxide mediated removal of 
pharmaceuticals from water 
A modified version of this chapter is in preparation for publication as 
Liu, W.; Langenhoff, A. A. M.; Sutton, N. B.; Rijnaarts, H. H. M., 
Biological regeneration of manganese (IV) using oxygen and iron (III) 
using nitrate for anaerobic metal oxide-mediated removal of 
pharmaceuticals from water.  
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ABSTRACT 
Application of manganese (IV) (Mn(IV)) and iron (III) (Fe(III)) 
(hydr)oxides in removing pharmaceuticals from water is attractive for their 
capacity in degrading these chemicals, and their potential regeneration. 
Pharmaceutical degradation under anaerobic conditions is energetically 
most favorable. Thus, regeneration of the Mn(IV) or Fe(III) should also be 
produced under these conditions, or with a minimum oxygen dosage. In the 
study presented here, batch experiments were carried out to investigate this 
in-process production of Mn(IV) and Fe(III) from Mn(II) and Fe(II), as well 
as the removal of pharmaceuticals coupled to the biological Mn(IV) and 
Fe(III) regeneration. Results show that biological production of (re-
oxidation to) Mn(IV) can be achieved under oxygen-limiting conditions. 
The biological production of Fe(III) can be achieved with nitrate under 
anaerobic conditions. Both biologically produced Mn(IV) and Fe(III) are 
amorphous. Pharmaceutical biodegradation during the regeneration is tested, 
as well as the abiotic removal of pharmaceuticals with different types of 
Mn(IV) or Fe(III). Biodegradation of pharmaceuticals with Mn(II)-
oxidizing bacteria resulted in an insignificant removal of the selected 
pharmaceuticals. Using Mn(IV) produced from drinking water treatment 
plants achieves a removal of 23% of metoprolol and 44% of propranolol, 
similar to the removal with chemically synthesized Mn(IV). When Fe(III) 
was produced with the help of nitrate, pharmaceutical biodegradation is 
insignificant. Anaerobic abiotic pharmaceutical tests showed that about 31 
– 43% of propranolol is removed when using Fe(III) originating from 
drinking water treatment plants, which is higher than with either 
biologically or chemically synthesized Fe(III). In addition, one of the 
commercially available Fe(III)-based sorbent tested, Fe(III)FerroSorp®RW, can 
also remove propranolol. This study indicates that the biological 
regeneration of Mn(IV) and Fe(III), from their reduced species produced in 
an anaerobic pharmaceutical degradation set up, is feasible. Mn(IV) and 
Fe(III) produced and obtained from different processes can be used for this.  
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6.1 Introduction 
Pharmaceutical compounds have been identified as important 
emerging environmental water contaminants in the last decades. 
Pharmaceuticals are detected not only in wastewater but also in groundwater, 
surface water, and even in drinking water [79]. The continuous discharge of 
these compounds to the water originating from industrial emissions and 
human consumption could lead to potential risks for ecosystems such as 
extended reproductive periods of aquatic organisms, and also for human 
health [79, 148]. Therefore, the presence of pharmaceuticals in aquatic 
environments is unwanted, even at the low concentrations currently 
encountered (ng·L-1 to µg·L-1) [6].  
Conventional wastewater treatment processes are insufficient in 
removing pharmaceuticals such as carbamazepine, diclofenac, or 
metoprolol [46], so many advanced technologies such as photocatalysis are 
applied [95, 354]. Such methods usually require aerobic conditions (presence 
of oxygen), leading to high energy consumption for aeration or oxygen 
generation. Manganese (Mn)- or iron (Fe)- based technologies, especially 
those applying Mn(IV)- or Fe(III)-(hydr)oxides, successfully remove 
various pharmaceuticals via both abiotic and biotic processes under 
anaerobic conditions (without oxygen) [170]. Previous research showed that 
anaerobic abiotic diclofenac removal with MnO2 is more efficient than 
under aerobic conditions [172]. The anaerobic biodegradation can also 
efficiently remove pharmaceuticals including naproxen with Mn(IV) or 
Fe(III) [171, 268]. Furthermore, the anaerobic conditions are more sustainable 
because they require less energy input for operations like aeration. 
An additional outstanding advantage is that Mn(IV) and Fe(III) can be 
regenerated after use, decreasing waste sludge outputs and increasing the 
sustainability in potential upscaled application. As anaerobic 
pharmaceutical degradation is foreseen, Mn(IV) or Fe(III) production under 
anaerobic conditions is most attractive, allowing these metals to be re-used 
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directly in the process. Both chemical and biological methods can be used 
to regenerate Mn(IV) and Fe(III) from the Mn(II) and Fe(II) released during 
pharmaceutical degradation. Chemical production is achieved through 
direct oxidation using oxygen (O2) or a strong oxidant such as chlorine, 
chlorine dioxide, ozone or KMnO4 [135]. For example, chemically produced 
Mn(IV) can be obtained via the oxidation of MnCl2 with KMnO4 [65]. Fe(II) 
can also be directly oxidized in the presence of O2.  
The chemical synthesis of Mn(IV) or Fe(III) usually uses strong 
oxidants and these oxidants can also produce unwanted by-products during 
the synthesis. The biological production, however, can be cleaner with no 
or fewer by-products. Since pharmaceutical removal with Mn(IV) or Fe(III) 
is more attractive under anaerobic conditions, the regeneration of Mn(IV) 
and Fe(III) should be preferentially also under anaerobic conditions. 
However, the high redox potential of Mn(IV) (+ 1.23 V) indicates that 
biological Mn(IV) production can only occur in the presence of O2 [301]. To 
limit the O2 transfer to the anaerobic step of biological Mn(IV) production 
and pharmaceutical removal, minimal O2-dosage need to be applied. Fe(III) 
can be produced by microorganisms under anaerobic conditions using NO3- 
as electron acceptor [292, 366]. In addition, biological Fe(III) production has 
the potential to remove pharmaceuticals via abiotic processes and/or biotic 
processes. Previous studies reported complete removal of atenolol and 70% 
removal of propranolol with NO3- via biological degradation [13, 268].  
In addition to regeneration, Mn(IV) or Fe(III) can be obtained from 
commercial sources or from various waste streams in the water sector. This 
results in other properties of the two metal oxide species , which may lead 
to more or less effective pharmaceutical degradation. Biologically produced 
Mn(IV) and Fe(III) (labelled as Mn(IV)bio-production and Fe(III)bio-production 
throughout) have a larger specific surface area and higher binding energy 
than chemically synthesized Mn(IV) and Fe(III) (labelled here as 
Mn(IV)chem-synthesis and Fe(III)chem-synthesis) [97, 301]. These properties are suitable 
for abiotic removal of pollutants such as pharmaceuticals or heavy metal. A 
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previous study showed that the removal of diclofenac with Mn(IV)bio-production 
at neutral pH is 10-fold faster compared to Mn(IV) chem-synthesis [65]. Another 
source of Mn(IV) and Fe(III) is waste from drinking water treatment plants. 
Mn(IV) or Fe(III) produced during drinking water treatment (Mn(IV)DWTP 
and Fe(III) DWTP) are usually produced via chemical or biological processes, 
or the combination of these two processes [135, 144]. Thus, Mn(IV)DWTP and 
Fe(III) DWTP likely have different properties than Mn(IV) or Fe(III) produced 
solely via defined chemical or biological processes. Little is known about 
applying these types of Mn(IV) or Fe(III) oxide species to remove of 
pharmaceuticals under anaerobic conditions.  
This paper aims to (1) investigate biological regeneration of Mn(IV) 
under O2-limiting conditions from Mn(II) formed during pharmaceutical 
degradation or drinking water production; (2) investigate biological 
regeneration of Fe(III) by applying NO3- under anaerobic conditions from 
Fe(II) formed during anaerobic pharmaceutical degradation or drinking 
water production; (3) investigate biodegradation of pharmaceuticals during 
these metal oxide regeneration steps; and (4) compare the abiotic removal 
of pharmaceuticals under anaerobic conditions with different Mn(IV) and 
Fe(III) metal oxide species. The results together contribute to an 
understanding of essential aspects of Mn and Fe regeneration and recycling 
during metal oxide mediated pharmaceutical removal from water. This 
brings future application of such a technology into view.  
6.2 Methods and materials 
6.2.1 Chemicals 
Anaerobic water was used in most of the experiments unless specified. 
Anaerobic water was prepared by boiling ultrapure water or demineralized 
water (demiwater) for 5 min and cooled to room temperature by flushing 
with N2. Ultrapure water was collected from a Millipore system (18.2 
MΩ·cm, TOC=18 ppb, USA).  
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Seven commonly used pharmaceuticals are tested in this study, 
including caffeine, carbamazepine, diclofenac, ibuprofen, metoprolol, 
naproxen, and propranolol, were purchased either from Sigma-Aldrich or 
from MP Biomedicals, as previously described [172].The stock solution of 
pharmaceutical mixture (20 mg⋅L-1 each) was prepared with ultrapure water. 
All other chemicals were purchased from Sigma-Aldrich at purity > 98% 
for solids and at HPLC or UPLC quality for liquids. 
The Mn(IV) and Fe(III) involved in this study are the same materials 
used in a previous study (Table 6.1) [171]. Mn(IV)bio-production was collected 
during the experiments and prepared as described [65]. In short, Mn(IV)bio-
production was centrifugation at 7,000 g for 15 min, and then was washed 
several times through centrifugation and resuspended with 10 mM 
anaerobic phosphate buffer (Na2HPO4/KH2PO4, Sørensen buffer). 
Mn(IV)chem-synthesis was prepared the same as previously described [172]. 
Mn(IV)DWTP was kindly provided by Water Laboratorium Noord (WLN, the 
Netherlands), originally from drinking water production plant 
‘Noordbargeres’ in Emmen. The Mn(IV)DWTP was dried under N2 flushing.  
Fe(III)bio-production was collected and prepared by washing the same as 
Mn(IV)bio-production by centrifugation and resuspended with 10 mM anaerobic 
phosphate buffer (Na2HPO4/KH2PO4, Sørensen buffer). Fe(III)chem-synthesis 
was prepared based on a previous study [153]. Briefly, the 0.4 M FeCl3 was 
neutralized with 1 N NaOH until pH 7. Then, the Fe(III)chem-synthesis was 
washed in the same way as Mn(IV) chem-synthesis. Fe(III)DWTP was kindly 
provided by Evides Waterbedrijf (the Netherlands). Two Fe(III)-based 
sorbents, FerroSorp®Plus and FerroSorp®RW was obtained from HeGo 
Biotec GmbH.  
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6.2.2 Experimental setup 
6.2.2.1 Biological production of Mn(IV) 
(1) Inoculum
The Mn(II)-oxidizing bacteria was kindly provided by Utrecht
University. The pre-cultivation of the bacteria was carried out in 150 mL 
flasks with 50 mL fresh Luria-Bertani (LB) medium at 30 ºC on a shaker 
(200 rpm) [295]. LB medium was freshly prepared before experiments 
consisted of (per liter of demiwater) 10 g tryptone, 10 g NaCl, and 5 g yeast 
extract [295]. The pH of the medium was adjusted to 7.0 with 10 N NaOH. 
The medium was sterilized by autoclaving at 120 ºC for 20 min prior to use. 
When the OD600 reached around 1.0, the bacterial culture was ready for use 
in our experiments. 
(2) Batch experiments
The batch experiments to produce Mn(IV)bio-production were carried out
in triplicate in 125 mL glass bottles containing 30 mL sterilized anaerobic 
LB medium. The preparation of the medium and the batch bottles was 
carried out in an anaerobic glovebox. Bottles were closed with butyl-rubber 
stoppers and then taken out of the glovebox. Thereafter, bottles were sealed 
with aluminum crimp caps. The headspace was exchanged with the N2/O2 
gas mixture to 1.2 bar. The total O2 amount, including gaseous O2 and 
dissolved O2, was expressed in the percentage in headspace, that is 0.3% 
(total O2 7 μmol), 5.8% (178 μmol), 10.1% (330 μmol), 24.3% (697 μmol). 
The calculation process was described in Text S6.1.  
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The bottles were sterilized by autoclaving at 120oC for 15 min. Bottles 
with cotton stoppers were carried as a positive control (no O2 limitation). 
Blank controls without bacteria were taken along as well. Filter-sterilized 
MnCl2 stock (9 mM) was added to the bottles to reach a final concentration 
of 0.3 mM Mn(II) (~9 μmol Mn). The experiments were started by adding 
0.3 mL pre-cultivated Mn(II)-oxidizing bacteria. All bottles were incubated 
at 30 ºC on a shaker (200 rpm). Liquid samples were collected regularly for 
analysis of bacteria and Mn(II). 
(3) Sample preparation 
The samples for bacteria growth were taken and measured immediately 
without treatment. Liquid samples for Mn(II) analysis were centrifuged at 
10,000rpm for 10 min. Then, the supernatant was collected and analyzed 
immediately based on standard methods [252]. 
6.2.2.2 Biological production of Fe(III)  
(1) Inoculum 
The inoculum was kindly provided by Wageningen University & 
Research, the Netherlands. The inoculum consisted of the pre-incubated 
activated sludge of WWTP Bennekom, the Netherlands in the presence of 
48.5 mg⋅L-1 Fe(II) and 10.1 mg⋅L-1 NO3-.  
(2) Batch experiments 
The batch experiments to produce Fe(III)bio-production were carried out in 
triplicate in 125 mL bottles with 100 mL medium (Table S6.1). Sufficient 
NO3-, 3mM, was used to biologically produce Fe(III). The pH of the medium 
was maintained at pH 7.5. The preparation of the medium and batch bottles 
was carried out in the anaerobic glovebox. The bottles were closed with 
butyl-rubber stoppers, taken out of the anaerobic glovebox and sealed with 
aluminum crimp caps. The headspace of the bottles was exchanged with the 
N2/CO2 gas mixture to achieve 80% N2 and 20% CO2 (v/v) and brought to 
1.2 bar. The experiments were started by adding 10 mL inoculum to all the 
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bottles. Abiotic controls were prepared with 3 mM NO3- along with the 
experiments without inoculum . The experiments were conducted in the 
dark at 30˚C, shaking at 120 rpm. Concentrations of NO3- and Fe were 
analyzed at the beginning and at the end of the experiments. 
(3) Sample preparation
Samples for NO3- measurement were prepared exactly the same as
those for pharmaceuticals. The samples for NO3- were stored at 4 ºC and 
analyzed within one month. 
Samples for Fe analysis were prepared by a modified HCl extraction 
method [52]. Briefly, 0.5 mL samples were mixed with 0.5 mL 1M HCl to fix 
Fe(II). Thereafter, Fe(II) was analyzed directly by colorimetric methods 
(Hach Dr. Lange Kit 340). The total Fe was analyzed by the same procedure, 
with the exception that 1mL 0.5 M NH2OH·HCl was added before analysis. 
The samples were stored at 4 ºC before analysis. 
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6.2.2.3 Pharmaceutical removal 
(1) Biodegradation during biological Mn(IV) production
Biodegradation of pharmaceuticals was carried out by the same method
as biological Mn(IV) production process in and add filter-sterilized stock of 
pharmaceutical mixture (20 mg·L-1) at a final concentration 0.5 mg·L-1.  
The samples for pharmaceutical measurement were centrifuged at 
10,000 rpm for 10 min immediately after taken. The supernatant was 
collected and pre-treated by solid phase extraction (SPE) as described 
previously [339]. The recovery rate of SPE is 85 – 115%. Thereafter, the 
samples were stored in amber vials at -20 ºC before analysis.  
(2) Abiotic removal with different Mn(IV)
The batch experiments on the abiotic removal of pharmaceuticals were
carried out in duplicate under anaerobic conditions. Batch experiments were 
similar to previous studies [169, 172], and the pH of solutions was maintained 
by 10 mM phosphate buffer which is also used to prepare Mn(IV)bio-production. 
Final concentrations in the batches were 7 mM Mn(IV)bio-production. The 
experiments were initiated by adding 1.25 mL stock of pharmaceutical 
mixture into the experimental bottles, resulting in a final concentration of 
0.5 mg·L-1. Samples were taken regularly to analyze the concentration of 
pharmaceuticals. 
Since the Mn(IV)DWTP is produced main via biological process but the 
chemical process is also possibly involved [307], it can have different 
properties from Mn(IV)chem-synthesis or Mn(IV)bio-production. Therefore, the 
abiotic removal of pharmaceuticals under anaerobic conditions with this 
Mn(IV)DWTP (granules and ground powder) was also tested.  
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The samples for pharmaceutical measurement were centrifuged at 
10,000 rpm for 10 min immediately after taken. The supernatant was 
collected and stored in amber vials at -20 ºC before analysis. Parallel 
samples were taken to investigate the contribution of adsorption to the 
removal. 0.5 mL samples were taken, and then 1mL reducing agent (0.5 mM 
NH2OH·HCl) were added immediately. Then, the mixture was centrifuged 
at 10,000 rpm for 10 min. The supernatant was collected and stored in amber 
vials at -20 ºC before analysis. The presence of NH2OH·HCl has no effects 
on the analysis of pharmaceuticals.  
(3) Biodegradation during biological Fe(III) production
Pharmaceutical biodegradation during biological Fe(III) production
was also tested. The experiments were carried out the same as biological 
Fe(III) production. Before adding the inoculum, the pharmaceutical mixture 
was added to batch bottles at a final concentration of each pharmaceutical 
at 1 mg⋅L-1. Samples were taken every 30 days for analyzing the 
concentrations of pharmaceuticals, NO3- and Fe. 
The samples for pharmaceutical measurement were prepared as those 
in experiments on biodegradation during biological Mn(IV) production. 
(4) Abiotic removal with different Fe(III)
Abiotic removal of pharmaceuticals with different types of Fe(III) was
carried out the same as with Mn(IV). The final concentration of Fe(III) is 
0.4 mM, and that of pharmaceutical is 0.5 mg·L-1. Sample preparation was 
the same as those in biodegradation of pharmaceuticals during biological 
Mn(IV) production. 
133 
6.2.3 Analysis 
The Mn analysis including total Mn and Mn(II) was performed by an 
inductively coupled plasma optical emission spectrometry (VISTA-MPX 
CCD Simultaneous, VARIAN co.) equipped with an megapixel (MPX) 
detector at wavelength 257.610 nm.  
Fe analysis including total Fe or Fe(II) was performed by Hach Dr. 
Lange Kit (LCK 340). NO3- concentrations were measured by a Hach Dr. 
Lange Kit (LCK 320, 321). Morphologies of Mnbio-production and Febio-production 
were analyzed by an X-ray powder diffraction (XRD, Bruker D8 advance, 
Bruker, Germany). The pharmaceutical analysis was performed by an ultra-
performance liquid chromatography with a diode array detector (UPLC, 
ultimate 3000, Thermo, USA), as previously described [95]. 
6.3 Results and discussion 
6.3.1 Biological regeneration 
(1) Biological Mn(IV) production under O2-limiting conditions
The biological production of Mn(IV) under O2-limiting conditions
occurs under all O2 concentrations (Figure 6.1). The initial O2 amount varies 
from 178 to 700 μmol, and similar amounts of Mn(IV)bio-production are 
produced during the first 24 hours (p > 0.05). During the period from 24 to 
48 hours, no further Mn(IV)bio-production production is observed, that resulting 
in a total Mn(IV)bio-production production of 0.7 μmol. In the group without O2 
limitation (positive control group), the Mn(IV)bio-production after 24 hours and 
48 hours is much higher than in the O2 -limiting groups. These results 
indicate that the amount of O2 limits biological Mn production. Mn(II)-
oxidizing bacteria are aerobic bacteria, and this limited initial amount of O2 
will affect bacterial activity. A certain level of O2 is necessary for their 
growth and biological processes. Therefore, a certain amount of O2 must be 
present during biological production of Mn, despite the inhibition of the 
biological Mn(IV) production.  
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FIGURE 6.1 Biologically produced Mn(IV) oxides from Mn(II) under O2-limiting 
conditions after 24 and 48 hours 
 
(2) Biological Fe(III) production with NO3- under anaerobic conditions 
During the biological production of Fe(III), 0.8 mM sodium acetate 
was added to promote the growth of the bacteria and biological production 
of Fe(III). The 3 mM NO3- is used in this experiment to make sure that NO3- 
is not the limiting factor. During the process, 0.61 mM Fe(III) biologically 
produced coincided with 0.59 mM NO3- consumption (Table 6.2). The molar 
ratio of Fe(III)bio-production and consumed NO3- in our study is around 1:1, 
while the ideal ratio is 5:1 (Equation 6.1) [215]. There are a number of 
processes that could contribute to additional nitrate consumption.  
 10𝐹𝐹𝐹𝐹(𝐼𝐼𝐼𝐼) + 2𝑁𝑁𝑃𝑃3− + 28𝐻𝐻2𝑃𝑃 → 10𝐹𝐹𝐹𝐹(𝑃𝑃𝐻𝐻)3 + 𝑁𝑁2 + 18𝐻𝐻+ (6.1) 
 
Since the redox pairs at pH 7 of during the nitrate reduction are more 
positive than that of Fe(III)/Fe(II) (Ferrihydrite/Fe2+, -100 to 100 mV) [291], 
they can all oxidise Fe(II) to Fe(III), forming different products. For 
example, when the final product is NO2, the ratio between Fe(III)bio-production 
and NO3- consumption is around 1:1 (Equation 6.2).  
 
𝐹𝐹𝐹𝐹(𝐼𝐼𝐼𝐼) + 𝑁𝑁𝑃𝑃3− + 2𝐻𝐻+ → 𝐹𝐹𝐹𝐹(𝑃𝑃𝐻𝐻)3 + 𝑁𝑁𝑃𝑃2 + 𝐻𝐻2𝑃𝑃 (6.2) 
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TABLE 6.2 Biological production of Fe(III) (Fe(III)bio-production) with a different initial 
concentration of NO3-. 
Initial NO3- 
(mM) 
Fe(III) 
production 
(mM) 
NO3- consumption 
(mM) 
Molar ratio 
[Fe(III) bio-production] : 
[NO3-]consumption 
0.08 
(Blank controls) 
n.d. a 0.02 n.a. b
2.8 0.61 0.59 1.04 : 1 
2.7 
(Abiotic 
controls) 
n.d. n.d. n.a.
a n.d. = not detected 
b n.a. = not applicable 
In addition, the presence of acetate promotes denitrification under 
anaerobic conditions: a portion of the nitrate is used to oxidize the acetate. 
In the process, bacteria will consume the NO3- without producing Fe(III). 
Therefore, the observed molar ratio between Fe(III) bio-production and NO3- 
consumption is 1:1, less than the theoretical value 5:1. 
(3) Properties
The properties of the Mn(IV) and Fe(III) used in this study are analyzed
by X-ray diffraction (XRD). Based on the XRD pattern, Mn(IV)bio-production is 
amorphous (Figure 6.2). The morphology of the two Mn(IV) species 
produced within this study, Mn(IV) bio-production and Mn(IV)chem-synthesis, are 
same [171]. Similar results are also reported in a previous study [322]. 
Furthermore, materials sourced from DWTP waste are also tested. From a 
previous study, the ground Mn(IV)DWTP powder has peaks which are also 
observed in crystalline MnO2. This indicates that the Mn(IV)DWTP has a 
semi-crystalline nature (Table 6.1) [171]. However, the raw materials of 
Mn(IV)DWTP could be amorphous. During the grinding, the specific area of 
Mn(IV)DWTP powder will increase, but it might also change its morphology 
of Mn(IV)DWTP from amorphous to semi-crystalline. In addition, the long-
term storage can slowly change the morphology of Mn(IV)DWTP via aging 
processes, for instance changing them from amorphous to crystalline [293].  
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FIGURE 6.2 X-ray diffraction spectrum of biologically produced Mn(IV) oxides (Mn(IV)bio-
production) and biologically produced Fe(III) hydroxides (Fe(III)bio-production) 
 
XRD patterns show that Fe(III)bio-production is amorphous and similar to 
that used in our other study (Figure 6.2) [272]. The other Fe(III) used in this 
study are the same as used in a previous study [171]. The Fe(III) from drinking 
water treatment (Fe(III)DWTP), and two Fe(III)-based sorbents are semi-
crystalline. They are all a mixture of Fe2O3 and Fe3O4. Based on the XRD 
pattern, the Fe(III)DWTP appears to be the most amorphous among these three 
materials while the Fe(III)FerroSorp®RW is the most crystalline. 
6.3.2 Removal of pharmaceuticals  
(1) Pharmaceutical removal during biological Mn(IV) production 
Mn(IV) production in this study occurs under oxygen-limiting, but 
nonetheless aerobic conditions. Pharmaceutical removal during Mn(IV) 
production is expected since aerobic biodegradation of pharmaceutical 
compounds has been reported previously [151]. In this study, biodegradation 
of pharmaceuticals with Mn(II)-oxidizing bacteria was tested. Results show 
that there is no significant removal of the selected pharmaceuticals (Table 
S6.2). Similar studies with Pseudomonas putida MnB6 (a strain of Mn(II)-
oxidizing bacteria) also show that the removal of diclofenac and other 
micropollutants is insignificant [67, 200]. The Mn(II)-oxidizing bacteria used 
to produce Mn(IV) is a pure strain specialized in Mn(IV) oxidation. These 
bacteria are growing under O2-limiting conditions. Thus, this individual 
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strain most likely had neither the degradation capacity nor optimal growth 
conditions to biodegrade challenging pharmaceutical structures.  
(2) Abiotic pharmaceutical removal with Mn(IV) 
Batch experiments were carried out to test the abiotic removal of 
pharmaceuticals with different types of Mn(IV). Due to experimental 
conditions, we were unable to produce sufficient Mn(IV)bio-production for our 
abiotic removal tests. Therefore, the experiments were carried out with 
Mn(IV)DWTP (granule and ground powder). The experiments on the abiotic 
removal of pharmaceuticals were carried out in anaerobic water in duplicate. 
Results show no abiotic anaerobic removal with the Mn(IV)DWTP granule but 
with ground Mn(IV)DWTP powder supported the efficient removal of 
metoprolol and propranolol (Table 6.3). With ground Mn(IV)DWTP powder , 
removal of metoprolol is 23% in 24 hours, of which 20% is removed due to 
adsorption. Similarly, 44% propranolol is removed, and 30% is a result of 
adsorption. 
The experimental conditions are exactly the same as applied in a 
previous study with Mn(IV)chem-synthesis. In that study, 78% diclofenac, 33% 
metoprolol and 51% propranolol are removed under anaerobic conditions 
with MnO2 in anaerobic water (Table 6.3) [172]. In this current study, the 
removal of metoprolol and propranolol with two different Mn(IV) types is 
similar, but no diclofenac removal is observed with Mn(IV)DWTP. No 
adsorption was observed during the abiotic removal of pharmaceuticals with 
Mn(IV)chem-synthesis. 
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TABLE 6.3 Abiotic removal of pharmaceuticals (%) with Mn(IV) from drinking water 
treatment plants (Mn(IV)DWTP) and manually synthesized, chemically produced Mn(IV) 
(Mn(IV)chem-synthesis) under anaerobic conditions 
 Mn(IV)DWTP granule a Mn(IV)DWTP powder a Mn(IV)chem-synthesis b 
Diclofenac 3(±2)  -4(±0) 78(±6) 
Metoprolol 5(±3) 23(±2) 33(±7) 
Propranolol 9(±3) 44(±3) 51(±5) 
a Data between brackets show the difference between the duplicates 
b Data are from a previous study of the same group [172]. The data in the bracket is the 
standard deviation of the triplicate 
 
Our research on anaerobic abiotic removal of diclofenac with Mn(IV) 
shows that the amorphous Mn(IV) is better than crystalline Mn(IV) [172]. 
Based on the XRD pattern, the Mn(IV)DWTP powder can be defined as semi-
crystalline. Therefore, it appears to be less effective in anaerobic abiotic 
pharmaceutical removal. In addition, even though both Mn(IV)DWTP granule 
and Mn(IV)DWTP powder are semi-crystalline, the Mn(IV)DWTP powder has 
a larger specific area and potentially has more reactive surface and sites. 
Previous studies indicated that more reactive surface sites of Mn(IV) 
generally lead to more removal of pharmaceuticals [172, 248]. This may explain 
the better performance by the ground Mn(IV)DWTP powder than Mn(IV)DWTP 
granule in pharmaceutical removal. 
The reason why Mn(IV)DWTP powder is only effective to remove two 
β-blockers but is inactive towards converting other pharmaceuticals could 
not yet be revealed. We hypothesize that there may be a relation with the 
molecular properties of the pharmaceuticals. The two β-blockers have quite 
a similar chemical structure, the aromatic ring, the oxygen molecule 
connected to the aromatic ring, and a long-chain structure. In addition, they 
have a similar pKa value (metoprolol 9.5, propranolol 9.42) [172]. During the 
abiotic removal, the compounds are firstly adsorbed onto MnO2 surface or 
forming a complex [172]. The adsorption capacity is related to the chemical 
structure and properties. Thus, the two pharmaceuticals are better removed 
than others. 
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(3) Pharmaceutical removal during biological Fe(III) production
The pharmaceutical removal units in application will also transfer
pharmaceuticals to the biological Fe(III) regeneration unit. Since organic 
compounds like acetate present in the media can lead to dentrification, the 
pharmaceuticals are likely to function in the same way, affecting biological 
Fe(III) production under anaerobic conditions. In addition, based on the 
literature, the degradation of pharmaceuticals in the presence of Fe(II) and 
NO3- could occur via (1) biodegradation with NO3-, (2) abiotic removal with 
Fe(II), or (3) abiotic removal with Fe(III)bio-production [206, 268, 327]. In this study, 
we aimed to better illuminate the removal processes by carrying out 
experiments without Fe(II) or NO3- to see the role of these compounds in 
pharmaceutical removal during the biological Fe(III) production step. 
Results show that biological production of Fe(III) occurs in the 
presence of pharmaceuticals, but the removal of pharmaceuticals is 
inefficient during the production. During the experiments, 0.17 mM 
Fe(III)bio-production is produced and 0.14 mM NO3- is consumed, a similar ratio 
of 1:1 to that is observed with acetate instead of pharmaceuticals (Table 6.4). 
But the biological production of Fe(III) is inhibited by the presence of 
pharmaceuticals. Both Fe(III)bio-production production and NO3- consumption 
is much less than the experiments with acetate without pharmaceuticals. 
Without Fe(II), 0.24 mM NO3- is consumed with pharmaceuticals as the 
electron donor, indicating that there is also a denitrification process 
consuming pharmaceuticals. No Fe(III) bio-production is produced in the 
experimental groups with only NO3- or with only Fe(II) (Table 6.4). 
140 
 
TABLE 6.4 Biological production of Fe(III) with NO3- coupled to the biodegradation of 
pharmaceuticals 
Experimental group NO3- consumption (mM) 
Fe(III) production 
(mM) 
Fe(II) + NO3- 0.14 0.17 
Fe(II) n.a. a n.d. b 
NO3- 0.24 n.a. 
a n.a.= not analysed 
b n.d. =not detected 
 
The degradation of pharmaceuticals is tested during the biological 
production of Fe(III) in the presence of Fe(II) and NO3-. Results show that 
the removal of pharmaceuticals is inefficient (Figure 6.3). During the 
biological Fe(III) production, about 20% diclofenac, 17% ibuprofen and 24% 
naproxen are removed, and the removal of caffeine, carbamazepine, and 
metoprolol is less than 10%. A slightly higher removal is seen in the 
experimental groups with only NO3-, e.g. with a removal of 34% for 
carbamazepine, 40% for diclofenac, 31% for metoprolol, and 26% for 
naproxen. Removal of pharmaceuticals with only Fe(II) is insignificant (< 
15%). The abiotic controls were carried out without inoculum. Results show 
that the removal of six pharmaceuticals in all abiotic controls is negligible 
(Figure S6.1, Text S6.2).  
 
Results show that biological Fe(III) production has no significant 
promoting effects on pharmaceutical removal. Pharmaceutical removal 
efficiency during biological Fe(III) production is similar, or even less than 
that with only NO3-. In previous studies, the biodegradation of six selected 
pharmaceuticals is inefficient with NO3- [268, 339], similar to the results in this 
study. In addition, the results indicate that in our experiments Fe(II) is a 
more reactive electron donor for denitrification than the pharmaceutical 
compounds tested.  
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FIGURE 6.3 Biodegradation of pharmaceuticals during the experiments of biological 
production of Fe(III) within 150 days. Experimental conditions: [Fe(II)]0= 1.2 mM , [NO3-]0= 
0.4 mM, [pharmaceutical]0=1 mg·L-1, T=30ºC, pH =7, shaking speed 120 rpm. Error bars 
stand for the standard deviation 
Biodegradation of some pharmaceuticals with NO3- has been observed 
previously [13, 268]. However, removal of pharmaceuticals like metoprolol is 
reported to be inefficient [268, 339]. In our study, the biodegradation of all six 
pharmaceuticals with NO3- is low (< 40%). Therefore, the bacteria appear 
to preferentially oxidize Fe(II) instead of pharmaceuticals, using NO3- as the 
electron acceptor. In addition, the Fe(III)bio-production usually attaches on the 
surface of bacteria [237], which may be of influence on their removal 
performance in processes.  
Previous studies reported that Fe(II) could also remove 
pharmaceuticals via abiotic processes [206, 327]. In this study, removal of 
pharmaceuticals with Fe(II) was found to be insignificant. Other authors 
revealed that removal of antibiotic pharmaceuticals with Fe(II) requires the 
presence of both Fe(II) and Fe(III) (goethite) [55, 206]. The amorphous 
Fe(III)bio-production produced in this process is different from highly crystalline 
goethite [377]. As a result, Fe(II) appears to have no contribution to the 
degradation of pharmaceuticals.  
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In summary, the biological production of Fe(III) from Fe(II) in the 
presence nitrate and pharmaceuticals can be successfully conducted, but the 
removal of pharmaceuticals during the process is inefficient and has no 
additional contribution to the anaerobic Fe(III) mediated pharmaceutical 
removal. These results also show that nitrate dosage should be controlled to 
prevent nitrate concentrations in the pharmaceutical degrading process step.  
(4) Abiotic removal with Fe(III) 
Abiotic removal of pharmaceuticals with Fe(III) compounds is also 
investigated in this study. Removal by Fe(III)bio-production is expected via 
adsorption since it has a large specific surface area [97]. Fe(III)DWTP is usually 
produced via chemical processes with O2 (aeration) while biological 
processes are also observed under conditions where substantial organic 
matter is present [135, 144]. The production process leads to potentially 
different Fe(III) compounds and thus different pharmaceutical removal from 
Fe(III)bio-production. In addition, Fe(III)-based sorbents also have large specific 
surface area. Similar to Fe(III)bio-production, these sorbents may also be suitable 
to remove pharmaceuticals via adsorption. Thus, we investigate 
commercially available Fe(III)FerroSorp®Plus, and Fe(III)FerroSorp®RW. 
The abiotic removal of pharmaceuticals under anaerobic conditions 
with different Fe(III) are tested. Both granule and ground powder of these 
Fe(III) are used to select the best materials for the future reactor 
development. Results show that 31% propranolol is removed within 5 days 
under anaerobic conditions with Fe(III)DWTP powder (Table 6.5). 
Furthermore, 20% of propranolol is removed with Fe(III)FerroSorp®RW powder. 
Like the results with powder, only propranolol is removed for 45% under 
anaerobic condition with Fe(III)DWTP granule and for 24% using 
Fe(III)FerroSorp®RW granule. This removal efficiency with the granules is 
higher than that with the same Fe(III) powder. Adsorption of 
pharmaceuticals is not observed with Fe(III)DWTP powder and 
Fe(III)FerroSorp®RW powder during the removal.  
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TABLE 6.5 Abiotic removal of propranolol under anaerobic conditions with different Fe(III) 
powder within 5 days. Experimental conditions: [Fe(III)]0=20 mM. Pharmaceutical]0=0.5 
mg·L-1, phosphate buffer pH=7, T=30 °C a 
Fe(III) (hydr)oxides Removal 
efficiency (%) b 
Fe(III) (hydr)oxides Removal 
efficiency (%) b 
Fe(III)DWTP granule 43(±2) Fe(III)FerroSorp®RW granule 25(±2) 
Fe(III)DWTP powder 31(±1) Fe(III)FerroSorp®RW powder 21(±1) 
a Fe(III)DWTP = Fe(III) (hydr)oxides from drinking water treatment plants, 
Fe(III)FerroSorp®RW = Fe(III)-based sorbent FerroSorp®RW 
b The data in the bracket is the difference between the duplicate
No removal is observed with other types of Fe(III) or without Fe(III) 
(Figure S6.2, S6.3, Table S6.3). Pharmaceutical removal under anaerobic 
conditions with Fe(III)bio-production was found to be insignificant. Adsorption 
is not observed at high levels, while is a critical step during the reactive 
removal [61, 327, 328]: after adsorption onto Fe(III) through molecular 
complexation at the oxide surface, pharmaceuticals are chemically 
converted. The previous study shows that phosphate ions can be adsorbed 
onto Fe(III)bio-production [250], blocking pharmaceuticals to reach the sorption 
sites. In this study, phosphate is used as a buffer to maintain the pH ~ 7. As 
a result, there may be few Fe(III)bio-production reactive sites available for 
pharmaceutical adsorption and subsequent conversion, leading to the 
insufficient removal of pharmaceuticals. 
Morphologies of Fe(III) may lead to the higher removal efficiency of 
propranolol with Fe(III)DWTP than with Fe(III)FerroSorp®RW. The Fe(III)DWTP is 
more amorphous than Fe(III)FerroSorp®RW. However, pharmaceutical removal 
with amorphous Fe(III)chem-synthesis is also inefficient. In addition, grinding 
the granule is expected to increase the specific surface area of Fe(III), 
potentially increasing the adsorption capacity and number of reactive sites 
per weight of Fe(III) oxide, and also increasing the corresponding abiotic 
removal. However, this study shows that abiotic pharmaceutical removal 
with Fe(III) granule is similar, even better than with powder. A detailed 
investigation is required to understand the abiotic pharmaceutical removal 
with different types of Fe(III) oxides under anaerobic conditions. 
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In this study, only anaerobic abiotic removal of propranolol with Fe(III) 
is observed. Base on the previous study, the pharmaceutical removal 
mechanisms with Fe(III) is similar to that with Mn(IV) [61]. Therefore, the 
removal of diclofenac, propranolol, and metoprolol is expected. Since the 
oxidant power of Fe(III) is weaker than Mn(IV), it is reasonable that 
pharmaceutical removal with Fe(III) is less efficient than that with Mn(IV), 
and that a less more extensive range of pharmaceuticals can be removed 
with Fe(III) than with Mn(IV). As a result, the only removal of propranolol 
is observed with Fe(III), that appears to have more suitable properties for 
the anaerobic abiotic removal of pharmaceuticals with Fe(III) than other 
pharmaceuticals. It is essential in future studies to reveal favourable 
properties present in the suit of pharmaceuticals to react with Fe(III).  
6.4 Conclusion 
This study aimed at investigating biological regeneration of 
manganese(IV) by oxygen and iron (III) by nitrate in support of the 
anaerobic metal oxide-mediated removal of pharmaceuticals from water.  
Results of this study show that the biological production of amorphous 
Mn(IV) occurs under O2-limiting conditions, despite the limited growth of 
the associated bacteria. There is no removal of pharmaceuticals mediated by 
Mn(II)-oxidizing bacteria. In the abiotic removal of pharmaceuticals with 
Mn(IV) under anaerobic conditions, ground Mn(IV)DWTP powder can 
remove pharmaceuticals like metoprolol and propranolol. 
Under anaerobic conditions, amorphous Fe(III)bio-production is formed 
under nitrate-reducing conditions. The biological production of Fe(III) is 
obtained with and without pharmaceuticals. However, pharmaceuticals 
appear to inhibit Fe(III) production. During production of Fe(III)bio-production, 
the degradation of pharmaceuticals is negligible. Abiotic removal with 
Fe(III) is only observed with propranolol. Based on the abiotic removal of 
propranolol under anaerobic conditions, Fe(III)DWTP, both granule and 
ground powder, has the best performance, followed by the Fe(III)FerroSorp®RW. 
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In conclusion, biological regeneration of Mn(IV) and Fe(III) is feasible 
with dosage of limited amounts of O2 or nitrate not changing the anaerobic 
conditions needed for pharmaceutical degradation. Mn(IV)DWTP and 
Fe(III)DWTP show potential for abiotic anaerobic removal of propranolol. 
The abiotic anaerobic removal of metoprolol is also achieved with 
Mn(IV)DWTP. These Mn(IV) and Fe(III) oxide species produced from 
biological, chemical or biological-chemical (like in drinking water 
treatment) procedures could be used to remove pharmaceuticals under 
anaerobic conditions. The results of this study indicate that biological 
processes can be used to produce or regenerate Mn(IV) and Fe(III). The 
proof of principle is given but scaling up towards a complete recycling of 
Mn or Fe in continuously operated reactor configurations is the next 
challenge for future research oriented at further development of this 
technology. 
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Chapter 7 
General Discussion: Towards a sustainable 
technology for removing pharmaceuticals 
from water using metal oxides 
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7.1 Introduction 
Concerns for the adverse effects of pharmaceutical compounds in 
water results in a societal demand for control and removal of these 
compounds. In this dissertation, anaerobic manganese (Mn)- or iron (Fe)- 
mediated pharmaceutical degradation is proposed as a treatment technology 
to remove these compounds from water. A series of experiments are 
designed and setup to study these processes, in which pharmaceuticals are 
converted via abiotic removal or biological degradation while in most cases, 
the Mn(IV) or Fe(III) is reduced to Mn(II) or Fe(II). Thereafter, these 
reduced metal ions can be re-oxidized via biological or chemical processes, 
and transferred back to the pharmaceutical removal processes for reuse 
(Figure 1.2). Since the Mn and Fe are abundant in the environment and are 
important to the transformation pathway of organic compounds, including 
contaminants, studying the anaerobic Mn- or Fe- mediated pharmaceutical 
degradation also contributes to understanding the fate of pharmaceuticals in 
the environments. 
This dissertation focuses on the principals and application of anaerobic 
degradation of pharmaceuticals in Mn(IV)- or Fe(III)-mediated system. 
Investigations have been carried out on the pharmaceutical removal 
efficiency, different types of Mn(IV) and Fe(III), environmental and 
operational conditions, as well as removal mechanisms. Biological 
regeneration of Mn(IV) and Fe(III) are tested, as well as the potential 
biodegradation of pharmaceuticals coupled to the regeneration. The 
outcomes are a step towards translating the results from this study into an 
affordable, environmentally friendly technology to remove pharmaceuticals 
during water treatment, and to improve and optimize pharmaceutical 
removal technologies. This technology can be used in wastewater treatment 
plants and in drinking water treatment plants (Figure 7.1), preventing the 
presence and accumulation of pharmaceuticals in the aquatic environment 
and soil, therefore reducing of potential long-term effects of 
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pharmaceuticals on human's health [156].  
The results of these studies are obtained through batch experiments 
under ideal conditions which can be different from the environmental and 
operational conditions in application. To apply in practice, these results need 
to be critically reviewed, and the influence of the actual situation on the 
pharmaceutical removal during the water treatment processes need to be 
taken into account. In this chapter, removal mechanisms and the removal 
efficiencies are summarized and compared. Finally, the gaps between the 
lab-scale experimental results and the potential full-scale treatment 
performance are emphasized, and the future research perspectives to cross 
these gaps are proposed.  
 
 
FIGURE 7.1 Source and pathway of pharmaceuticals in the environment controlled by the 
application of anaerobic Mn- or Fe- mediated pharmaceutical degradation  
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7.2 Outcomes 
7.2.1 Removal mechanisms 
The main mechanisms of anaerobic pharmaceutical removal in the 
Mn(IV)- or Fe(III)-mediated systems include adsorption, chemical 
oxidation, and biological degradation. Often, these mechanisms act 
simultaneously in reactors and the natural environment and contribute 
together to the overall removal of the pharmaceuticals. For example, the 
anaerobic pharmaceutical removal coupled to dissimilatory Mn(IV) 
reduction is mainly through biodegradation but adsorption is still an 
important process in the chain of interactions occurring leading to 
biodegradation.  
(1) Adsorption 
Adsorption is an important step during the pharmaceuticals removal in 
both abiotic removal and biodegradation of pharmaceuticals. In the 
anaerobic abiotic removal of pharmaceuticals, the adsorption and the 
chemical oxidation are involved. The compounds are first adsorbed onto the 
Mn(IV) or Fe(III). Thereafter, these pharmaceuticals are oxidized. During 
the anaerobic abiotic pharmaceutical removal with Mn(IV), adsorption 
contributes to over 30% removal of propranolol (Chapter 6). 
Adsorption is also observed in anaerobic biodegradation of 
pharmaceuticals coupled to dissimilatory Mn(IV) reduction. During the 
process, about 10% removal is observed in the first 10 days in the abiotic 
controls, resulting from the adsorption (Chapter 3).  
  
151 
(2) Chemical oxidation
Chemical oxidation is the main removal mechanism in anaerobic
abiotic pharmaceutical removal with Mn(IV) or Fe(III). In this thesis, 
diclofenac, metoprolol, and propranolol are efficiently removed by Mn(IV) 
through chemical oxidation (Chapter 4 – 6), and oxidation of propranolol 
by Fe(III) is also observed (Chapter 6).  
Interestingly, even though the chemical oxidation efficiently removes 
pharmaceuticals in anaerobic abiotic conditions with Mn(IV) and Fe(III) 
(Chapter 4 – 6), the abiotic controls in anaerobic biodegradation 
demonstrate insignificant pharmaceutical removal (Chapter 3). This could 
be due to the different matrix used in these two experiments (Table 7.1). The 
matrix used in anaerobic abiotic removal experiments is water or a simple 
buffer system while the anaerobic biodegradation experiments are 
performed with synthetic cultivation medium. Results in this thesis show 
that the presence of co-solutes such as metal ions or low concentration of 
phosphate could occupy the Mn(IV) surface reactive sites via interactions 
between negatively charged phosphate ions and positively charged oxide 
surfaces (Chapter 5). As a result, there are less surface reactive sites 
available for pharmaceuticals and their removal is inhibited. Similarly, the 
nutrient and trace elements in synthetic medium and the inhibitors in abiotic 
controls are more likely to block the surface reactive sites. Therefore, the 
pharmaceutical removal in abiotic controls in anaerobic biodegradation with 
Mn(IV) or Fe(III) is insignificant. 
Similarly, the microbial inoculum in biodegradation studies could also 
influence the availability of the reactive sites, by bacterial adhesion using 
(generally negatively charged) cell surface polymers that adsorb on the 
positively charged metal oxide surfaces [253, 254]. This could be of effect in 
both biotic experimental groups and in abiotic controls with sterilized 
biomass. Based on previous study, the bacteria are expected to attach on the 
solid Mn(IV) or Fe(III) to transfer the electrons [175]. Therefore, the 
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pharmaceuticals are not able to directly contact to the Mn(IV), leading to 
insignificant removal of pharmaceuticals via chemical oxidation in abiotic 
controls, as well as via adsorption. 
(3) Biological degradation 
Biological degradation is another important removal mechanism 
described in this dissertation. The anaerobic biodegradation with Mn(IV) 
can remove caffeine, naproxen, metoprolol, and propranolol (Chapter 3). 
The anaerobic biodegradation with Fe(III) has been tested with metoprolol, 
and is found to be over 50% (Chapter 3). The biodegradation of 
pharmaceuticals is also tested coupled to the biological production of 
Mn(IV) and Fe(III). No removal is obtained with Mn(II)-oxidizing bacteria. 
The pharmaceutical removal efficiency during the biological production of 
Fe(III) is less than 20% (Chapter 6). 
 
TABLE 7.1 Critical experimental parameters investigated and presented in this dissertation 
Conditions 
Anaerobic pharmaceutical 
biodegradation 
Anaerobic abiotic pharmaceutical 
removal 
Biodegradation 
with Mn(IV) 
(Chapter 3) 
Biodegradation 
with Fe(III) 
(Chapter 3) 
Abiotic removal 
with Mn(IV) 
(Chapter 4 – 6) 
Abiotic removal 
with Fe(III) 
(Chapter 6) 
T (ºC) 30 35 10 – 30 30 
pH ~7 ~7 4~9 ~7 
Redox 
conditions 
Mn(IV)-
reducing  
Fe(III)-
reducing  
Anaerobic Anaerobic 
Matrix Synthetic 
medium 
Synthetic 
medium 
Demineralized 
water, 10 mM 
MOPS buffer + 
10 mM NaCl 
10 mM 
phosphate 
buffer + 10 mM 
NaCl 
Initial 
pharmaceutical 
(mg·L-1) 
10 1 – 10 0.25 – 1 0.5 
Experimental 
period (d) 
40 – 70 60 – 160 1 – 1.4 5 
Other 
conditions 
Dark and static Dark and static Dark and static Dark and static 
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7.2.2 Comparison of processes     
In this thesis research, anaerobic pharmaceutical degradation is studied 
with Mn(IV) and Fe(III), and abiotic and biotic processes are considered 
and compared which one holds the most promise for successful application. 
When reviewing the literature on current Mn- or Fe-related pharmaceutical 
removal technologies, a framework is proposed and used (Chapter 2). Based 
on that, the anaerobic pharmaceutical degradation in Mn- or Fe-mediated 
systems are evaluated in the following aspects: 
(1) Process performance 
The primary objective of this dissertation research is to develop a 
mechanistic understanding and assessment on potential technologies to 
remove the pharmaceuticals from water using metal oxides. Therefore, 
important criteria are the extent and the rate of removal of different 
pharmaceuticals. The removal rate is for most experiments calculated for 
experimental time frames where the pharmaceutical removal is stable. 
However, in some experiments this is not possible, leading to samples taken 
at the beginning and at the end of the experiments, leading to rate 
calculations with a relatively high uncertainty range. Nevertheless these 
data are useful as first rough estimates.  
(2) Condition 
In addition to pharmaceutical removal, the environmental and 
operational conditions, such as pH, temperature, or presence of co-solutes, 
are found to affect the removal efficiency of pharmaceuticals in different 
processes, as well as the matrix or cultivation medium. The processes are 
better if they are effective under conditions which are similar or close to 
natural conditions, because these processes are required less cost and energy 
to maintain a special operational conditions.  
  
154 
 
(3) Sustainability 
In the process evaluation and comparison, the sustainability of the 
pharmaceutical removal processes should be taken into account. In 
sustainability, the energy consumption of the process, and the effects of the 
products on environment are important factors, and the newly proposed and 
current water treatment processes can be compared on these aspects.  
(4) Metal oxide types.  
Various forms of Mn- or Fe- (hydr)oxides are the main materials 
consumed during the removal processes studied. The proper type of metal 
oxide is critical in application to achieve high enough removal efficiency. In 
addition, the costs and availability of the metal oxides must be considered. 
In case the Mn or Fe species can be used that are e.g. waste by-products 
such as Mn or Fe containing sludge produced at drinking water treatment 
plants. These could be favourable materials to be used in the application.  
7.2.2.1 Process performance 
The process performance is mainly evaluated by the extent and rate of 
removal of pharmaceuticals. The results indicated that the anaerobic Mn- or 
Fe-mediated removal is effective for different pharmaceuticals (Table 7.2). 
In general, the pharmaceutical removal rate in the anaerobic biodegradation 
is slower than that for abiotic removal but both of them can achieve removal 
efficiency over 90% of certain specific pharmaceuticals (Chapter 3 – 6). 
The pharmaceutical removal technology can be applied as a tertiary 
treatment in wastewater treatment processes to protect the surface water and 
groundwater from pollution by these compounds. Also, it can be used to 
protect drinking water as a pre-treatment treatment unit. The 
pharmaceuticals, which are recalcitrant in conventional water treatment 
plants are the target compounds of pharmaceutical removal units. Based on 
literature, the seven pharmaceuticals selected in this dissertation can be 
classified into two groups; poorly removable pharmaceuticals (<45%), and 
highly removable pharmaceuticals (> 60%) (Table 7.2). Among the poorly 
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removable pharmaceuticals found in this study, carbamazepine, diclofenac, 
metoprolol, and propranolol can be listed. These compounds are also 
generally found to pass standard wastewater treatment plants, and are thus 
more likely to enter a tertiary pharmaceutical removal unit when placed in 
water treatment plants. Highly removable pharmaceuticals include caffeine, 
ibuprofen, and naproxen. Although degradable in WWTP, these compounds 
are also generally found in WWTP effluent due to their relatively high 
concentrations in the influent. For example, removal of ibuprofen in 
wastewater treatment plants (WWTPs) is around 72 – 100%, but the 
maximum concentration of ibuprofen in WWTP effluent can be 95 μg·L-1, 
much higher than other investigated pharmaceuticals in this thesis (Table 
1.1). In addition, concentrations of ibuprofen observed in WWTPs effluents 
are found to be up to 60 times higher than the lowest predicted no effect 
concentrations (Table 1.1, Table 7.2). Therefore, tertiary treatment well 
degradable compounds like ibuprofen is also required.  
The pharmaceutical removal by using metal oxides as assessed in this 
work varied greatly based on the pharmaceutical studied and experimental 
setups. Removal of carbamazepine is not observed in any of the experiments 
conducted in this study (Chapter 3 – 6). Complete removal of diclofenac at 
removal rate of 24.3 mg·L-1·d-1 is obtained in the anaerobic abiotic removal 
process using Mn(IV) (Chapter 5), whereas only 20% is removed when 
biodegradation is coupled to Fe(III) production at a rate of 0.0015 mg 
pharmaceutical·L-1·d-1 (Chapter 6). The fastest removal of metoprolol (0.36 
mg pharmaceutical ·L-1·d-1 achieving 33% removal, Chapter 4 & 6) is 
obtained in anaerobic abiotic removal with Mn(IV), followed by the 
anaerobic pharmaceutical biodegradation with Mn(IV) (0.17 mg 
pharmaceutical ·L-1·d-1 and 96%, Chapter 3). In the anaerobic 
pharmaceutical biodegradation with Fe(III), 57% metoprolol is removed at 
0.05 mg·L-1·d-1 (Chapter 3). In propranolol removal, anaerobic abiotic 
pharmaceutical removal with Mn(IV) is the most efficient process (51% at 
0.53 mg·L-1·d-1, Chapter 4 & 6), while the removal rate of anaerobic 
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pharmaceutical biodegradation with Mn(IV), and the anaerobic abiotic 
pharmaceutical removal with Fe(III) is the same (0.04 mg·L-1·d-1, Chapter 
3 & 6). For ibuprofen, only 17% is biologically degraded coupled to Fe(III) 
production at an extremely slow removal rate, namely 0.60×10-3 mg·L-1·d-1 
(Chapter 6).  
7.2.2.2 Condition 
In addition to pharmaceutical removal, the conditions are found to 
affect the removal efficiency of pharmaceuticals, which is very relevant for 
the future reactor design and operation. The environmental and operational 
conditions applied in this thesis are quite similar to those in current water 
treatment technologies (Table 7.1).  
The environmental conditions in both anaerobic biodegradation and 
abiotic removal of pharmaceuticals in Mn- or Fe-mediated systems are the 
same as natural conditions, namely at 10 – 40 ºC, pH ~7. These conditions 
are also widely used in wastewater and drinking water treatment processes 
such as upflow anaerobic sludge blanket reactor, or a slow sand filter [3, 363]. 
The specific operational conditions vary for different pharmaceutical 
removal processes. In the anaerobic pharmaceutical biodegradation with 
Mn(IV) or Fe(III), the operational parameters require further optimization 
and adaptation. First of all, the concentrations of pharmaceuticals in the 
studies in this thesis (1 -10 mg·L-1, Chapter 3 & 6) are much higher than 
that in the wastewater (ng·L-1 – μg·L-1). Thus, in the experiments in this 
study, pharmaceuticals can act as the only carbon and energy source 
supporting growth of bacteria involved in the biodegradation, giving these 
a selective pressure benefit. If these biological processes are applicable at 
lower level of concentrations of pharmaceuticals requires further study. In 
addition, the time needed for biodegradation of pharmaceuticals as found 
in our experimental work (40 – 160 days, Chapter 3 & 6) is much longer 
than the retention time generally considered acceptable for tertiary 
treatments (maximum 10 – 30 days) [290]. When the influent is stable, longer 
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retention times for pharmaceutical biodegradation will lead to a larger 
reactor, and higher cost of construction and operation. Due to the different 
properties of the pharmaceuticals, the time needed in biodegradation could 
also be different. 
In the anaerobic abiotic pharmaceutical removal with Mn(IV) or 
Fe(III), the required operational conditions are quite similar to the slow sand 
filter [3]. For example, the abiotic anaerobic pharmaceutical removal with 
Mn(IV) usually takes 1 – 1.5 days with the most efficient removal during 
the first 0.2 – 0.3 days (5 – 7 hours). Generally the retention time of a slow 
sand filter is 0.2 – 0.5 days (5 – 13 hours). This is long enough to efficiently 
remove pharmaceuticals using these Mn(IV) and Fe(III) mediated processes. 
In addition, a typically constructed slow sand filter consists of a layer of fine 
sand supported by gravel. Those can be replaced by fine Mn(IV) particles 
supported by Mn(IV) granules, giving higher reative surface areas per unit 
of volume, thus reducing the filter size are allowing higher loading 
capacities.  
The (liquid) matrix in which the pharmaceuticals are removed is also 
important. In the anaerobic biodegradation, the matrix is the synthetic 
medium containing nutrient compounds, trace elements, and vitamin 
solutions (Chapter 3 & 6). In the abiotic removal, however, the matrix is 
much simpler, namely demineralized water or phosphate buffer (Chapter 4 
– 6). The presence of co-solutes is found to inhibit the anaerobic abiotic
pharmaceutical removal. For example, the removal of diclofenac is
observed in anaerobic abiotic removal with Mn(IV) but not in the abiotic
controls of anaerobic biodegradation with Mn(IV) (Chapter 3 – 5). Thus,
the anaerobic biodegradation of pharmaceuticals with Mn(IV) or Fe(III) is
more suitable in wastewater treatment effluents because wastewater can
supply the nutrient compounds for the bacterial activity. On the other hand,
the anaerobic abiotic removal with Mn(IV) or Fe(III) is more suitable in
drinking water treatment plants because the matrix is much simpler.
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7.2.2.3 Sustainability 
In general, the anaerobic pharmaceutical degradation with Mn(IV) or 
Fe(III) is a potential sustainable pharmaceutical removal technology. Firstly, 
pharmaceutical removal is achieved under anaerobic conditions, requiring 
no aeration or other high energy consumption input. For another thing, the 
main products in pharmaceutical removal, Mn(II) or Fe(II), can be recycled 
and reused (Chapter 6). This further reduces the Mn(II) or Fe(II) enter the 
effluent of this technology. In addition, the Mn(IV) or Fe(III) from drinking 
water treatment plants (DWTPs) can be used as an alternative metal oxide 
source (Chapter 3 & 6). These Mn or Fe species are –thus far- waste by-
products in drinking water production, and which by application in water 
treatment for removing pharmaceuticals become a valuable product. 
Therefore, the anaerobic pharmaceutical removal with Mn or Fe can be 
considered sustainable. 
However, the other products from anaerobic Mn(IV)- or Fe(III)- 
mediated pharmaceutical removal, such as pharmaceutical intermediates, 
might affect the ecosystem, human health, and the current water treatment 
chain. Previous studies indicate that some transformation intermediates 
from pharmaceuticals could be more toxic than their parent compounds [309]. 
Since the toxicity assessment is not included in this dissertation, it is 
impossible to determine if the intermediates are more toxic when they are 
formed in the anaerobic pharmaceutical biodegradation or in anaerobic 
abiotic pharmaceutical removal.  
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In the anaerobic biodegradation of pharmaceuticals, the growth of 
bacteria results in waste biomass. The waste biomass should be treated, for 
example, via anaerobic digestion. However, the biomass from 
pharmaceutical removal contains Mn or Fe, both of which will affect the 
anaerobic digestion. Previous studies show Mn or Fe can promote the 
production of butyric acid during the fermentation process [173]. The Fe(III) 
can also affect the removal and recovery of phosphate in anaerobic sludge 
digestion [37, 288]. Adsorption of phosphate onto MnO2 has also been reported 
previously [227, 228]. In addition, the anaerobic biodegradation with Fe(III) is 
also efficient in nitrogen (ammonia) removal [232, 372]. 
In drinking water treatment processes, the pharmaceutical removal 
units are expected before sand filtration. The Mn(II) and Fe(II) generated 
during the anaerobic pharmaceutical degradation will enter the DWTPs. 
However, the Mn(II) and Fe(II) are also target compounds for drinking 
water production [135, 307]. Therefore, anaerobic metal-mediated 
pharmaceutical degradation will increase the loading of Mn and Fe removal 
in DWTPs. When anaerobic pharmaceutical biodegradation is applied, the 
loading in disinfection units in DWTPs will also be increased.  
In summary, the anaerobic pharmaceutical degradation with Mn(IV) or 
Fe(III) is generally a sustainable process but the environmental influence of 
this pharmaceutical removal technology should be considered in follow-up 
studies. On one side, the toxic effects of pharmaceutical intermediates 
produced in this process require further assessment. On the other side, 
influence of applying this process in the current water treatment chain 
should be taken into account. Compared to the influence on wastewater 
treatment processes and in drinking water production, the anaerobic 
pharmaceutical degradation with Mn or Fe has less negative effects as a 
post-treatment unit in WWTPs. 
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7.2.2.4 Metal oxide types 
The Mn and Fe species are important consumable materials during the 
pharmaceutical removal. In this dissertation, Mn and Fe species from 
different sources and synthesis methods are tested (Table 7.3). The removal 
efficiency of pharmaceuticals with different Mn or Fe species in both 
biological degradation and abiotic removal are summarised in Table 7.4. 
The results indicate that amorphous chemically synthesized Mn(IV) is 
the most suitable material in both anaerobic pharmaceutical biodegradation 
and anaerobic abiotic pharmaceutical removal (Chapter3 – 6). It can be used 
for the removal of caffeine, diclofenac, naproxen, metoprolol and 
propranolol. Also the Mn(IV) from drinking water treatment plants are 
suitable for removal of metoprolol and propranolol (Chapter 3 & 6). The 
pharmaceutical removal with Fe(III) is also effective, more pharmaceuticals 
should be tested (Chapter 3 & 6). 
The reduced Mn(II) and Fe(II) species generated during the anaerobic 
pharmaceutical degradation with Mn(IV) or Fe(III) can be re-oxidized and 
reused in application (Chapter 6). Therefore, the biogenic regenerated 
Mn(IV) and Fe(III) oxides are the most suitable input source in stable 
removal process. In addition, the Mn and Fe removal process in drinking 
water production can also be regarded as Mn and Fe cycling. Thus, the 
Mn(IV) and Fe(III) from drinking water treatment plants are also suitable 
source in pharmaceutical removal.  
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TABLE 7.3 Mn and Fe species tested in different pharmaceutical removal processes in this 
thesis 
Pharmaceutical 
removal processes 
Mn species Fe species 
Anaerobic 
pharmaceutical 
biodegradation with 
Mn(IV) or Fe(III) 
(Chapter 3) 
 Chemically synthesized
Mn(IV) oxides (self-
synthesized)
 Mn(IV) from drinking
water treatment plants
 Chemically synthesized
Fe(III) hydroxides (self-
synthesized)
 Fe(III) from drinking water
treatment plants
 Fe(III)-citrate (commercial
products)
 Fe(III)-based sorbents
(commercial products)
Anaerobic abiotic 
removal with Mn(IV) 
or Fe(III) a
(Chapter 4 – 6) 
 Chemically synthesized
Mn(IV) oxides (self-
synthesized)
 Chemically synthesized
MnO2 (commercial
products)
 Mn(IV) from drinking
water treatment plants
 Chemically synthesized
Fe(III) hydroxides (self-
synthesized)
 biogenic Fe(III) hydroxides
 Fe(III) from drinking water
treatment plants
 Fe(III)-based sorbents
(commercial products)
Pharmaceutical 
biodegradation during 
biological Mn(IV) or 
Fe(III) production 
(Chapter 6) 
 Not tested b  FeCl2
a In the abiotic removal of pharmaceuticals with Mn(IV), both oxic and anaerobic 
conditions were tested while in the removal with Fe(III), only anaerobic conditions 
were tested 
b The pharmaceutical biodegradation during biological Mn(IV) production was tested 
with only Mn(II)-oxidizing bacteria without Mn(II). The detailed information can be 
found in Chapter 6 
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7.3 Future perspective 
7.3.1 From lab to application 
The ultimate objective of this study is to develop anaerobic Mn- or Fe-
mediated pharmaceutical degradation into an efficient, cost-effective, 
environmental friendly technology in water treatment. It is still a long 
process from the batch studies as performed in this thesis research to the 
full-scale application in the field. For this development, three steps are 
proposed. 
Step 1: Exploring the limits of Mn- and Fe-mediated pharmaceutical 
removal 
This thesis demonstrates that anaerobic Mn- or Fe-mediated 
pharmaceutical degradation in water is possible and it is an indication of 
relevant treatment conditions. To apply this process in practice, more studies 
are required. First of all, only seven pharmaceuticals are used in this thesis 
and only some of them are removed. More pharmaceuticals should be tested 
to further understand the pathway of pharmaceutical degradation, and to 
determine wider classes of compounds that can be removed. Can the 
anaerobic Mn- or Fe-mediated pharmaceutical degradation used as function 
efficient at actual concentrations? This is another important question to 
answer. Since the pharmaceutical concentration used in this thesis is in the 
range of mg·L-1, which is thousand times higher than that in often observed 
in waste water effluents (ng·L-1 – μg·L-1), it is essential to test the anaerobic 
biodegradation and anaerobic abiotic removal of pharmaceuticals at that 
level through batch experiments. 
An advantage of anaerobic Mn- or Fe-mediated pharmaceutical 
degradation is the cycling and reuse of Mn and Fe species. Therefore, future 
studies on applying the regenerated Mn(IV) and Fe(III), namely, 
biologically produced Mn(IV) and Fe(III) is necessary. In this thesis, 
anaerobic abiotic pharmaceutical removal with these biologically produced 
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Mn(IV) and Fe(III) has been tested, and further investigation on applying 
them in anaerobic pharmaceutical biodegradation is needed. 
The effects of co-solutes on anaerobic abiotic pharmaceutical removal 
are described in this thesis. However, they can also affect the anaerobic 
pharmaceutical biodegradation. For example, ammonia in the wastewater 
can be used by the bacteria to reduce Fe(III) [162, 267], thus competing with 
pharmaceuticals. In addition, the organic matter can promote biodegradation 
of pharmaceuticals via co-metabolism [92], or inhibit by competing with 
pharmaceuticals as a carbon source. The effects of organic matter on 
anaerobic Mn- or Fe-mediated pharmaceutical biodegradation are unknown, 
and worthwhile studying.  
Studying the kinetics of both anaerobic biodegradation and anaerobic 
abiotic removal will contribute to determining the needed hydraulic 
retention time (HRT) and/or the solid retention time (SRT). The HRT will 
ensure that the pharmaceuticals are staying at a shortest time in the reactor 
achieving the most efficient removal. The SRT will ensure the bacteria and 
oxidants like MnO2 stay in the reactor long enough to contact with 
pharmaceuticals and then remove these compounds. Previous studies have 
shown that both HRT and SRT affect the degradation of pharmaceuticals 
and other micropollutants in current water treatment technologies [7, 22, 39, 189]. 
These factors highly affect the design of the treatment reactor. 
Results from previous studies have shown that the intermediates from 
pharmaceutical removal technologies can be more toxic than parent 
compounds [205]. Therefore, evaluation of the anaerobic Mn- or Fe-mediated 
pharmaceutical degradation should continue beyond the removal efficiency 
of pharmaceutical parent compounds, with a focus on the intermediates. 
Due to the improvement of analytical methods, it is possible to directly 
identify the possible intermediates of pharmaceuticals in anaerobic 
degradation. Furthermore, toxicity and risk assessment can be used as a new 
tool to evaluate the performance of the technology, which is more 
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comprehensive than the simple intermediates identification. In addition, the 
toxicity assessment could reveal the "cocktail effects" of the intermediates, 
which is hard to predict based on the intermediates analysis. 
In this first step, most suggested studies are application-orientated. 
Some studies on mechanism and intermediates are also interesting to know, 
to better understand the pharmaceutical removal process. The results 
collected in this step can also be used to design a lab-scale reactor and settle 
the operational parameters. 
Step 2: Simulating the pharmaceutical removal in a lab-scale reactor 
Once the potential of Fe- and Mn- mediated pharmaceutical removal 
have been further explored, these conditions must be translated into process 
conditions for application. This thesis envisions that the anaerobic Mn- or 
Fe-mediated pharmaceutical degradation in water contains two units - a 
pharmaceutical removal unit, and a metal cycling system (also has potential 
to remove pharmaceuticals) (Figure 7.2). The results obtained from this 
dissertation and batch experiments in Step 1, together with data from 
literature, are sufficient for the design of a lab-scale reactor. For example, 
the lab-scale reactor can be designed by modifying the bed filter reactors 
based on the experimental results because bed filter has been used 
previously to remove pharmaceutical compoundss with MnO2 under aerobic 
conditions [108, 109]. Similarly, the sand filter can be used as the Mn(II) or 
Fe(II) oxidation unit (metal cycling system), because this reaction has been 
used in DWTPs to remove (oxidize) Mn(II) and Fe(II) via both chemical 
and biological processes [239]. The lab-scale reactor can be used to test if the 
selected operational parameters are suitable for anaerobic Mn- or Fe-
mediated pharmaceutical degradation, such as HRT, SRT, flow rate, etc. In 
addition, the lab-scale reactor can also be used to simulate and monitor 
application parameters like loading shock.  
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Another focus of this step is the start-up and operational strategy of the 
pharmaceutical removal reactor applying the anaerobic Mn- or Fe-mediated 
degradation, especially the bioreactor. In this dissertation, it took 
approximately 3 years to enrich the active culture from anaerobic sediment 
(Chapter 3). This is an enormous drawback for the application of the 
anaerobic pharmaceutical biodegradation with Mn(IV) or Fe(III). A wise 
start-up strategy is therefor to develop a pre-adapted inoculum and this 
should be studied during this step. 
Biological techniques like bioaugmentation are also options in 
procedures for start-up. Results show that bioaugmentation can successfully 
improve the biodegradation of pharmaceuticals in wastewater treatment 
processes [210, 214, 374]. By adding adapted inocula which are efficient in 
anaerobic pharmaceutical biodegradation with Mn(IV) or Fe(III), it is 
expected to shorten the adaption period and improve the pharmaceutical 
removal.  
The lab-scale reactor will help accumulate the experience of starting 
and operating the reactor in application. Combining with batch experiments, 
the operational parameters will be optimized to achieve the highest 
pharmaceutical removal efficiency. 
 
 
FIGURE 7.2 Proposed water treatment systems applying anaerobic pharmaceutical 
degradation with Mn(IV) or Fe(III) 
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Step 3. Translating the pharmaceutical removal to pilot-scale systems 
before application 
The final step before real scale application is to build a pilot-scale 
reactor to evaluate the performance with real wastewater or groundwater, to 
gain operation experience, to monitor the long-term operation, and to further 
optimize the pharmaceutical removal. After that the anaerobic Mn- or Fe-
mediated pharmaceutical degradation is ready as a market applicable 
technology to remove pharmaceuticals from water.  
When there are enough data on the anaerobic Mn- or Fe-mediated 
pharmaceutical degradation, a mathematic model can be developed to 
describe the adsorption, chemical oxidation, as well as the biological 
degradation of pharmaceuticals under anaerobic conditions with Mn or Fe. 
This model can then be used to estimate or predict the performance of the 
technology in a given situation. In addition, it will promote the 
understanding of anaerobic degradation of pharmaceuticals with metals. 
7.3.2 Other perspective 
In addition to research developing the anaerobic Mn- or Fe-mediated 
pharmaceutical degradation into a technology, there are other research 
related to the future application. 
A simple framework is used to partially evaluate the sustainability of 
pharmaceutical removal in this thesis. The investigation is missing the 
environmental influence of the anaerobic pharmaceutical degradation with 
Mn(IV) or Fe(III), such as the ecotoxicity of the (by-)products from the 
process. Therefore, toxicity assessment, together with pharmaceutical 
removal, is a good method to evaluate the process, and can be used as an 
indicator to compare this technology with other technologies. In addition, 
methods like life-cycle approach (LCA) could be more suitable. The LCA 
has been applied in water treatment including pharmaceutical removal 
technologies [249, 257]. The analysis could provide adequate assessment of 
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environmental changes related to the anaerobic degradation of 
pharmaceuticals with metal, qualification the energy consumption and 
intermediates emission, and their effects on human's health. 
Molecular biology, such as Fluorescent in situ hybridization, and 
cloning of 16S rDNA, have often been used in environmental studies. These 
techniques are used to described the microbial community and biodiversity 
in the systems, and can be useful when it is incorporated into design and 
operation of water treatment processes [266]. In the anaerobic biological 
degradation of pharmaceuticals with Mn(IV) and Fe(III), molecular 
biological methods can be used to describe the microbial community in the 
process, contributing to better understanding which bacteria degrade the 
pharmaceuticals, and which genes and enzymes are involved. The structure 
of the microbial community, together with other conventional operational 
information, can also be used as an indicator to assess the stability of the 
system, and to diagnose the problems in operation. 
In summary, the anaerobic Mn- or Fe-mediated biological degradation 
and abiotic removal processes can remove pharmaceuticals. The abiotic 
removal of pharmaceuticals is effective to remove compounds like 
diclofenac, metoprolol and propranolol. The anaerobic biodegradation can 
also remove pharmaceuticals including caffeine, naproxen, metoprolol and 
propranolol. The long incubation time for activating metal oxide using 
biomass calls for the further optimization and investigation on this 
promising pharmaceutical removal process. In general, the anaerobic Mn- 
or Fe-mediated pharmaceutical degradation process offers great potential 
for developing a sustainable and affordable technology to remove specific 
pharmaceuticals from water. With further fundamental and application-
oriented research, the anaerobic pharmaceutical degradation with Mn or Fe 
will become an attractive technology in both WWTPs and DWTPs to 
remove pharmaceuticals from water. The process will contribute to the safe 
reuse of wastewater effluents for sustaining ecosystems and cleaner and 
safer water cycle. 
Supplementary materials 
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Supplementary materials for Chapter 1 
Introduction: Pharmaceuticals in the environment and pharmaceutical 
removal technology 
 
TABLE S1.1 Abbreviation of countries 
Abbreviation Country Abbreviation Country 
BRA Brazil JOR Jordan 
CAN Canada KOR Republic of Korea 
CHN China SGP Singapore 
CRI Costa Rica GBR United Kingdom 
HRV Croatia USA United States 
IND India VNM Vietnam 
JPN Japan SER Yugoslavia 
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Supplementary materials for Chapter 3 
Anaerobic biodegradation of pharmaceutical compounds coupled to 
dissimilatory manganese (IV) or iron (III) reduction 
TEXT S3.1 Adaption of the inoculum 
The inoculums used in this study was the mixture anaerobic sediment 
of effluent channel at different wastewater treatment plants (WWTPs) in the 
Netherlands, including WWTP Bennekom, WWTP Ede, and WWTP 
Driebergen. The content of organic matter in the raw mixture is around 11 
mg per kg dry matter. Before the inoculum showing the capacity of 
degrading metoprolol biologically with Mn(IV), it has been cultivated in the 
presence of 10 mg·L-1 metoprolol and 15 mM chemically produced Mn (IV) 
over 800 days. 
TEXT S3.2 Theoretical calculation of Mn(IV) and Fe(III) reduction during 
anaerobic pharmaceutical biodegradation 
The Mn(IV) and Fe(III) reduction during the anaerobic pharmaceutical 
biodegradation is calculated based on the balance of electron transfer. 
During the calculation, the O2 is used as a bridge. The total electrons 
provided by complete mineralization of pharmaceuticals is calculated. Then 
the same amount of electrons should be accepted by Mn(IV) or Fe(III) 
reduction. However, the electron transferred during the pharmaceutical 
oxidation with Mn(IV) or Fe(III) is difficult to estimate. The calculation of 
pharmaceutical mineralization with O2 is estimated based on mass balance 
(Table S3.3). 
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TABLE S3.2 Medium recipe for anaerobic biodegradation of pharmaceuticals with Mn(IV) 
or Fe(III) 
Compounds 
Final 
concentration 
(µg⋅L-1) 
Compounds 
Final 
concentration 
(µg⋅L-1) 
AlK(SO4)2 0.1 NaCl 10 
Biotin 
(Vitamin H) 
20 NaH2PO4·2H2O 3.75 mM 
CaCl2⋅2H2O 0.75mM NaHCO3 30 mM 
CoSO4 1 NH4Cl 28.0 mM 
CuSO4⋅5H2O 0.1 NiCl2⋅6H2O 24 
Cyanocobalamine 
(vitamin B12) 
1 Nicotinamide 50 
FeSO4⋅7H2O 1 NTA 15 
Folic acid  
(dihydrate) 
20 
p-Aminobenzoic acid
(Na – salt)
50 
H3BO3 0.1 
Pantothenate
(Ca – salt)
55 
KCl 1.34mM 
Pyridoxine
(vitamin B6)
100 
Lipoic acid  
(thioctic acid) 
50 
Riboflavine
(vitamin B2)
50 
MnSO4⋅2H2O 5 
Thiamine HCl
( vitamin B1)
50 
Na2MoO4 25 ZnSO4 1 
Na2S⋅9H2O 1 mM Yeast extract 0.02% (w/w) 
TABLE S3.3 Theoretical calculation of Mn(IV) and Fe(III) reduction during anaerobic 
pharmaceutical degradation (mol/mol pharmaceutical) 
Pharmaceutical Proposed reaction 
Total 
electron 
transfer 
Mn(IV) 
reduction 
Fe(III) 
reduction 
Caffeine 
(C8H10N4O2) 
𝐶𝐶8𝐻𝐻10𝑁𝑁4𝑃𝑃2 + 9.5𝑃𝑃2
→ 8𝐶𝐶𝑃𝑃2 + 5𝐻𝐻2𝑃𝑃 + 2𝑁𝑁2 38 19 38 
Carbamazepine 
(C15H12N2O) 
𝐶𝐶15𝐻𝐻12𝑁𝑁2𝑃𝑃 + 17.5𝑃𝑃2
→ 15𝐶𝐶𝑃𝑃2 + 6𝐻𝐻2𝑃𝑃 + 𝑁𝑁2 70 35 70 
Ibuprofen 
(C13H18O2) 
𝐶𝐶13𝐻𝐻18𝑃𝑃2 + 16.2𝑃𝑃2 → 13𝐶𝐶𝑃𝑃2 + 9𝐻𝐻2𝑃𝑃 66 33 66 
Metoprolol 
(C15H25NO3) 
𝐶𝐶15𝐻𝐻25𝑁𝑁𝑃𝑃3 + 21.25𝑃𝑃2
→ 15𝐶𝐶𝑃𝑃2 + 12.5𝐻𝐻2𝑃𝑃+ 0.5𝑁𝑁2 85 42.5 85 
Naproxen 
(C14H14O3) 
𝐶𝐶14𝐻𝐻14𝑃𝑃3 + 16𝑃𝑃2 → 14𝐶𝐶𝑃𝑃2 + 7𝐻𝐻2𝑃𝑃 64 32 64 
Propranolol 
(C16H21NO2) 
𝐶𝐶16𝐻𝐻21𝑁𝑁𝑃𝑃2 + 20.25𝑃𝑃2
→ 16𝐶𝐶𝑃𝑃2 + 10.5𝐻𝐻2𝑃𝑃+ 0.5𝑁𝑁2 81 40.5 81 
Citrate 
(C6H8O7) 
𝐶𝐶6𝐻𝐻8𝑃𝑃7 + 4.5𝑃𝑃2 → 12𝐶𝐶𝑃𝑃2 + 8𝐻𝐻2𝑃𝑃 18 9 18 
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FIGURE S3.1 Image of (a) granule and powder of Mn(IV) from drinking water treatment 
plants; (b) ground powder of Fe(III) from drinking water treatment plants, Fe(III)-based 
sorbent, FerroSorp®Plus, and Fe(III)-based sorbent, FerroSorp®RW (from left to right) 
FIGURE S3.2 X-ray diffraction spectrum of reference compounds (a) chemically produced 
MnO2 (commercial products) and quartz (from RRUFF database R060604); (b) Fe(OH)3, 
Fe3O4, and Fe2O3 
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FIGURE S3.3 Presence of potential intermediates from anaerobic metoprolol biodegradation 
with Fe(III)chem-synthesis and Fe(III)-citrate at t= 0 day, t= 60 day, t= 120 day in 
chromatography. The relative area is the ratio between the area of the potential intermediates 
and the area of internal standard (fenoprofen)
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Supplementary materials for Chapter 4 
Anaerobic conditions promote abiotic diclofenac removal with 
manganese oxides 
 
TEXT S4.1 Solution preparation 
(1) Anaerobic water 
The anaerobic water was prepared by boiling the demineralised water 
for 5 minutes. Then the boiled water was transferred to a glass bottle and 
bubbled with N2 until it had cooled down to room temperature. The water 
was then sealed and stored at room temperature. 
(2) Pharmaceutical stock 
The pharmaceutical stock was included pharmaceutical mixture stock 
and diclofenac stock. The pharmaceutical mixture stock was prepared by 
dissolving 20 mg of every seven pharmaceuticals with 1 L ultrapure water. 
The final concentration of each pharmaceutical in pharmaceutical mixture 
stock is about 20mg·L-1. The diclofenac stock was prepared by dissolving 
125 mg diclofenac with 50 mL ultrapure water. The final diclofenac 
concentration in diclofenac stock is about 2500 mg·L-1. 
(3) Reaction solution 
The reaction solution contained 7 mM MnO2, 50 mM buffer to 
maintain constant pH at 7, and an appropriate amount of NaCl to maintain 
constant ionic strength at 0.1 M. The buffer is H3PO4/NaH2PO4 for pH ~ 4.5, 
NaH2PO4/K2HPO4 for pH~7.0, and K2HPO4 for pH ~8.5. The reaction 
solution was prepared with both normal demineralised water and anaerobic 
water.  
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TEXT S4.2 MnO2 generation 
Both 0.4 mM MnCl2 and 0.4 mM KMnO4 were prepared with 
demineralised water. While stirring the KMnO4 solution continuously, equal 
volume of MnCl2 was added. Then, NaOH (1N) was added into the mixture 
to bring the pH to 10. The MnO2 solid then centrifuged at 5000 rpm for 15 
min and then resuspended by anaerobic water. The centrifigation and 
suspended in anaerobic water were repeated for six times. Suspension of 
MnO2 in anaerobic water were stored at 4ºC for the addition to batch 
experiment. 
TEXT S4.3 Analysis 
(1) Pharmaceutical analysis
1 mL samples were collected and centrifuged at 10000 rpm for 10 min.
The supernatant then transferred to amber vials. 50 μL of internal standard 
(5mg L-1 fenoprofen) was added into the sample. The samples were stored 
at -20 ˚C before analysis. 
The pharmaceutical analysis was performed as described [95] by a ultra-
performance liquid chromatography (UPLC, ultimate 3000, Thermo, USA) 
with a diode array detector, and a CSH phenyl-Hexyl column (1.7μm, 130 
Å, 2.1 × 150 mm). A mixture of water with 0.1% formic acid (solution A) 
and acetonitrile with 0.1% formic acid (solution B) was used as the mobile 
phase. The analysis started with 100% solution A for 0.5 min. Then it 
decreased to 20% at 13 min. After staying for 3 min, it went back to 100% 
at 17 min and stopped at 22.4 min. The flow rate is 0.3mL/min while the 
oven is at 40 ℃. The injection volume of samples was 10 μl. The 
pharmaceutical concentration was calculated based on relative area (area of 
pharmaceutical/area of internal standard) and the slope of the calibration 
curve. 
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(2) Mn(II) analysis 
The Mn(II) generated during the removal processes was determined by 
an inductively coupled plasma spectrometer with optical emission 
spectroscopy (ICP-OES, Vista MPX Simultaneous, Varian Inc. (Part A), 
USA). Controls with only MnO2 and buffers but without pharmaceuticals 
showed no Mn2+ produced.  
(3) MnO2 morphologies analysis 
The two kinds of MnO2 were characterized by X-ray diffraction (XRD, 
D2 PHASER, Bruker, Germany). The results showed in Figure S1. In 
addition, microscopes were also used to characterized the MnO2 
morphologies (Figure S4.2). 
Fournier-Transform Infra-Red spectrometers 
The MnO2 solid with diclofenac or metoprolol as described in 
previously (section 4.2.3) were collected by centrifugation (5000rpm, 15 
min) after 24h under both oxic and anaerobic conditions in deminerized 
water. Control sample, bare MnO2 without pharmaceuticals, was also 
collected based on the same method. The samples were freeze-dried before 
analysis. All the samples were analyzed by a Fournier-Transform Infra-Red 
spectrometers (Bruker TENSOR 27). The reference spectrum of untreated 
diclofenac and metoprolol standard was also acquired in the same analytical 
condition. 
TEXT S4.4 Intermediates 
In the chromatography spectrum, the peaks at different retention time 
(RT) are representative different intermediates of diclofenac. The diclofenac 
is observed at RT=14.64 min. Due to the practical limits, it is impossible for 
us to identify the formula or structure of intermediates in diclofenac removal 
with MnO2. However, the chromatography clearly shows that the 
intermediates formed under aerobic and anaerobic conditions are different. 
This may indicate that oxygen contributes to forming the intermediates.  
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TEXT S4.5 Size analysis 
Size analysis was performed by a laser size analyzer (Mastersizer 2000, 
Malven, UK). The size of MnO2 particles keep increasing during the 
analysis process. Therefore, it is impossible to compare the size between 
amorphous MnO2 and crystalline MnO2. Generally, the amorphous MnO2 is 
smaller than crystalline MnO2 (Figure S4.2). 
TEXT S4.6 FTIR analysis 
The bare MnO2 under oxic and anaerobic conditions are the same, 
therefore, we only use the FTIR spectra of oxic MnO2 in Figure S4.6.The 
FTIR spectra show the MnO2 changed before and after reacting with 
diclofenac. The spectra of bare MnO2 is similar to previous study [32]. The 
broad peak at 3380 cm-1 was assigned to the stretching vibration of -OH 
group in water and Mn-O-H. The peaks at 1634 cm-1 and 1056 cm-1 were 
assigned to the bending vibrations of the -OH in Mn-OH. These peaks are 
also the indications of the reactive sites on MnO2 surface. The peak at 428 
cm-1 was assigned to the bending vibration of Mn-O [32, 278].
Due to the extremely huge amount of MnO2 added into the system
comparing to diclofenac, the spectra of MnO2 after reacting are still similar 
to the bare MnO2. However, there are still some peaks appeared between 
800 – 2000 cm-1 showing the MnO2 is changed. Three new peaks at 1379 
cm-1 , 1017 cm-1 and 828 cm-1 were not attributed to the pure diclofenac
either (Figure S4.6 (c)). Therefore, they are probably from the intermediates.
The peak at 1379 cm -1 is assigned to alkynes, aromatics or C=O, the peak
at 1017 cm-1 is assigned to C-O (2-bands) and the peak at 828 cm-1 is
assigned to N-H wagging [278].
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In addition, the peak shift and peak change were also observed. The 
peak at 1632 cm-1 decreased after reacting with diclofenac under aerobic 
condition while it increased under anaerobic conditions. The higher peak 
probably indicates that the reactive sites are activated and more available 
for diclofenac. Another peak shift is observed from 1272 cm-1 to 1287 cm-1. 
The peak also larger. That peak is assigned to alkynes or NO2.  
All these peaks showed that under anaerobic conditions, the MnO2 
changed more than that under aerobic conditions. The change may be caused 
by the intermediates. The change of MnO2 under anaerobic conditions can 
be the reason why anaerobic conditions promote diclofenac removal. 
 
TABLE S4.1 Structure and properties of selected pharmaceuticals in this study 
Pharmaceutical a CAS No. Chemical Structure pKa LogKow 
diclofenac  
(DFC) 
15307-79-6  
 
 
4.15 4.57 
Caffeine 
(CAF) 
58-08-2 
 
10.4  
(at 40ºC) 
-0.07 
Carbamazepine 
(CBZ) 
298-46-4  
 
13.9 2.45 
Ibuprofen 
(IBP) 
15687-27-1 
 
4.91 3.97 
Metoprolol 
(MET) 
56392-17-7  
 
9.5 1.88 
Naproxen 
(NAP) 
22204-53-1  
 
 
4.15 3.18 
Propranolol 
(PROP) 
318-98-9 
 
9.42 3.48 
a Text in the brackets is the abbreviation of each pharmaceutical 
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TABLE S4.2 Pharmaceutical concentration (C/C0 at t= 24 h) in absence of MnO2 in 
demineralised water. Experimental conditions: [pharmaceutical]0=1mg·L-1, pH ~8.5 
Compounds Aerobic conditions Anaerobic conditions 
caffeine 1.02 1.02 
carbamazepine 1.01 1.01 
diclofenac 1.00 1.09 
ibuprofen 1.03 1.04 
metoprolol 1.01 1.01 
naproxen 1.02 1.02 
propranolol 1.01 1.02 
 
 
 
 
TABLE S4.3 Structure and properties of glyphosate and sulfamethazine 
Compound CAS No. Chemical Structure pKa LogKow 
glyphosate 1071-83-6 
 
0.8  
 (1st phosphonic) 
-2.8 
sulfamethazine 57-68-1 
 
7.59 0.89 
 
 
 
 
 
 
FIGURE S4.1 X-ray diffraction spectrum of amorphous MnO2 and crystalline MnO2 
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FIGURE S4.2 Microscopy of (a) amorphous MnO2 and (b) crystalline MnO2 at 100 times 
magnified 
 
 
 
 
 
FIGURE S4.3 Pharmaceutical removal with MnO2 in demineralised water with 
pharmaceutical mixture under aerobic conditions (■) and anaerobic conditions (▲). 
Experimental conditions: [MnO2]0=7 mM, [pharmaceutical]0=1mg·L-1, pH ~8.5. Error bars 
are standard deviations 
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FIGURE S4.5 Size analysis of amorphous MnO2 (eight times analysis in one single run, 40 
sec/sample) 
FIGURE S4.4 Presence and variation of intermediates from pharmaceuticals under aerobic 
and anaerobic conditions at different reaction time point showed in chromatography spectrum 
in demineralised water system. The relative area was the ratio between the area of the 
potential intermediates and the area of internal standard (fenoprofen). Error bars are standard 
deviations 
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FIGURE S4.6 FTIR spectra of MnO2 before (solid line) and after reacting with diclofenac 
under aerobic condition (dash line) and anaerobic condition (dot line) at (a) 350 – 4000 cm-1, 
and (b) 800 – 2000 cm-1. The pure diclofenac (c) was diclofenac sodium, used as a reference 
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Supplementary Material for Chapter 5 
Application of manganese oxides under anaerobic conditions to 
remove diclofenac from water 
TEXT S5.1 Kinetic model selection 
Four kinetics models were used to fit the DFC removal data at 20ºC. 
Since the DFC removal is an obvious two-stage removal, we used both the 
all the data and the data from the first 9 hours to fit the pseudo-first-order 
model. Based on the corresponding R2 values in Figure S1 , pseudo-first-
order model with first 9 hour data, pseudo-second-order model, and 
mechanism-based model fitted the data similarly in general. The removal 
kinetics was fitted slightly better to the mechanism-based model than the 
other two models. All the data in the experiments were used to fit the 
mechanism-based model (Table S5.1). However, the plateau concentration 
(Ce) was not obtained in all experiments, thus will lead to inconsistent 
transformation trends of DFC removal. Since the other three models have 
similar performance, the simplest model was selected to fit all the data under 
different experimental conditions in this paper, which is the pseudo-first-
order model with first 9 hour data.  
TEXT S5.2 Results of blank experiments 
The experiments without MnO2 were carried out as the blank 
experiments. The results showed that no DFC was removed without MnO2
(Table S5.2). To investigate the effects of humic acids on DFC removal 
under anaerobic conditions with MnO2, the experiments without MnO2 as 
controls were carried out at the lowest and highest HA concentration in 
this study, that is, 5mg⋅L-1 and 20 mg⋅L-1. The results show that no DFC is 
removed after 33 hours (Figure S5.2). 
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TABLE S5.2 DFC removal under anaerobic conditions without MnO2 under different 
experimental conditions after 33 hours 
T(˚C) Matrix 
[MnO2]0 
(mM) 
[DFC]0 
(µM) 
C/C0a 
Standard 
deviation 
(%) 
10 10 mM MOPS 7 3.14 0.98 5.9 
20 10 mM MOPS 7 3.14 0.94 7.2 
30 10 mM MOPS 7 3.14 1.05 1.4 
40 10 mM MOPS 7 3.14 1.02 1.9 
      
20 10 mM MOPS 1.5 3.14 1.13 9.2 
20 10 mM MOPS 3 3.14 1.08 5.2 
20 10 mM MOPS 6 3.14 1.08 9.6 
20 10 mM MOPS 7 3.14 0.94 7.2 
20 10 mM MOPS 7 0.79 1.06 13.8 
20 10 mM MOPS 7 1.57 1.01 3.4 
      
30 10 mM MOPS, no metal ions 7 3.14 1.05 1.4 
30 0.1 mM MnCl2 + 10 mM MOPS 7 3.14 1.10 1.4 
30 0.1 mM CaCl2 + 10 mM MOPS 7 3.14 1.00 3.8 
30 0.1 mM MgCl2 + 10 mM MOPS 7 3.14 0.98 3.6 
30 0.1 mM FeCl3 + 10 mM MOPS 7 3.14 0.99 3.6 
30 1 mM MnCl2 + 10 mM MOPS 7 3.14 1.05 1.7 
30 1 mM CaCl2 + 10 mM MOPS 7 3.14 0.98 2.2 
30 1 mM MgCl2 + 10 mM MOPS 7 3.14 1.02 2.8 
30 1 mM FeCl3 + 10 mM MOPS 7 3.14 0.95 4.1 
      
30 10 mM MOPS, no HA 7 3.14 1.02 9.7 
30 5 mg·L-1 HA +10 mM MOPS 7 5.57 1.00 4.0 
30 20 mg·L-1 HA +10 mM MOPS 7 5.57 1.02 1.2 
a C is the average DFC concentration of triplicate samples at t= 33 h in the experiment, C0 
is the average DFC concentration of triplicate samples at t=0 h 
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TEXT S5.3 Change of MnO2 particles 
Based on the microscopies, it is clear that the MnO2 particle size at 
20ºC is smaller than that at 40 ºC (Figure S5.3 (a) – (d)). In addition, when 
the MnO2 particles was settled at 20ºC for a longer time (6 months in this 
case), the MnO2 particle size was also increased (Figure S5.3(e), (f)). The 
settlement ability test also supported this indirectly (Figure S5.4). 
However, we failed to analyze the change of MnO2 particles due to the 
practical limits as mentioned previously [172]. 
FIGURE S5.2 DFC removal without MnO2 under anaerobic conditions at different HA 
concentrations. Experimental conditions: [MnO2]0= 7 mM; [DFC]0= 5.57 µM, 30℃, pH~7, 
I=0.01 M. Error bars are standard deviations 
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FIGURE S5.3 Microscopy of MnO2 at (a) 20˚C, 33 hours, × 10 ; (b) 20˚C, 33 hours, × 100; 
(c) 40˚C, 33 hours, × 10; (b) 40˚C, 33 hours, × 100, (e) 20˚C, 6 months, × 10, (f) 20˚C, 6
months, × 100. Experimental condition: [DFC]0 =3.14µM, [MnO2]0=7 mM, pH=7, I=0.01M.
The yellow bar -represents 100 μm length in (a), (c) and (e) and 10 μm in (b), (d) and (f)
FIGURE S5.4. Settlement ability of MnO2 treated after 33 hours at different temperatures at 
(a) t=0min; (b) t=30min
(a) (b) 
(a) (b) 
(c) (d) 
(e) (f) 
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Supplementary materials for Chapter 6 
Biological regeneration of manganese (IV) using oxygen and iron 
(III) using nitrate for anaerobic metal oxide mediated removal of
pharmaceuticals from water
Text S6.1 Calculation of total O2 amount 
The total O2 amount includes the O2 in the headspace and that dissolved 
in the medium. The amount O2 in the headspace is calculated according to 
the ideal gas law (Equation S6.1).  
𝑝𝑝𝑝𝑝 = 𝑀𝑀𝑛𝑛𝑛𝑛 S6.1 
in which  
p is the partial pressure of the gas (O2). 
V is the volume of the O2, 70 mL in this experiment 
n is the amount of oxygen in mole 
R is gas constant, 8.314 m3·Pa·mol-1·K-1 
T is the absolute temperature, 303.15 K 
The in O2 dissolved is calculated according to Henry’s Law (Equation S6.2). 
𝑝𝑝 = 𝐾𝐾𝐻𝐻𝑝𝑝𝑝𝑝𝑐𝑐𝑎𝑎𝑎𝑎 S6.2
In which  
p is the partial pressure of O2
𝐾𝐾𝐻𝐻
𝑝𝑝𝑝𝑝 is the Henry’s Law constant. To simply the calculation, the value is O2
in water at 30ºC, 1.18×10-3 mol·L-1·atm-1 
𝑐𝑐𝑎𝑎𝑎𝑎 is the molar concentration of dissolved O2 
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TEXT S6.2 Abiotic control results 
The abiotic controls show that the degradation of pharmaceutical 
during the anaerobic biological production of Fe(III) is insignificant without 
bacteria. The recovery rate of solid phase extraction (SPE) is 85 – 115%, so 
when the removal efficiency is less than 20%, it is hard to conclude if that 
is removal or that is caused by the SPE and detection deviation. In addition, 
propranolol was also included in the experiments. However, the recovery 
with the current SPE methods is poor and various from 10 – 30%. Therefore, 
the data is not shown here. 
TABLE S6.1 Medium recipe for bioregeneration of Fe(III) 
Compounds 
Final 
concentration  
(g⋅L-1) 
Compounds 
Final 
concentration 
(g⋅L-1) 
FeCl2 0.11 NaHCO3 2.5 
KCl 0.10 NH4Cl 0.15 
KNO3 0.02 Vitamin 1 mL⋅L-1 
Trace element 1 mL⋅L-1   
Trace element solution 
CaCl2.2H2O 1.00 Na2MoO4.2H2O 0.10 
CoSO4.7H2O 1.80 Na2SeO3 0.002 
CuSO4.5H2O 0.10 Na2WO4.2H2O 0.004 
FeSO4.5H2O 0.87 NaCl 10.00 
H3BO3 0.10 NiCl2.6H2O 0.30 
KAl(SO4)2.12H2O 0.20 Nitrilotriacetic acid 15.00 
MgSO4.5H2O 25.61 ZnSO4.5H2O 1.57 
MnSO4.5H2O 5.00   
Vitamin solution 
Biotin 0.02 Nicotinic acid 0.05 
Cyanocobalamine 
(vitamin B12) 
0.001 
p-Aminobenzoic acid  
(Na – salt) 
0.05 
Pantothenate  
(Ca – salt) 
0.05 Pyridocine-HCl 0.10 
Folic acid 0.02 Riboflavine (vitamin B2) 0.05 
Lipoic acid (thioctic 
acid) 
0.05 Thiamine HCl ( vitamin B1) 0.05 
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TABLE S6.2 Biodegradation of pharmaceuticals (C/C0) with Mn(II)-oxidizing bacteria 
Pharmaceutical Biodegradation Pharmaceutical Biodegradation 
Caffeine 1.05 Metoprolol 1.14 
Carbamazepine 1.06 Naproxen 0.96 
Diclofenac 0.95 Propranolol 1.12 
Ibuprofen 0.90 
TABLE S6.3 Abiotic removal of pharmaceuticals (C/C0) under anaerobic conditions in the 
blank groups 
Pharmaceutical Removal Pharmaceutical Removal 
Caffeine 1.00 Metoprolol 1.00 
Carbamazepine 1.00 Naproxen 1.00 
Diclofenac 1.00 Propranolol 0.95 
Ibuprofen 1.00 
FIGURE S6.1 Degradation of pharmaceuticals in the abiotic groups during the biological 
Fe(III) production within 150 days. Experimental conditions: [Fe(II)]0= 1.2 mM , [NO3-]0= 
0.2 mM, [pharmaceutical]0=1 mg·L-1, T=30ºC, pH =7, shaking speed 120 rpm. Error bar 
stands for the standard deviation 
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FIGURE S6.2 Abiotic removal of pharmaceuticals under anaerobic conditions with different 
Fe(III) powder within 5 days. Fe(III)bio-production = biologically produced Fe(III), Fe(III)chem-
synthesis = chemically synthesized Fe(III), Fe(III)DWTP = Fe(III) from drinking water treatment 
plant, Fe(III)FerroSorp®RW = Fe(III)-based sorbent, FerroSorp®RW , Fe(III)FerroSorp®Plus = 
Fe(III)-based sorbent, FerroSorp®Plus. Experimental conditions: [Fe(III)]0=20 mM. 
Pharmaceutical]0=0.5 mg·L-1, phosphate buffer pH=7, T=30 °C 
 
 
 
FIGURE S6.3 Abiotic removal of pharmaceuticals under anaerobic conditions with different 
Fe(III) granule within 5 days. Fe(III)DWTP = Fe(III) from drinking water treatment plant, 
Fe(III)FerroSorp®RW = Fe(III)-based sorbent, FerroSorp®RW , Fe(III)FerroSorp®Plus = Fe(III)-based 
sorbent, FerroSorp®Plus. Experimental conditions: [Fe(III)]0=20 mM. Pharmaceutical]0=0.5 
mg·L-1, phosphate buffer pH=7, T=30 °C 
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摘要 
水体中的药品残留物主要来自于制药工业和公众的日常使用。这
种污染物在地表水，地下水，城市污水和饮用水中以极低的浓度存
在。目前，已经有水中药品残留物及其代谢产物不利影响的研究，包
括对人类和生态系统的毒性，以及耐药性。为了防止这些不利的影
响，需要通过各种技术手段去除水体中的药品残留物，包括使用在有
氧气存在（好氧）和没有氧气存在（厌氧）环境下的非生物去除和生
物降解技术。厌氧技术通常更具有可持续性和吸引力，因为这些技术
与好氧技术相比能耗更低，产生的诸如温室气体等的污染物更少。利
用锰和铁的厌氧降解技术在饮用水处理和污水处理过程中具有明显的
优势。研究利用锰和铁的厌氧技术去除水中的药品残留物，并将其发
展成一项水处理工艺很有前景。本论文研究了利用锰和铁处理水中药
品残留物的厌氧技术，包括生物降解和非生物去除。论文第一章主要
阐述了本论文研究的必要性和动机。  
论文第二章对能够去除水中药品残留物的与锰和铁相关的技术进
行了回顾。根据出去机理，这些技术被分为了 3类：物理化学技术，
化学技术，以及生物相关技术。之前的研究表明，利用锰和铁的相关
技术能够高效的除去水中的药品残留物，去除效率因技术而异。之后
我对各项技术的非特异性、处理条件、产生的中间产物和副产物以及
含锰和铁的化合物的影响进行比较，对于这些技术的优缺点进行了评
估。第二章还介绍了一些能够在将来用于药品残留物去除的新兴锰和
铁相关技术。其中异化锰铁还原技术因其的运行条件接近自然条件，
并且最终能够将污染物完全矿化等优势，而成为极具吸引力，可持续
性，以及低成本的药品残留物处理技术。  
论文第三章主要研究了利用异化金属还原出去药品的厌氧生物降
解，以及不同类型的锰和铁对药品生物降解的影响。此研究中使用的
微生物是经过美特普洛和化学方法制备的四价锰驯化的底泥混合物。
这些微生物能够在 42天内利用化学制备的无定形态的四价锰去除
26%的咖啡因和 52%的萘普生。此外，这些微生物还能利用给水厂产
生的四价锰。经过 196天的培养，这些微生物能够去除 96%的美特普
洛和 31%的普萘洛尔。这些微生物同样能够利用三价铁作为电子受体
去除美特普洛。实验结果表明这些微生物利用不可溶性的化学制备的
三价铁和可溶性的柠檬酸铁取得 57%和 52%的去除率。在整个研究
过程中，所有实验的非生物对照组都没有明显的药品残留物的去除，
这表明生物降解是利用异化金属还原出去药品厌氧技术的主要机理。
论文第四章比较了好氧环境和厌氧环境对于利用二氧化锰出去药
品残留物的影响。结果表明厌氧环境能够促进双氯芬酸的去除，但却
会抑制美特普洛和普萘洛尔的去除。在纯水中，厌氧环境下二氧化锰
对双氯芬酸的去除率为 78%，高于好氧环境下的 59%。在 50mM的
磷酸盐缓冲液中，二氧化锰能够在好氧环境下将双氯芬酸完全去除，
而其在厌氧环境下的去除率与在纯水中没有区别。初步研究表明，酸
性条件（pH 4-5）对二氧化锰厌氧去除双氯芬酸有利。同时，相比于
二氧化锰晶体，无定形态的二氧化锰更适合用于双氯芬酸的去除。有
上述结果得知，药品的化学结构和性质，二氧化锰的性质以及二氧化
锰的表面活性位是决定厌氧环境下利用二氧化锰对药品的出去了程
度。
论文第五章进一步研究了厌氧环境下利用二氧化锰去除双氯芬酸
的过程。实验结果表明，将实验温度从 10°C提高到 30°C能够提高双
氯芬酸的去除。然而当温度再次提升到 40°C时，双氯芬酸的出去收
到了抑制。这可能是由奥氏熟化，或者老化，或者两者共同造成的。
增加二氧化锰的相对量能够提高双氯芬酸的去除。但是当二氧化锰与
双氯芬酸的物质的量的比从 2200：1提高到 8900：1时，双氯芬酸的
去除没有进一步增加。这可能是由于二氧化锰氧化双氯芬酸的能力有
限。金属离子对双氯芬酸的去除有强烈的抑制作用，并遵循以下顺
序：Mn2+> Ca2+ ≈ Mg2+ >Fe3+。 金属离子能够吸附在二氧化锰的表
面，并和双氯芬酸竞争二氧化锰表面的活性位。磷酸盐对双氯芬酸的
去除有不同的作用：在低浓度时，磷酸盐回抑制双氯芬酸的去除，而
在高浓度时回促进去除。腐殖酸能够显著的提高二氧化锰对双氯芬酸
的去除。只是由于腐殖酸能够释放二氧化锰表面被其他物质占据的活
性位，并激活新的活性位。
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为了能够将药品去除过程中使用过的锰和铁再次使用，论文第六
章研究了限制氧气浓度环境下四价锰的生物产生过程，以及硝酸盐还
原条件下三价铁的生物产生过程。在限制氧气浓度的条件下，二价锰
氧化菌成功产生出四价锰，并且产生的四价锰固体为无定形态的。二
价锰氧化菌不能降解药品物质。在非生物去除部分，厌氧环境中，给
水厂产生的四价锰能够 有效的去除美特普洛和普萘洛尔。通过生物
过程，三价铁也曾成功的在硝酸盐还原条件下制备。这种三价铁固体
也是无定形态的。在此生物铁氧化过程中，没有发现药品的去除。对
比研究中使用的各种三价铁化合物，只有给水厂生产的三价铁和一种
三价铁吸附剂能够去除普萘洛尔。 
论文的最后一章对本论文的实验结果进行了讨论，并且对利用锰
和铁处理水中药品残留物的厌氧技术的实际应用提供了见解（第七
章）。利用锰和铁处理水中药品残留物的机理主要包括吸附，化学氧
化和生物降解。在不通的处理技术中，各种机理对药品残留物去除的
贡献不同。对于不同去除过程的评估比较主要基于对药品残留物的去
除效果，环境状态和运行条件，去除过程的可持续性，以及不同锰和
铁化合物的应用。本论文的实验结果证明，利用锰和铁处理水中的厌
氧技术可以去除水中的药品残留物。为了将这一过程转化为实际的水
处理单元，未来的研究需要经过三个步骤：（1）探索利用锰和铁处
理水中药品残留物的厌氧技术的极限；（2）在可控范围内进行小规
模的实验模拟；（3）中试实验。此外，论文中也提出了一些其他相
关的研究课题。总的来说，利用锰和铁的厌氧技术可以通过生物和非
生物的过程去除水体中的药品残留物。这一过程有希望发展成高效，
经济，环境友好并且可持续发展的水中药品残留物去除技术。
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